2023 VIRBAC Product Guide

Virbac

Shaping the future of animal health

WHO IS VIRBAC?

The Virbac Group is driven by a passion for enhancing the health of all animals.

In the U.S., our focus is on meeting the unique needs of veterinarians and animal care providers for many different species of animals. We are thrilled to announce our entry into Pet Nutrition as well as Livestock Health. We recognize that meeting these needs starts with listening.

Ultimately, the essence of Virbac U.S. is found in our relationships with people who put their trust in us and our products. It is through these relationships that, together, we can find the right answers by first asking the right questions.

us.virbac.com | vet-us.virbac.com | iVet.com

TABLE OF CONTENTS

If you have any questions regarding these products, please contact Virbac Product Safety & Consulting Team at 1-800-338-3659 or your local Virbac representative.

PRODUCT LISTING

Companion Animals

Product Description	Product No.	Size
ANTIBIOTICS	**PAGE 14**	
CLINTABS® brand of clindamycin hydrochloride tablets, USP (25 mg)	902540	400 ct.
CLINTABS® brand of clindamycin hydrochloride tablets, USP (75 mg)	907520	200 ct.
CLINTABS® brand of clindamycin hydrochloride tablets, USP (150 mg)	915010	100 ct.
RILEXINE® (cephalexin) Chewable Tablets (150 mg)	07620	100 ct.
RILEXINE® (cephalexin) Chewable Tablets (300 mg)	07630	100 ct.
RILEXINE® (cephalexin) Chewable Tablets (600 mg)	07640	100 ct.
BEHAVIOR	**PAGES 15-16**	
CLOMICALM® (clomipramine hydrochloride) tablets - 5 mg	10506	30 ct.
CLOMICALM® (clomipramine hydrochloride) tablets - 20 mg	10507	30 ct.
CLOMICALM® (clomipramine hydrochloride) tablets - 80 mg	10508	30 ct.
ANXITANE® (L-Theanine) Chewable Tablets - S - 50 mg	10432	30 ct.
ANXITANE® (L-Theanine) Chewable Tablets - M & L - 100 mg	10435	30 ct.
ZENIDOG® Gel Diffuser	10514	8.1 oz.
ZENIDOG® Long-Acting Collar	10512	18.3 in. collar
ZENIDOG® Long-Acting Collar	10513	29.5 in. collar
DENTAL HEALTH	**PAGES 17-21**	
C.E.T. AQUADENT® FR3SH® Dental Solution	90508	8.45 fl oz.
C.E.T. AQUADENT® FR3SH® Dental Solution	90516	16.9 fl oz.
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Extra Small	90601	8.4 oz.
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Small	90603	8.5 oz.
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Medium	90605	12.8 oz.
C.E.T.® Enzymatic Oral Hygiene Chews for Dogs - Large	90607	1.13 lb.
C.E.T.® Enzymatic Tartar Control Toothpaste - Beef	CET201	2.5 oz.
C.E.T.® Enzymatic Tartar Control Toothpaste - Malt	CET102	2.5 oz.
C.E.T.® Enzymatic Tartar Control Toothpaste - Poultry	CET101	2.5 oz.
C.E.T.® Enzymatic Tartar Control Toothpaste - Seafood	CET202	2.5 oz.
C.E.T.® Enzymatic Tartar Control Toothpaste - Vanilla-Mint	CET103	2.5 oz.
C.E.T.® Enzymatic Tartar Control Toothpaste - Trial Packet Dispenser - Poultry	CET002	0.4 oz. (25 ct.)
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - Extra Small	90612	8.4 oz.
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - Small	90614	8.5 oz.
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - Medium	90616	12.8 oz.
C.E.T.® HEXTRA® Premium Oral Hygiene Chews for Dogs - Large	90618	1.13 lb.
C.E.T.® Oral Hygiene Kit w/ 2.5 oz - Poultry	CET401	1 each
C.E.T.® Oral Hygiene Kit for Cats w// 2.5 oz - Seafood	CET402	1 each
C.E.T.® Dual-Ended Toothbrush	CET305	1 each
C.E.T.® Fingerbrush w/ 0.4 oz Trial Packet	CET301	1 each
C.E.T.® Mini-Toothbrush w/ 0.4 oz Trial Packet	CET302	1 each
C.E.T.® Cat Toothbrush w/ 0.4 oz Trial Packet	CET303	1 each
C.E.T.® Pet Toothbrush	CET304	1 each
C.E.T.® Pet Toothbrush Bulk Dispenser	CET350	24 ct.
C.E.T.® VEGGIEDENT® Flex Tartar Control Chews for Dogs - Extra Small	90085	30 ct.
C.E.T.® VEGGIEDENT® Flex Tartar Control Chews for Dogs - Small	90086	30 ct.
C.E.T.® VEGGIEDENT® Flex Tartar Control Chews for Dogs - Medium	90087	30 ct.
C.E.T.® VEGGIEDENT® Flex Tartar Control Chews for Dogs - Large	90088	30 ct.

Product Description	Product No.	Size
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - Extra Small	90055	30 ct.
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - Small	90056	30 ct.
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - Medium	90057	30 ct.
C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs - Large	90058	30 ct.
C.E.T.® VEGGIEDENT® Zen Tartar Control Chews for Dogs - Extra Small	90075	30 ct.
C.E.T.® VEGGIEDENT® Zen Tartar Control Chews for Dogs - Small	90076	30 ct.
C.E.T.® VEGGIEDENT® Zen Tartar Control Chews for Dogs - Medium	90077	30 ct.
C.E.T.® VEGGIEDENT® Zen Tartar Control Chews for Dogs - Large	90078	30 ct.
C.E.T.® INTELLIDENT® Cat Bites	90700	90 ct.
EAR HEALTH	**PAGE 22**	
EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentaminicin sulfate) Otic Suspension for Dogs	09360	10 mL
EPIOTIC® *Advanced* Ear Cleanser	003104	4 fl oz.
EPIOTIC® *Advanced* Ear Cleanser	003108	8 fl oz.
OTOMITE PLUS® Ear Miticide	601712	0.5 fl oz.
HEARTWORM	**PAGES 23-26**	
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Toy	50102	10 Boxes of 6 Doses
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Small	50104	10 Boxes of 6 Doses
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Medium	50106	10 Boxes of 6 Doses
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) - Large	50108	10 Boxes of 6 Doses
IVERHART PLUS® (ivermectin/pyrantel) *Flavored Chewables* - Small	0170DS	10 Boxes of 6 Doses
IVERHART PLUS® (ivermectin/pyrantel) *Flavored Chewables* - Medium	0170DM	10 Boxes of 6 Doses
IVERHART PLUS® (ivermectin/pyrantel) *Flavored Chewables* - Large	0170DL	10 Boxes of 6 Doses
MILBEHART™ (milbemycin oxime) Flavored Tablets - Toy	31024	10 Boxes of 6 Doses
MILBEHART™ (milbemycin oxime) Flavored Tablets - Small	31025	10 Boxes of 6 Doses
MILBEHART™ (milbemycin oxime) Flavored Tablets - Medium	31026	10 Boxes of 6 Doses
MILBEHART™ (milbemycin oxime) Flavored Tablets - Large	31027	10 Boxes of 6 Doses
PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution - 2-5 lbs	51120	10 Boxes of 3 Doses
PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution - 5.1-9 lbs	51121	10 Boxes of 3 Doses
PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution - 9.1-18 lbs	51122	10 Boxes of 3 Doses
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution - 3-9 lbs	51115	10 Boxes of 3 Doses
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution - 9.1-20 lbs	51116	10 Boxes of 3 Doses
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin)Topical Solution - 20.1-55 lbs	51117	10 Boxes of 3 Doses
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution - 55.1-88 lbs	51118	10 Boxes of 3 Doses
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution - 88.1-110 lbs	51119	5 Boxes of 3 Doses
SENERGY® (selamectin) - Kitten and Puppy	50090	10 Boxes of 3 Doses

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com. VIRBAC PRODUCT GUIDE | 5

Companion Animals

Product Description	Product No.	Size
SENERGY® (selamectin) for Cats - 5.1-15 lbs	50095	10 Boxes of 3 Doses
SENERGY® (selamectin) for Cats - 15.1-22 lbs	50097	10 Boxes of 3 Doses
SENERGY® (selamectin) for Dogs - Toy	50005	10 Boxes of 3 Doses
SENERGY® (selamectin) for Dogs - Small	50010	10 Boxes of 3 Doses
SENERGY® (selamectin) for Dogs - Medium	50020	10 Boxes of 3 Doses
SENERGY® (selamectin) for Dogs - Large	50040	10 Boxes of 3 Doses
SENERGY® (selamectin) for Dogs - X-Large	50085	10 Boxes of 3 Doses
HIP & JOINT HEALTH	**PAGE 27**	
MOVOFLEX® Advanced Soft Chews - Small	10418	60 ct.
MOVOFLEX® Advanced Soft Chews - Medium	10419	60 ct.
MOVOFLEX® Advanced Soft Chews - Large	10420	60 ct.
IN-CLINIC USE	**PAGES 28-29**	
EUTHASOL® (pentobarbital sodium and phenytoin sodium) Euthanasia Solution	710101	100 mL
STELFONTA® (tigilanol tiglate injection)	10101	2 mL
SUPRELORIN® F (deslorelin acetate) Implant - 4.7 mg	44402	2 ct.
SUPRELORIN® F (deslorelin acetate) Implant - 4.7 mg	44405	5 ct.
ZOLETIL™ for Injection (tiletamine and zolazepam for injection)	71805	100 mL
PAIN RELIEF	**PAGE 34**	
MOVODYL™ Chewable Tablets (carprofen) - 25 mg	10021	60 ct.
MOVODYL™ Chewable Tablets (carprofen) - 75 mg	10022	60 ct.
MOVODYL™ Chewable Tablets (carprofen) - 100 mg	10023	60 ct.
MOVODYL™ Chewable Tablets (carprofen) - 25 mg	10024	180 ct.
MOVODYL™ Chewable Tablets (carprofen) - 75 mg	10025	180 ct.
MOVODYL™ Chewable Tablets (carprofen) - 100 mg	10026	180 ct.
PARASITICIDES	**PAGES 35-37**	
EFFIPRO® PLUS Topical Solution for Cats	60463	10 Boxes of 3 Doses
EFFIPRO® PLUS Topical Solution for Dogs - Small	60473	10 Boxes of 3 Doses
EFFIPRO® PLUS Topical Solution for Dogs - Medium	60483	10 Boxes of 3 Doses
EFFIPRO® PLUS Topical Solution for Dogs - Large	60503	10 Boxes of 3 Doses
EFFIPRO® PLUS Topical Solution for Dogs - X-Large	60513	10 Boxes of 3 Doses
EFFITIX® PLUS Topical Solution for Dogs - Toy	60520	10 Boxes of 3 Doses
EFFITIX® PLUS Topical Solution for Dogs - Small	60522	10 Boxes of 3 Doses
EFFITIX® PLUS Topical Solution for Dogs - Medium	60524	10 Boxes of 3 Doses
EFFITIX® PLUS Topical Solution for Dogs - Large	60526	10 Boxes of 3 Doses
EFFITIX® PLUS Topical Solution for Dogs - X-Large	60528	10 Boxes of 3 Doses
KNOCKOUT® Area Treatment	612014	14 oz.
KNOCKOUT® E.S. Area Treatment	612216	16 oz.
KNOCKOUT® Room & Area Fogger	612106	6 oz.
VIRBANTEL® (pyrantel pamoate/praziquantel) Flavored Chewables - Small Dogs & Puppies	54030	50 ct.
VIRBANTEL® (pyrantel pamoate/praziquantel) Flavored Chewables - Medium & Large Dogs	51114	50 ct.

Product Description	Product No.	Size
PET NUTRITION	**PAGES 38-39**	
VETERINARY HPM® Spay & Neuter Diets:		
Canine Diets - Small & Toy - Junior	10900	3.0 lb.
Canine Diets - Small & Toy - Junior	10901	6.5 lb.
Canine Diets - Small & Toy - Adult	10902	3.0 lb.
Canine Diets - Small & Toy - Adult	10903	6.5 lb.
Canine Diets - Small & Toy - Adult	10904	15.0 lb.
Canine Diets - Large & Medium - Junior	10905	3.0 lb.
Canine Diets - Large & Medium - Junior	10914	15.0 lb.
Canine Diets - Large & Medium - Junior	10906	26.0 lb.
Canine Diets - Large & Medium - Adult	10907	3.0 lb.
Canine Diets - Large & Medium - Adult	10915	15.0 lb.
Canine Diets - Large & Medium - Adult	10908	26.0 lb.
Feline Diets - Junior	10909	3.0 lb.
Feline Diets - Junior	10910	6.5 lb.
Feline Diets - Adult	10911	3.0 lb.
Feline Diets - Adult	10912	6.5 lb.
Feline Diets - Adult	10913	15.0 lb.
SKIN HEALTH	**PAGES 40-43**	
ALLERDERM® Foaming Cleanser	13500	6.76 oz.
ALLERDERM OMEGADERM® Essential Fatty Acids Supplement	14149	4 mL (28 ct.)
ALLERDERM OMEGADERM® Essential Fatty Acids Supplement	14186	8 mL (28 ct.)
ALLERGROOM® Shampoo	12208	8 fl oz.
ALLERGROOM® Shampoo	12216	16 fl oz.
ALLERMYL® (Piroctone Olamine) Medicated Shampoo	002409	8 fl oz.
ALLERMYL® (Piroctone Olamine) Medicated Shampoo	002417	16 fl oz.
CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED 100 mg/mL	20301	15 mL
CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED 100 mg/mL	20303	50 mL
EPI-SOOTHE® Cream Rinse	001808	8 fl oz.
EPI-SOOTHE® Cream Rinse	001816	16 fl oz.
EPI-SOOTHE® Shampoo	11708	8 fl oz.
EPI-SOOTHE® Shampoo	11716	16 fl oz.
GENESIS® Topical Spray (0.015% triamcinolone acetonide)	410508	8 fl oz.
GENESIS® Topical Spray (0.015% triamcinolone acetonide)	410500	16 fl oz.
ITRAFUNGOL® (itraconazole oral solution) 10 mg/mL	11605	52 mL
KERATOLUX® (Piroctone Olamine) Medicated Shampoo	002009	8 fl oz.
KERATOLUX® (Piroctone Olamine) Medicated Shampoo	002017	16 fl oz.
KETOCHLOR® (Chlorhexidine Gluconate, Ketoconazole) Medicated Shampoo	002908	8 fl oz.
KETOCHLOR® (Chlorhexidine Gluconate, Ketoconazole) Medicated Shampoo	002916	16 fl oz.
SUPPLEMENTS	**PAGE 44**	
REBOUND® Recuperation Formula for Cats	10851	5.1 fl oz.
REBOUND® Recuperation Formula for Dogs	10850	5.1 fl oz.
TUMIL-K® (potassium gluconate) Powder	846004	4 oz.
TUMIL-K® (potassium gluconate) Tablets	845100	100 ct.
VETASYL® Fiber Capsules - 500 mg	VF410	100 ct.

Continues next page >>

INTRODUCING OUR

LIVESTOCK HEALTH PRODUCTS

NEW!

Product Description	Product No.	Size
LIVESTOCK HEALTH	**PAGES**	**30-33**
Tenotryl™ (enrofloxacin) injectable solution - 100 mL bottle	66716	20 bottles/case
Tenotryl™ (enrofloxacin) injectable solution - 250 mL bottle	66717	15 bottles/case
Tenotryl™ (enrofloxacin) injectable solution - 500 mL bottle	66718	6 bottles/case
TIA™ 12.5% (tiamulin hydrogen fumarate) liquid concentrate - 1 L bottle	92601	15 bottles/case
TULISSIN® 100 (tulathromycin injection) injectable solution - 50 mL bottle	66703	48 bottles/case
TULISSIN® 100 (tulathromycin injection) injectable solution - 100 mL bottle	66704	20 bottles/case
TULISSIN® 100 (tulathromycin injection) injectable solution - 250 mL bottle	66705	12 bottles/case
TULISSIN® 100 (tulathromycin injection) injectable solution - 500 mL bottle	66706	6 bottles/case
TULISSIN® 25 (tulathromycin injection) injectable solution - 100 mL bottle	66701	20 bottles/case
TULISSIN® 25 (tulathromycin injection) injectable solution - 250 mL bottle	66702	15 bottles/case

TAILORED NUTRITION FOR SPAYED & NEUTERED PETS

VETERINARY HPM® PET NUTRITION

Spaying and neutering cause physiologic changes that can lead to a 2-3X increase in risk for obesity.[1,2] **VETERINARY HPM®** Spay & Neuter Diets are tailored to the unique needs of spayed and neutered pets and are specifically formulated to help pets maintain body condition.

NUTRITIONAL SUPPORT FOR:

- Appetite Control
- Healthy Metabolism
- Healthy Muscles
- Healthy Digestion
- Healthy Skin & Coat
- Healthy Body Condition

iVet® — BY VIRBAC® —

Veterinary Exclusive Wellness Nutrition
Register Your Clinic and Order Today
Visit iVet.com/vets/orderHPM

1. Lefebvre SL, Yang M, Wang M, Elliott DA, Buff PR, Lund EM. Effect of age at gonadectomy on the probability of dogs becoming overweight. J Am Vet Med Assoc. 2013;243(2):236-243. doi:10.2460/javma.243.2.236.
2. Nguyen PG, Dumon HJ, Siliart BS, Martin LJ, Sergheraert R, Biourge VC. Effects of dietary fat and energy on body weight and composition after gonadectomy in cats. Am J Vet Res. 2004;65(12):1708-13. doi:10.2460/ajvr.2004.65.1708.

Virbac Shaping the future of animal health

Advance your recommendation **for hip & joint support**

New MOVOFLEX® Advanced Soft Chews support overall hip and joint structure and flexibility. Mobility improvement can be seen in as little as 7 days.[1]

Advanced ingredients

Two additional ingredients strengthen the formula's effectiveness:

Krill oil
Contains omega-3 fatty acids in a form bound to phospholipids, helping improve the absorption capabilities of astaxanthin and hyaluronic acid[2,3]

Low molecular weight hyaluronic acid
Supports joint health in combination with krill oil and astaxanthin[4,5]

Pet owner perceptions

A 30-day trial[1] of MOVOFLEX Advanced Soft Chews assessed the perceptions of pet owners currently administering the original formulation to their dogs.

90% said they would purchase if recommended by a veterinarian

63% recognized an improvement in their dog's mobility compared with the original MOVOFLEX Soft Chews

SMALL DOGS (<40 lb) | MEDIUM DOGS (40–80 lb) | LARGE DOGS (>80 lb)

everyday **CARE**

Warnings: Not for human consumption. Keep out of the reach of children and animals. In case of accidental overdose, contact a health professional immediately.

Cautions: If animal's condition worsens or does not improve, stop product administration and consult your veterinarian. Safe use in pregnant animals or animals intended for breeding has not been proven.

References: 1. Data on file. Virbac Corporation. 2. Mercke Odeberg J, Lignell A, Pettersson A, Höglund P. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci. 2003;19(4):299-304. doi: 10.1016/s0928-0987(03)00135-0. 3. Huang SL, Ling PX, Zhang TM. Oral absorption of hyaluronic acid and phospholipids complexes in rats. World J Gastroenterol. 2007;13(6):945-949. doi: 10.3748/wjg.v13.i6.945. 4. Park DR, Ko R, Kwon SH, et al. FlexPro MD, a mixture of krill oil, astaxanthin, and hyaluronic acid, suppresses lipopolysaccharide-induced inflammatory cytokine production through inhibition of NF-κB. J Med Food. 2016;19(12):1196-1203. doi: 10.1089/jmf.2016.3787. 5. Park MH, Jung JC, Hill S, et al. FlexPro MD®, a combination of krill oil, astaxanthin and hyaluronic acid, reduces pain behavior and inhibits inflammatory response in monosodium iodoacetate-induced osteoarthritis in rats. Nutrients. 2020;12(4):956. doi: 10.3390/nu12040956.

MOVOFLEX®
ADVANCED SOFT CHEWS

Scan code for more information. Talk with your distributor/Virbac representative or call 1-844-484-7222.

ECO FRIENDLY PACKAGING | QUALITY SEAL nasc NATIONAL ANIMAL SUPPLEMENT COUNCIL | Virbac | Shaping the future of animal health

STELFONTA®
(tigilanol tiglate injection)

THE OPTION PET OWNERS PREFER[1]

See for yourself why veterinarians and pet owners are choosing STELFONTA® (tigilanol tiglate injection) to treat mast cell tumors (MCTs).

STELFONTA "SEEING IS BELIEVING" SURVEY[1]

Wound healing via second intention with minimal intervention*

STELFONTA promotes complete healing of the wound site, typically with minimal intervention and minimal scarring.[2] In most cases, pet owners didn't have to worry about changing bandages or confining their dogs in Elizabethan collars.

77% of pet owners reported that STELFONTA removed their dog's tumors by day 28.[1]



Ensure that all concomitant medications are administered as required, and consider appropriate pain control.

**Minimal intervention: Antibiotics, bandages and e-collars aren't usually required.*

STELFONTA® (tigilanol tiglate injection) HELPS PETS AND THEIR OWNERS RETURN TO THE ACTIVITIES THEY LOVE.

Meet Olga & Lila

My experience was really good. If there was anything weird, I would ask, and my veterinarian would tell me if it was normal or not. It was really fast and was almost like it was melting away or consuming itself. And even though we talked about everything, I wasn't quite prepared for it to fall off!



10-year-old mutt Lila had a nonmetastatic MCT that was successfully treated with STELFONTA.

Treatment with STELFONTA has been associated with cellulitis and severe tissue sloughing extending away from the treated site, resulting in extensive wounds that require additional treatment and prolonged recovery time.

Meet Ally and Dixie

My husband did some research and learned about STELFONTA. We ended up finding a different veterinarian who was willing to try it. Dixie went through the procedure beautifully without sedation.

Dixie was diagnosed with a mast cell tumor when she was 7 years old. Due to the location, her veterinarian did not think they could operate and achieve the necessary margins — alternative options were radiation therapy or amputation of the limb.

To decrease the risk of accidental self-injection, sedation of the dog may be necessary.

See what a difference STELFONTA makes while earning CE credits.
View the e-learning modules at https://vet-us.virbac.com/stelfonta or scan here.

To place an order, contact your Virbac representative or call 1-844-4-VIRBAC (1-844-484-7222).
See package insert at the end of the Product Guide for full product information.

For case consultation, contact our Product Safety and Consulting Team at 1-800-338-3659 Option 1. Visit https://vet.us.virbac.com/stelfonta for more information.

References: 1. Data on file. Virbac Corporation. **2.** Reddell P, De Ridder TR, Morton JM, et al. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. *J Vet Intern Med.* 2021;35(1):430–441. doi:10.1111/jvim.16009 **3.** US STELFONTA packaging insert. [2020]

Virbac
Shaping the future of animal health

CLINTABS® brand of clindamycin hydrochloride tablets, USP

- Easy-to-swallow tablet form
- A bacteriostatic antibiotic indicated for the treatment of susceptible dental and skin infections (wounds and abscesses) and osteomyelitis for dogs only

Available in:
25 mg (400 tablets) SKU 902540
75 mg (200 tablets) SKU 907520
150 mg (100 tablets) SKU 915010

Important Safety Information
CLINTABS® brand of clindamycin hydrochloride tablets, USP: Keep out of reach of children. Not for human use. Contraindicated in animals with a history of hypersensitivity to clindamycin or lincomycin. Do not use in rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals. Use with caution in patients with very severe kidney or liver disease and in animals receiving neuromuscular blocking agents such as succinylcholine. Safety in pregnant females or breeding males has not been established. Monitor blood work in animals on either high dose or prolonged therapy. Side effects occasionally observed include vomiting and diarrhea.

See package insert at the end of the Product Guide for full product information.

RILEXINE® (cephalexin tablets) Chewable Tablets

The first and only veterinary-approved cephalexin indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of *S. pseudintermedius*.

- Proven palatability means at-home dosing is easy for your clients
- Tablets available in three sizes and scored for precise dosing

Available in scored, flavored chewable tablets:
150 mg (100 count) SKU 07620
300 mg (100 count) SKU 07630
600 mg (100 count) SKU 07640

Important Safety Information
RILEXINE® (cephalexin tablets) Chewable Tablets: For oral use in dogs only. People with sensitivities to penicillins or cephalosporins should avoid contact with this product. RILEXINE Chewable Tablets are very palatable for pets and should be stored in a secure location where pets cannot access them. Do not give to dogs with known allergy to penicillins or cephalosporins. Safety in pregnant females or breeding males has not been established. The most common adverse reactions in dogs include diarrhea, vomiting, anorexia and lethargy.

See package insert at the end of the Product Guide for full product information.

NEW FOR DOGS ZENIDOG® Gel Diffuser

- Contains an analogue of a dog-appeasing pheromone emitted by nursing mother dogs which helps manage stress-related signs and behaviors in dogs
- Lasts up to two months (twice as long as the main competitor)
- Eco-friendly: No electricity required and packaged in a recyclable box
- Effective in rooms up to 750 square feet and fully portable
- Discreet appearance and no perceptible odor to humans

Available in:
8.1 oz SKU 10514

NEW FOR DOGS ZENIDOG® Long-Acting Collar

- Contains an analogue of a dog-appeasing pheromone emitted by nursing mother dogs which helps manage stress-related signs and behaviors in dogs
- Lasts up to three months (three times as long as the main competitor)
- Eco-friendly: Less waste with fewer collars per year, and packaged in a recyclable box
- Fully adjustable, with one size for puppies/small dogs up to 22 lbs, and one for medium/large dogs 22.1-110 lbs
- Unobtrusive and stylish
- Not recommended for use with hyperactive or aggressive dogs

Available in:
18.3 in. collar (puppies/small dogs up to 22 lbs) SKU 10512
29.5 in. collar (medium/large dogs 22.1-110 lbs) SKU 10513

CLOMICALM® (clomipramine hydrochloride) tablets

- Effective treatment for canine separation anxiety as part of a behavioral management program for use in dogs greater than 6 months of age
- Clomipramine hydrochloride, the active ingredient in CLOMICALM tablets, binds to the serotonin uptake receptor and prevents the removal of excess serotonin; increases positive neural signaling in the brain
- Artificial beef flavoring
- Scored tablet

Available in 30-count bottles:
5 mg (one tablet) for dogs 2.75-5.5 lbs SKU 10506
20 mg (one tablet) for dogs 11-22 lbs SKU 10507
80 mg (one tablet) for dogs 44.1-88 lbs SKU 10508

Important Safety Information
CLOMICALM® (clomipramine hydrochloride) tablets: For use in dogs only. Keep out of reach of children. In children, accidental ingestion should be regarded as serious. Do not administer to dogs with hypersensitivity to clomipramine or other tricyclic antidepressants. CLOMICALM tablets should not be used in: 1) male breeding dogs; 2) combination or within 14 days before or after treatment with a monoamine oxidase inhibitor; 3) dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold. CLOMICALM tablets are not recommended for other behavior problems such as aggression. Effectiveness and clinical safety for long-term use (i.e., for >12 weeks) has not been evaluated. To reduce the incidence of vomiting that may be experienced by some dogs, CLOMICALM tablets may be given with a small amount of food.

See package insert at the end of the Product Guide for full product information.

ANXITANE® (L-Theanine) Chewable Tablets

- Supplement for dogs and cats for anxious behavior
- Promotes relaxation in cats and dogs exhibiting nervousness, responding to environmentally induced stress or are anxious without causing drowsiness or sedation
- Containing a pure synthetic form of L-Theanine, an amino acid naturally found in green tea leaves
- ANXITANE Chewable Tablets are a palatable option that both cats and dogs will enjoy
- Not intended for use in animals with severe phobias, separation anxiety or in animals with a known history of aggression

Available in 30-count box:
Small (dogs and cats up to 22 lbs); 50 mg tablets SKU 10432
Medium/Large (dogs > 22 lbs); 100 mg tablets SKU 10435

C.E.T. ® VEGGIEDENT® DENTAL CHEWS

C.E.T.® VEGGIEDENT® FR3SH® Tartar Control Chews for Dogs

- Multifunctional dental chew to support digestive health
- Made with FR3SH® Technology that delivers fresh breath and more
- Just one chew per day reduces tartar and plaque
- Highly palatable
- Unique Z-shape allows the chew to reach front to back
- Supports at-home dental care between professional cleanings

Available in 30 chews per bag:
Extra Small: < 11 lbs SKU 90055
Small: 11-22 lbs SKU 90056
Medium: 22-60 lbs SKU 90057
Large: > 60 lbs SKU 90058

Available in single chew displays:
Extra Small: 45 Single Ct. SKU 90015
Small: 30 Single Ct. SKU 90016
Medium: 28 Single Ct. SKU 90017
Large: 24 Single Ct. SKU 90018

C.E.T.® VEGGIEDENT® Flex Tartar Control Chews for Dogs

- Multifunctional dental chew to support joint health
- Made with FR3SH® Technology that delivers fresh breath and more
- Formulated with BIOVAFLEX® eggshell membrane
- Just one chew per day reduces tartar and plaque
- Highly palatable
- Unique Z-shape allows the chew to reach front to back
- Supports at-home dental care between professional cleanings

Available in 30 chews per bag:
Extra Small: < 11 lbs SKU 90085
Small: 11-22 lbs SKU 90086
Medium: 22-60 lbs SKU 90087
Large: > 60 lbs SKU 90088

C.E.T.® VEGGIEDENT® Zen Tartar Control Chews for Dogs

- Multifunctional dental chew to support mental well-being
- Made with FR3SH® Technology that delivers fresh breath and more
- Formulated with L-Theanine
- Just one chew per day reduces tartar and plaque
- Highly palatable
- Unique Z-shape allows the chew to reach front to back
- Supports at-home dental care between professional cleanings

Available in 30 chews per bag:
Extra Small: < 11 lbs SKU 90075
Small: 11-22 lbs SKU 90076
Medium: 22-60 lbs SKU 90077
Large: > 60 lbs SKU 90078

DENTAL HEALTH

CHEWS AND SOLUTIONS

C.E.T.® INTELLIDENT® Cat Bites

- Freshens breath by working with cat's natural chewing action to help reduce plaque and tartar
- Results shown with only 3 bites per day
- Crunchy porous texture to provide an effective clean

Available in:
90 bites per bag SKU 90700

C.E.T. AQUADENT® FR3SH® Dental Solution

- Daily water additive to fight the source of bad breath
- Supports healthy teeth and gums by controlling plaque in dogs and cats
- Combination of 3 natural ingredients:
  - Erythritol: a natural sweetener, has a freshening effect in mouth
  - Inulin: a natural prebiotic to help control bad breath
  - Pomegranate Extract: a natural antioxidant
- For use in dogs and cats

Available in:
8.45 fl oz (250 mL) SKU 90508
16.9 fl oz (500 mL) SKU 90516

C.E.T.® Enzymatic Oral Hygiene Chews for Dogs

- Features an exclusive Dual-Enzyme System, plus an abrasive texture that works with the dog's chewing action to remove tartar and provide plaque control
- Contains single layer beef hide for a natural abrasive cleansing action
- Appealing poultry flavor

Available in:
Extra Small: < 11 lbs, 8.4 oz SKU 90601
Small: 11-25 lbs, 8.5 oz SKU 90603
Medium: 26-50 lbs, 12.8 oz SKU 90605
Large: > 50 lbs, 1.13 lbs SKU 90607

C.E.T.® HEXtra® Premium Oral Hygiene Chews for Dogs

- Natural rawhide coated with solution of Chlorhexidine that helps reduce plaque and tartar
- Contains single layer beef hide for a natural abrasive cleansing action
- Appealing poultry flavor
- Chew size and thickness may vary

Available in:
Extra Small: < 11 lbs, 8..4 oz SKU 90612
Small: 11-25 lbs, 8.5 oz SKU 90614
Medium: 26-50 lbs, 12.8 oz SKU 90616
Large: > 50 lbs, 1.13 lbs SKU 90618

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

TOOTHPASTES, TOOTHBRUSHES AND KITS

C.E.T.® Enzymatic Tartar Control Toothpaste

- Formulated using an enzyme system to reduce plaque, freshen breath and ensure a clean mouth
- No foaming agents, so it is safe for pets to swallow
- Available in 5 flavors: Beef, Malt, Poultry, Seafood, Vanilla-Mint
- For use in dogs and cats

Available in:
2.5 oz (70 g) tube – Beef SKU CET201
2.5 oz (70 g) tube – Malt SKU CET102
2.5 oz (70 g) tube – Poultry SKU CET101
2.5 oz (70 g) tube – Seafood SKU CET 202
2.5 oz (70 g) tube – Vanilla-Mint SKU CET103
Poultry flavor is also available in 0.4 oz (12 g) trial-size packets in a 25-count dispenser SKU CET002

C.E.T.® Pet Toothbrush

- Soft bristles for pet comfort and acceptance
- Small end with reverse angle allows for easy application
- Individually packaged, assorted colors
- Available individually or in a 24 ct. dispenser

C.E.T. Pet Toothbrush SKU CET304
C.E.T. Pet Toothbrush Bulk Dispenser SKU CET350

C.E.T.® Dual-Ended Toothbrush

- Long handle with reverse angle allows for easy application
- Tapered end conforms to pet's mouth and teeth
- Dual-ended for large and small tooth surfaces
- Soft bristles assure a gentle, well-tolerated application
- Individually packaged, assorted colors

C.E.T. Dual-Ended Toothbrush SKU CET305

C.E.T.® Mini-Toothbrush

- Soft bristles for pet comfort and acceptance
- Small end and fingertip design allow for easy access
- Also contains a 0.4 oz (12 g) trial-size packet of poultry-flavored toothpaste

C.E.T. Mini-Toothbrush w/ 0.4 oz Trial Packet SKU CET302

C.E.T.® Cat Toothbrush

- Soft, gentle, easy to use
- Long, soft bristles with a pointed tuft
- Unique shape is designed for the limited confines of the feline mouth
- Also contains a 0.4 oz (12 g) trial-size packet of poultry-flavored toothpaste

C.E.T. Cat Toothbrush w/ 0.4 oz Trial Packet SKU CET303

DENTAL HEALTH

C.E.T.® Fingerbrush

- Ideal beginner toothbrush to help acquaint dogs, cats and their owners with the toothbrushing experience
- Convenient design and excellent pet acceptance
- Made of durable, dishwasher-safe material
- Helps remove plaque from tooth surface
- Massages and strengthens gums
- Also contains a 0.4 oz (12 g) trial-size packet of poultry-flavored toothpaste

C.E.T. Fingerbrush w/ 0.4 oz Trial Packet SKU CET301

C.E.T.® Oral Hygiene Kit for Cats

- Contains:
  – C.E.T.® Enzymatic Tartar Control Toothpaste
  – C.E.T.® Fingerbrush
  – C.E.T.® Cat Toothbrush

Oral Hygiene Kit for Cats, Seafood-flavor Toothpaste 2.5 oz (70 g) SKU CET402

C.E.T.® Cat Toothbrush with 0.4 oz (12 g) Trial Packet

- Contains:
  – C.E.T.® Cat Toothbrush
  – C.E.T.® Enzymatic Tartar Control Toothpaste

Cat Toothbrush with 0.4 oz (12 g) Trial Packet SKU CET303

C.E.T.® Fingerbrush with 0.4 oz (12 g) Trial Packet

- Contains:
  – C.E.T.® Fingerbrush
  – C.E.T.® Enzymatic Tartar Control Toothpaste

Fingerbrush with 0.4 oz (12 g) Trial Packet SKU CET301

C.E.T.® Oral Hygiene Kit for Dogs

- Contains:
  – C.E.T.® Enzymatic Tartar Control Toothpaste
  – C.E.T.® Fingerbrush
  – C.E.T.® Dual-Ended Toothbrush

Oral Hygiene Kit for Dogs, Poultry-flavor Toothpaste 2.5 oz (70 g) SKU CET401

C.E.T.® Mini-Toothbrush with 0.4 oz (12 g) Trial Packet

- Contains:
  – C.E.T.® Mini-Toothbrush
  – C.E.T.® Enzymatic Tartar Control Toothpaste

Mini-Toothbrush with 0.4 oz (12 g) Trial Packet SKU CET302

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs

- Fast, effective, innovative and easy[1]
- Proven results for the treatment of canine otitis externa
- Unique anti-inflammatory, hydrocortisone aceponate (HCA) is a new-generation di-ester steroid with a favorable benefit/risk ratio
- Contains proven effective antimicrobial and antifungal agents
- Features an ergonomically designed applicator
- Shown to provide sustained treatment of otitis externa with 5 once-a-day doses
- For use in dogs only
- Active ingredients:
  – Hydrocortisone aceponate (1.11 mg/mL)
  – Miconazole nitrate (17.4 mg/mL)
  – Gentamicin sulfate (1.5 mg/mL)

Available in:
10 mL (10 doses) SKU 09360

Important Safety Information
EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs: For otic (ear) use in dogs only. Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product. Contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or amino-glycoside antibiotics. Do not use in dogs with known tympanic membrane (ear drum) perforation. The safe use of EASOTIC Otic Suspension in dogs used for breeding purposes has not been evaluated. Do not administer orally.

See package insert at the end of the Product Guide for full product information.

1 Boda C, Liege P, Rème C. Evaluation of owner compliance with topical treatment of acute otitis externa in dogs: a comparative study of two auricular formulations. Intern J Appl Res Vet Med. 2011;9(2):157-165.

EPIOTIC® *Advanced* Ear Cleanser

Ideal for supporting ear health in cats and dogs, particularly those predisposed to otitis externa. This includes:
  – Allergic/atopic animals
  – Frequent swimmers
  – Those with floppy ear anatomy, creating an environment that can encourage microbial overgrowth
- Cleans gently and powerfully with pH-neutral, low-alcohol, non-stinging, non-irritating formula
- Can be used daily or 2-3 times per week
- Limits the bonding of microorganisms to the ear canal surface
- Facilitates the removal of cellular debris and excessive aural exudate
- Provides a drying effect
- Keeps ears smelling fresh

Available in:
4 fl oz (118 mL) SKU 003104
8 fl oz (237 mL) SKU 003108

OTOMITE PLUS® Ear Miticide

- For treatment of ear mites in dogs, cats, puppies and kittens over 12 weeks of age
- Contains pyrethrins with two synergist ingredients:
  — Piperonyl butoxide
  — n-Octyl bicycloheptene dicarboximide
- Soothing olive oil base facilitates the dispersal and penetration
- Active ingredients:
  – 0.15% Pyrethrins
  – 1.50% Piperonyl Butoxide
  – 0.48% n-Octyl bicycloheptene dicarboximide

Available in:
0.5 fl oz (14.7 mL) SKU 601712

IVERHART MAX® Chew (ivermectin/ pyrantel pamoate/praziquantel)

- Prevents heartworm disease
- Treats and controls roundworms, hookworms and tapeworms
- Satisfaction guaranteed
- Administer once a month, year-round
- Bacon-flavored
- Recommended for dogs 8 weeks of age or older

Available in four sizes, depending on the dog's weight:
Toy: 6-12 lbs SKU 50102
Small: 12.1-25 lbs SKU 50104
Medium: 25.1-50 lbs SKU 50106
Large: 50.1-100 lbs SKU 50108
For dogs over 100 lbs, use the appropriate combination of these chews.
6-dose card display box / 10 cards per display (60 doses)

Important Safety Information
IVERHART MAX® Chew (ivermectin/pyrantel pamoate/praziquantel) is well tolerated. All dogs should be tested for heartworm disease before starting a preventive protocol. Following the use of IVERHART MAX Chew, gastrointestinal and neurological side effects have been reported.

See package insert at the end of the Product Guide for full product information.

IVERHART PLUS® (ivermectin/ pyrantel) *Flavored Chewables*

- Prevents heartworm disease
- Treats and controls roundworm and hookworm infections in dogs
- Satisfaction guaranteed
- Administer once a month, year-round
- Pork liver-flavored
- Recommended for dogs 6 weeks of age and older

Available in three sizes, depending on the dog's weight:
Small: < 25 lbs SKU 0170DS
Medium: 26-50 lbs SKU 0170DM
Large: 51-100 lbs SKU 0170DL
For dogs over 100 lbs, use the appropriate combination of these chews.
6-dose card display box / 10 cards per display (60 doses)

Important Safety Information
IVERHART PLUS® (ivermectin/pyrantel) *Flavored Chewables* is well tolerated. All dogs should be tested for heartworm disease before starting a preventive protocol. There are rare reports of digestive or neurological side effects following use of *IVERHART* PLUS *Flavored Chewables*.

See package insert at the end of the Product Guide for full product information.

PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution

- Prevents heartworm disease
- Treatment of *Dirofilaria immitis circulating microfilariae* in heartworm positive dogs
- Kills adult fleas and is indicated for the treatment of flea infestations
- Treatment and control of sarcoptic mange
- Treatment and control of hookworms, roundworms and whipworms
- Administer once a month year-round
- The safe use has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs body weight.
- Topical Application
- Satisfaction guaranteed

Available in five sizes depending on dog's weight:
Toy: Dogs 3-9 lbs SKU 51115
Small: Dogs 9.1-20 lbs SKU 51116
Medium: Dogs 20.1-55 lbs SKU 51117
Large: Dogs 55.1-88 lbs SKU 51118
3-dose card display box / 10 cards per display (30 doses)
X-Large: Dogs 88.1-110 lbs SKU 51119
3-dose card display box / 5 cards per display (15 doses)

Important Safety Information
PARASEDGE® Multi for Dogs (imidacloprid + moxidectin) Topical Solution: Children should not come in contact with the application site for two (2) hours after application. Wash hands after use. Do not use this product on cats. DO NOT ADMINISTER THIS PRODUCT ORALLY. Do not use on puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight. Ensure that dogs cannot lick the product on themselves or other treated pets for 30 minutes after application. Use with caution on sick, debilitated, or underweight dogs. Safety in breeding, pregnant, or lactating dogs has not been established.

See package insert at the end of the Product Guide for full product information.

PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution

- Prevents heartworm disease
- Kills adult fleas and is indicated for the treatment of flea infestations
- Treatment and control of ear mite infestations
- Treatment and control of hookworms and roundworms
- Administer once a month year-round
- Do not use in cats less than 9 weeks of age or less than 2 lbs.
- Topical Application
- Satisfaction guaranteed

Available in three sizes depending on cat's weight:
Cats 2-5 lbs SKU 51120
Cats 5.1-9 lbs SKU 51121
Cats 9.1-18 lbs SKU 51122
3-dose card display box / 10 cards per display (30 doses)

Important Safety Information
PARASEDGE® Multi for Cats (imidacloprid + moxidectin) Topical Solution: Children should not come in contact with the application site for 30 minutes after application. Wash hands after use. DO NOT ADMINISTER THIS PRODUCT ORALLY. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not use on sick, debilitated, or underweight cats. Evaluation in geriatric cats with subclinical conditions, and safety in breeding, pregnant, or lactating cats has not been established.

See package insert at the end of the Product Guide for full product information.

MILBEHART™ (milbemycin oxime) Flavored Tablets

- Prevents heartworm disease
- Controls adult hookworm infection in dogs
- Removes and controls adult roundworms and whipworms in dogs and puppies
- Removes adult hookworms and roundworms in cats and kittens
- Administer once a month, year-round
- Meat-flavored (no animal protein)
- Do not use in puppies less than four weeks of age or less than two pounds of body weight; do not use in kittens less than six weeks of age or less than 1.5 pounds of body weight
- Satisfaction guaranteed

Available in four sizes, depending on the dog's or cat's weight:
Toy: Dogs 2-10 lbs SKU 31024
Small: Dogs 11-25 lbs / Cats 1.5-6 lbs SKU 31025
Medium: Dogs 26-50 lbs / Cats 6.1-12 lbs SKU 31026
Large: Dogs 51-100 lbs / Cats 12.1-25 lbs SKU 31027
For dogs over 100 lbs, use the appropriate combination of these chews.
6-dose card display box / 10 cards per display (60 doses)

Important Safety Information
MILBEHART™ (milbemycin oxime) Flavored Tablets is well tolerated in dogs and cats. Dogs should be tested for heartworm prior to use. In a small percentage of treated dogs, digestive and neurologic side effects may occur. Safety in heartworm positive cats has not been established. Safety in breeding, pregnant, and lactating queens and breeding toms has not been established.

See package insert at the end of the Product Guide for full product information.

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.
For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

SENERGY® (selamectin) for Cats and Dogs

Indications:

- Kills adult fleas
- Prevention and control of flea infestations
- Prevention of heartworm disease
- Treatment and control of ear mites
- Treatment and control of hookworms and roundworms (cats only)
- Treatment and control of sarcoptic mange and control of tick infestations (dogs only)
- Topical application
- Administer once a month, year-round
- Quick drying

Available in eight sizes, depending on the dog's or cat's weight:
Kitten (at least 8 weeks old) and Puppy (at least 6 weeks old):
Cats and Dogs: Up to 5 lbs SKU 50090
Cats: 5.1-15 lbs SKU 50095
Cats: 15.1-22 lbs SKU 50097
Dogs, Toy: 5.1-10 lbs SKU 50005
Dogs, Small: 10.1-20 lbs SKU 50010
Dogs, Medium: 20.1-40 lbs SKU 50020
Dogs, Large: 40.1-85 lbs SKU 50040
Dogs, X-Large: 85.1-130 lbs SKU 50085
3-dose card display box / 10 cards per display (30 doses)

Important Safety Information
SENERGY® (selamectin) may be irritating to the skin and eyes for people. Wash hands after use. Do not use in sick, debilitated or underweight animals. All dogs should be tested for heartworm disease before starting a preventive protocol. Use only on cats that are at least 8 weeks old and dogs that are at least 6 weeks old.

See package insert at the end of the Product Guide for full product information.

NEW FOR DOGS

MOVOFLEX® Advanced Soft Chews

QUALITY SEAL nasc NATIONAL ANIMAL SUPPLEMENT COUNCIL

- Supplement designed to support dogs' short- and long-term mobility, flexibility and joint function for optimal joint health
- A NEW complex balance of ingredients with synergistic functions, in addition to other trusted ingredients:
  - Krill oil, providing omega-3 fatty acids to help lubricate joints
  - Low molecular weight hyaluronic acid, shown to support joint health
- No loading dose required for these tasty chicken-flavored chews
- For use in dogs
- NASC quality seal
- Eco-friendly packaging
- Made in the USA, including U.S. and globally sourced ingredients

Available in 60-count bottles:
Small: Up to 40 lbs (120 g / 4.2 oz) SKU 10418
Medium: 40-80 lbs (240 g / 8.5 oz) SKU 10419
Large: Over 80 lbs (360 g / 12.7 oz) SKU 104120

SUPRELORIN® F (deslorelin acetate) implant

- For the management of adrenal gland cortical disease (ACD) in the male and female domestic ferret
- Reduces clinical signs of ACD with a return to normalcy in 2-8 weeks[1-2]
- 4.7 mg dose implant has been shown to be well tolerated with clinical monitoring[1]

Available in:
2-count SKU 44402
5-count SKU 44405

Important Safety Information
SUPRELORIN® F (deslorelin acetate) Implant: For use in ferrets only. DO NOT HANDLE THIS PRODUCT IF YOU ARE PREGNANT OR NURSING OR SUSPECT YOU MAY BE PREGNANT. Accidental administration in humans may lead to disruption of the menstrual cycle. Do not use in animals intended for breeding. The safe use of this product has not been evaluated in pregnant or lactating ferrets. Do not use this product in ferrets with known hypersensitivity to deslorelin acetate or other synthetic hormones.

See package insert at the end of the Product Guide for full product information.

1. Wagner RA, Piché CA, Jöchle W, Oliver JW. Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease. *Am J Vet Res*. 2005;66(5):910–914. doi:10.2460/ajvr.2005.66.910.
2. Wagner RA, Finkler MR, Fecteau KA, Trigg TE. The treatment of adrenal cortical disease in ferrets with 4.7 mg deslorelin acetate implants. *J Exotic Pet Med*. 2009;18(2):146–152. doi:10.1053/j.jepm.2008.11.003.

STELFONTA® (tigilanol tiglate injection)

Treat mast cell tumors (MCTs) with a single intratumoral injection, without surgery or anesthesia. STELFONTA injection is indicated for use in dogs for the treatment of nonmetastatic mast cell tumors all over the body, and nonmetastatic subcutaneous mast cells located at or distal to the elbow or the hock.

- Destroys 75% of the MCTs with one treatment and 87% with one or two injections[3]
- Tumor sites typically healed within 28 days with minimal intervention[3]

Available in:
2 mL vial SKU 10101

Important Safety Information
Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising, and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation.

See package insert at the end of the Product Guide for full product information.

For more product information scan the QR code.

3. DeRidder TR, Campbell JE, Burke-Schwarz C, et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). *J Vet Intern Med*. 2021;35(1):415–429. doi: 10.1111/jvim.15806 doi:10.1111/jvim.15806.

IN-CLINIC USE

EUTHASOL® (pentobarbital sodium and phenytoin sodium) Euthanasia Solution

- Intravenous solution for humane, painless and rapid euthanasia
- For dogs only

Available in:
100 mL multiple dose vials SKU 710101

Important Safety Information
EUTHASOL® (pentobarbital sodium and phenytoin sodium) Euthanasia Solution: WARNING: Keep out of reach of children. If eye contact, flush with water and seek medical advice/attention. CAUTION: Caution should be exercised to avoid contact of the drug with open wounds or accidental self-inflicted injections. For canine euthanasia only. Must not be used for therapeutic purposes. Do not use in animals intended for food. Euthanasia may be delayed in dogs with severe cardiac or circulatory deficiencies.

ENVIRONMENTAL HAZARD: This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with state and local laws, to prevent consumption of carcass material by scavenging wildlife. For full prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

See full prescribing information at the end of the Product Guide for complete boxed warning.

ZOLETIL® for Injection (tiletamine and zolazepam for injection)

- Nonnarcotic, nonbarbiturate, injectable anesthetic agent for dogs and cats
- Intramuscular and intravenous injection in dogs
- Intramuscular injection only in cats

Available in:
5 mL SKU 71805

Important Safety Information
Zoletil™ for Injection should not be used 1) in dogs and cats with severe cardiac or pulmonary dysfunction, or pancreatic disease 2) at any stage of pregnancy or for Cesarean section, 3) in cats suffering from renal insufficiency 4) with phenothiazine-derivative drugs as the combination produces respiratory and myocardial depression, hypotension, and hypothermia. Pulmonary edema has been reported in cats. Respiratory depression may occur following administration of high doses. Copious salivation that may occur during anesthesia can be controlled by concurrent administration of atropine sulfate. Reduce dosage in geriatric dogs and cats. Patients should be continuously monitored.

See full prescribing information at the end of the Product Guide for complete boxed warning.

Tulissin®-100-
(tulathromycin injection)

Protect Your Investment



If you trust tulathromycin, then you need TULISSIN® 100 injectable solution.

Built-in Protective Shell

Patented container design on the 250mL and 500mL bottles features an easy-grip silicone shell that offers excellent shock-absorption properties that protect against breakage.

Scan the QR code to see the shock-absorbing shell in action.

Ask your vet about TULISSIN® 100 injectable solution

IMPORTANT SAFETY INFORMATION FOR CATTLE

TULISSIN® 100 (tulathromycin injection): Not for use in humans. Ensure a pre-slaughter withdrawal time of eighteen (18) days in cattle. Do not use in dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. The effects of tulathromycin on bovine reproductive performance, pregnancy and lactation have not been determined. Do not use in animals known to be hypersensitive to the product.

Virbac Shaping the future of animal health

Tulissin® 25 (tulathromycin injection) Injectable Solution

Tulathromycin, a first choice therapy[1] for treating swine respiratory disease (SRD):

- Goes to work in minutes[2]
- Concentrates in the most susceptible areas of the respiratory system
- Provides nine days of lung activity to treat and control SRD[3]

Suckling Calves, Dairy Calves and Veal Calves
BRD - TULISSIN 25 Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni* and *Mycoplasma bovis*.

Available in:
100 mL bottle (20 bottles/case) SKU 66701
250 mL bottle (15 bottles/case) SKU 66702

Important Safety Information

TULISSIN® 25 (tulathromycin injection): Not for use in ruminating cattle. Ensure a pre-slaughter withdrawal time of twenty-two (22) days in calves and five (5) days in swine. The effects of tulathromycin on bovine and swine reproductive performance, pregnancy and lactation have not been determined. Do not use in animals known to be hypersensitive to the product.

See package insert at the end of the Product Guide for full prescribing information.

1 CEESA data, Q2 2021, injectable antibiotics brands used in swine segment.
2 Villarino N, Brown SA, Martin-Jimenez T. Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. *J Vet Pharmacol Ther.* 2014;37(3):211-221. doi:10.1111/jvp.12080.
3 Waag TA, Bradford JR, Lucas MJ, et al. Duration of effectiveness of tulathromycin injectable solution in an Actinobacillus pleuropneumoniae respiratory-disease challenge model in swine. *J Swine Health Prod.* 2008;16(3):126–130.

Tulissin® 100 (tulathromycin injection) Injectable Solution

Based on the trusted active ingredient tulathromycin, TULISSIN® 100 injectable solution offers:

- Fast-acting treatment and control of bovine respiratory disease (BRD) and swine respiratory disease (SRD)
- Single shot convenience with 18-day pre-slaughter withdrawal period in cattle and five days in swine
- Convenient dosages with availability of TULISSIN® 100 (tulathromycin injection) for use in large pigs with the same preslaughter withdrawal time of five days

Available in:
50 mL bottle (48 bottles/case) SKU 66703
100 mL bottle (20 bottles/case) SKU 66704
250 mL bottle (12 bottles/case) SKU 66705
500 mL bottle (6 bottles/case) SKU 66706

Important Safety Information

TULISSIN® 100 (tulathromycin injection): Not for use in humans. Ensure a pre-slaughter withdrawal time of eighteen (18) days in cattle and five (5) days in swine. Do not use in dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. The effects of tulathromycin on bovine and swine reproductive performance, pregnancy and lactation have not been determined. Do not use in animals known to be hypersensitive to the product.

See package insert at the end of the Product Guide for full prescribing information.

Tenotryl™ (enrofloxacin) injectable solution

Cattle:

- For treatment and control of bovine respiratory disease (BRD)
- Designed to be fast and reliable[(1)] One shot, two active molecules. Once injected into cattle, enrofloxacin is metabolized into enrofloxacin and ciprofloxacin.[(1)]
- Convenience of single or multiple doses
- Adaptable injection supports judicious use of antibiotics

Swine:

- For treatment and control of swine respiratory disease (SRD) and control of colibacillosis
- Convenient, single-dose use

Available in:
100 mL bottle (20 bottles/case) SKU 66716
250 mL bottle (15 bottles/case) SKU 66717
500 mL bottle (6 bottles/case) SKU 66718

Cattle Important Safety Information
Tenotryl™ (enrofloxacin) 100 mg/mL Antimicrobial Injectable Solution: Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in the calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not exceed a 20 mL dose per injection site. Federal (USA) law prohibits the extra-label use of this drug in food producing animals.

Swine Important Safety Information
Tenotryl™ (enrofloxacin) 100 mg/ml Antimicrobial Injectable Solution: Animals intended for human consumption must not be slaughtered within 5 days of receiving a single injection dose. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options. Federal (USA) law prohibits the extra-label use of this drug in food producing animals.

See package insert at the end of the Product Guide for full prescribing information.

1. McKellar, Q., Gibson, I., Monteiro, A., Bregante, M. 1999. Pharmacokinetics of Enrofloxacin and Danofloxacin in Plasma, Inflammatory Exudate, and Bronchial Secretions of Calves following Subcutaneous Administration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1999, p. 1988–1992.

LIVESTOCK HEALTH

TIA™ (tiamulin hydrogen fumarate) liquid concentrate

- Liquid concentrate for the treatment of swine dysentery associated with *Brachyspira* (formerly *Serpulina* or *Treponema*) *hyodysenteriae* and swine pneumonia due to *Actinobacillus pleuropneumoniae* susceptible to tiamulin
- Quick implementation: Easy administration in water so you can react quickly and treat pigs as soon as a diagnosis is made
- Helps overcome treatment delivery challenges, because sick pigs are likely to continue drinking water when feed intake declines as a result of illness[1]
- Quickly absorbed: Tiamulin can be found in pigs' bloodstream within 30 minutes after dosing
- Works where it's needed: Achieves high tissue concentrations in the lungs, tonsils and intestinal tract lining[2] – where bacteria invade

Available in:
1 L bottle (15 bottles/case) SKU 92601

Important Safety Information
TIA™ 12.5% (tiamulin hydrogen fumarate) liquid concentrate: Withdraw medicated water 3 days before slaughter after treatment at 3.5 mg per pound body weight and 7 days before slaughter after treatment at 10.5 mg per pound body weight. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. Refer to the label for complete directions for use, precautions and warnings. Do not use undiluted.

See package insert at the end of the Product Guide.

1. Neumann EJ, Ramirez A, Schwartz KJ, eds. *Swine Disease Manual*. 5th ed. American Association of Swine Veterinarians; 2020.
2. Walter D, Knittel J, Schwartz K, Kroll J, Roof M. Treatment and control of porcine proliferative enteropathy using different tiamulin delivery methods. *J Swine Health Prod*. 2001;9(3):109-115.

NEW FOR DOGS MOVODYL™ Chewable Tablets (carprofen)

Indications:

- Nonsteroidal anti-inflammatory drug (NSAID) for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs
- Easy-to-administer scored tablet
- For use in dogs only

Available in:
25 mg (60 tablets) SKU 10021
75 mg (60 tablets) SKU 10022
100 mg (60 tablets) SKU 10023
25 mg (180 tablets) SKU 10024
75 mg (180 tablets) SKU 10025
100 mg (180 tablets) SKU 10026

Important Safety Information
MOVODYL™ Chewable Tablets (carprofen): Not for human use. FOR USE IN DOGS ONLY. DO NOT USE IN CATS. As a class, NSAIDS may be associated with gastrointestinal, kidney and liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including MOVODYL Chewable Tablets. Use with other NSAIDS or corticosteroids should be avoided.

See package insert at the end of the Product Guide for full product information.

KNOCKOUT® Area Treatment

- Kills adult fleas and controls preadult fleas for four months
- Kills ticks
- Leaves no objectionable odor or sticky residue; when used as directed, does not stain furniture
- Apply this product only as specified on the labeling
- DO NOT TREAT PETS WITH THIS PRODUCT

Available in:
14 oz (397 g) aerosol can SKU 612014

KNOCKOUT® E.S. Area Treatment

- Contains Nylar® insect growth regulator
- Kills active flea infestations
- Prevents flea infestations from developing
- Prevents flea reinfestations for 7 months
- Kills ticks
- One 16-ounce. spray can treats up to 2,100 square feet
- Apply this product only as specified on the labeling
- DO NOT TREAT PETS WITH THIS PRODUCT

Available in:
16 oz (454 g) inverted aerosol can SKU 612216

KNOCKOUT® Room and Area Fogger

- Kills adult fleas, preadult fleas and flea eggs for 7 months
- Reaches fleas (and ticks) in rugs, draperies, upholstery, pet bedding, floor cracks and open cabinets
- One 6-ounce fogger treats a room measuring up to 27 feet by 27 feet with an 8-foot ceiling
- Apply this product only as specified on the labeling
- DO NOT TREAT PETS WITH THIS PRODUCT

Available in:
6 oz (170 g) size SKU 612106

See full product labeling for Directions of Use and Cautionary statements.

Nylar is a registered trademark of McLaughlin McGormley King Company.

EFFIPRO® PLUS Topical Solution for Cats

- Dual action of fipronil and pyriproxyfen to break flea life cycle
- Kills fleas, ticks, lice, mosquitoes and *Sarcoptes* mites for up to one month in cats and kittens

Repels and kills:
- Adult fleas
- All stages of Deer Tick, Brown Dog Tick,
- Lone Star Tick and American Dog Tick
- Mosquitoes

- Only use on cats and kittens 8 weeks or older
- DO NOT USE ON DOGS, PUPPIES OR RABBITS
- One convenient dose for cats and kittens weighing 1.5 pounds or more

Active ingredients:
- Fipronil
- Pyriproxyfen

EFFIPRO® PLUS Topical Solution for Cats: Read entire label before each use.

Available in three applicators per carton:
For cats weighing 1.5 lbs and over SKU 60463
3-dose card display box / 10 cards per display (30 doses)

EFFIPRO® PLUS Topical Solution for Dogs

- Dual action of fipronil and pyriproxyfen to break flea life cycle
- Kills fleas, ticks, lice, mosquitoes and *Sarcoptes* mites for up to one month in dogs and puppies

Repels and kills:
- Adult fleas
- All stages of Deer Tick, Brown Dog Tick,
- Lone Star Tick and American Dog Tick
- Mosquitoes

- Only use on dogs and puppies 8 weeks or older
- DO NOT USE ON CATS

Active ingredients:
- Fipronil
- Pyriproxyfen

EFFIPRO® PLUS Topical Solution for Dogs:
DO NOT USE ON CATS.
Read entire label before each use.

Available in four sizes, depending on dog's weight:
Small: 5-22.9 lbs SKU 60473
Medium: 23-44.9 lbs SKU 60483
Large: 45-88.9 lbs SKU 60503
X-Large: 89-132 lbs SKU 60513
3-dose card display box / 10 cards per display (30 doses)

EFFITIX® PLUS Topical Solution for Dogs

- Effective monthly application repels and kills fleas, flea eggs, flea larvae, ticks, lice and mosquitoes
- Repels biting flies
- Kills fleas and flea eggs
- Aids in the control of *Sarcoptes* mites

Repels and kills:
- Adult fleas
- All stages of Deer Tick, Brown Dog Tick, Lone Star Tick and American Dog Tick
- Mosquitoes

- Easy to apply, quick-drying, waterproof
- Starts working on contact
- Only use on dogs and puppies 8 weeks or older

Active ingredients:
- Fipronil
- Permethrin
- Pyriproxyfen

EFFITIX® PLUS Topical Solution for Dogs:
DO NOT USE ON CATS.
Read entire label before each use.

Available in five sizes, depending on dog's weight:
Toy: 5-10.9 lbs SKU 60520
Small: 11-22.9 lbs SKU 60522
Medium: 23-44.9 lbs SKU 60524
Large: 45-88.9 lbs SKU 60526
X-Large: 89-132 lbs SKU 60528
3-dose card display box / 10 cards per display (30 doses)

VIRBANTEL® (pyrantel pamoate/ praziquantel) Flavored Chewables

- Flavored chewables to treat and control roundworms, hookworms and tapeworms in dogs and puppies 12 weeks and older
- Safety in breeding and pregnant dogs has not been evaluated

Available in 50-count bottles:
30 mg for dogs 6.0-25 lbs SKU 54030
114 mg for dogs 25.1-200 lbs SKU 51114

Important Safety Information
VIRBANTEL® (pyrantel pamoate / praziquantel) Flavored Chewables: Do not use in sick animals. Safety in breeding dogs and pregnant dogs has not been evaluated.

See package insert at the end of the Product Guide for full product information.

BENEFITS OF VETERINARY HPM® PET NUTRITION IN YOUR CLINIC

FOR YOUR PATIENTS

Provide an innovative product that fills an unmet need for today's pets

- Helps start the conversation about anticipated post-procedure changes, and provides a specialized solution
- Takes a proactive approach to weight management
- Can serve as a tool for soft weight-loss plans
- Delivery to the client's doorstep from iVet.com
- Brings the nutrition conversation back to the team most familiar with each patient's health history

FOR YOUR CLINIC

Detailed nutrient analysis data so you can feel confident in your recommendations

- Concise portfolio easily integrates into existing clinic protocols
- Specialized wellness nutrition for your spayed and neutered patients
- Veterinary-exclusive products available in-clinic or via iVet.com
- Competitive profit margins for all your clients' in-clinic and iVet.com purchases

VETERINARY HPM®
Spay & Neuter Diets

- Tailor-made for the unique needs of spayed & neutered pets
- Supports appetite control and a healthy metabolismsm
- Available in Junior and Adult diets
- Helps maintain a healthy body condition
- Provides proactive weight management nutrition

Available in:

Canine Diets:

Small & Toy Junior
3.0 lb bag SKU 10900
6.5 lb bag SKU 10901

Small & Toy Adult
3.0 lb bag SKU 10902
6.5 lb bag SKU 10903
15.0 lb bag SKU 10904

Large & Medium Junior
3.0 lb bag SKU 10905
15.0 lb bag SKU 10914
26.0 lb bag SKU 10906

Large & Medium Adult
3.0 lb bag SKU 10907
15.0 lb bag SKU 10915
26.0 lb bag SKU 10908

Feline Diets:

Junior
3.0 lb bag SKU 10909
6.5 lb bag SKU 10910

Adult
3.0 lb bag SKU 10911
6.5 lb bag SKU 10912

Visit ivet.com/vets to register your clinic and order today.
Call 1-800-436-5909, fax 1-877-398-4838 or orders@ivet.com.

GENESIS® Topical Spray 0.015% solution of triamcinolone acetonide

- Controls pruritus associated with allergic dermatitis in dogs
- Low concentration (0.015%) of triamcinolone acetonide in a topical spray with potent topical anti-inflammatory action

Available in:
8 fl oz (237 mL) bottle with sprayer SKU 410508
16 fl oz (478 mL) bottle with sprayer SKU 410500

Important Safety Information
GENESIS® Topical Spray 0.015% solution of triamcinolone acetonide: For use on dogs only. Wear gloves when applying the product. The use of this product on dogs less than 8 pounds, less than one year of age, breeding, pregnant, or lactating has not been evaluated. Adverse events of polyuria and polyphagia have been reported in <6% of dogs receiving treatment.

See package insert at the end of the Product Guide for full product information.

CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED 100 mg/mL

- Indicated for the control of atopic dermatitis in dogs weighing at least 4 lbs (1.8 kgs)
- The effective cyclosporine you know and trust — in liquid form
- Convenient and easy dosing to help promote compliance
- Precise dosing — CYCLAVANCE oral solution eliminates the inefficiencies of dosing with capsules
- Both sizes come with a syringe and adaptor cap for easy dosing with no leaks or spills

Available in two vial presentations:
15 mL SKU 20301
50 mL SKU 20303

Important Safety Information
CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED: For use in dogs only. Wear gloves during and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose of CYCLAVANCE oral solution. CYCLAVANCE oral solution should be used with caution: 1) in cases with diabetes mellitus as it may cause elevated levels of serum glucose; 2) in dogs with renal insufficiency since the effect of cyclosporine use on dogs with compromised renal function has not been studied; 3) in simultaneous administration with drugs that suppress the P-450 enzyme system, such as azoles (e.g., ketoconazole), that may lead to increased plasma levels of cyclosporine. Killed vaccines are recommended for dogs receiving CYCLAVANCE oral solution because the impact of cyclosporine on the immune response to modified live vaccines has not been evaluated.

See package insert at end of the Product Guide for full product information.

ITRAFUNGOL® (itraconazole oral solution) 10 mg/mL

The only oral FDA-approved treatment for feline dermatophytosis (ringworm)

- Cherry-caramel liquid formulation
- Can be dosed with or without food
- Shelf life is two years unopened or five weeks once opened
- In a clinical study, 80 cats infected with *Microsporum canis* were treated with either placebo or ITRAFUNGOL oral solution, pulse-dosed (5 mg/kg/day) over alternate weeks for three treatments and followed by a 4-week follow-up period. No topical therapy was used. In the group treated with ITRAFUNGOL:

  – Clinical cure occurred well in advance of mycological cure

  – 90% had at least one negative fungal culture by the end of the study

  – 98% had complete resolution of all clinical lesions, compared to 15% of untreated cats by the end of the study

Available in:
52 mL bottle SKU 11605
One bottle provides treatment course for a 10 lb cat

Important Safety Information
ITRAFUNGOL™ (itraconazole oral solution): For use in cats only. Wash hands and exposed skin after use. Do not administer to cats with hypersensitivity to itraconazole. ITRAFUNGOL oral solution has not been shown to be safe in pregnant cats and should only be used in pregnant or lactating cats when the benefits outweigh the potential risks. Administer orally using the enclosed graduated dosing syringe. Use with caution in cats with renal dysfunction or impaired liver function. If clinical signs suggestive of liver dysfunction develop, treatment should be discontinued. ITRAFUNGOL oral solution is a cytochrome P-450 inhibitor and may increase or prolong plasma concentrations of other drugs metabolized by this pathway. Cats suffering from heart disease should be carefully monitored during treatment. The most common adverse reactions reported in clinical trials were elevated hepatic enzymes and gastrointestinal upset such as increased salivation, vomiting, diarrhea, and decreased appetite.

See package insert at end of the Product Guide for full product information.

KETOCHLOR® (Chlorhexidine Gluconate, Ketoconazole) Medicated Shampoo

- An antiseptic shampoo for the management of conditions responsive to ketoconazole or chlorhexidine in dogs and cats
  – Promotes natural skin microbial defenses (Defensin technology) with natural plant extracts
- Specifically designed to meet the needs of dogs and cats with skin microbial imbalances, its antiseptic and cleansing properties help manage bacterial and fungal skin infections in dogs and cats
  – Neutralizes unpleasant odors
  – Reduces microorganism adhesion (Glycotechnology)

Available in:
8 fl oz (237 mL) SKU 002908
16 fl oz (473 mL) SKU 002916

ALLERMYL® (Piroctone Olamine) Medicated Shampoo

- With S-I-S SKIN INNOVATIVE SCIENCE® Technology, ALLERMYL is a soothing shampoo for the management of allergic skin conditions. Specifically designed to meet the needs of dogs and cats with sensitive and itchy skin, ALLERMYL Medicated Shampoo is a unique micro-emulsified formulation that combines ingredients that help:
  – Maintain skin barrier integrity
  – Provide moisturizing and soothing effects (Skin Lipid Complex)
  – Reduce microorganism adhesion (Glycotechnology)
  – Promote natural skin microbial defenses (Defensin technology) supporting the immune response — antimicrobial peptides (AMPs) with natural plant extracts
  – Promote a healthy microbial balance in animals with allergic skin conditions *(Piroctone Olamine)*
  – ONLY a hypoallergenic and moisturizing shampoo will avoid causing more allergy and skin irritation

Available in:
8 fl oz (237 mL) SKU 002409
16 fl oz (473 mL) SKU 002417

KERATOLUX® (Piroctone Olamine) Medicated Shampoo

- With S-I-S SKIN INNOVATIVE SCIENCE® Technology, KERATOLUX Medicated Shampoo is a unique cleanser that removes scales, crusts and excessive oil on the skin surface of dogs and cats for management of keratoseborrheic conditions. With regular bathing, KERATOLUX Medicated Shampoo helps manage normal sebum production, resulting in a pleasant smell and healthy appearance to the skin coat.

KERATOLUX Medicated Shampoo:
– Contains plant extracts that promote natural skin microbial defenses (Defensin technology) by supporting the innate immune response — antimicrobial peptides (AMPs)
– Improves hair and skin balance
– Removes excess sebum and scales
– Neutralizes unpleasant odors
– Provides microorganism anti-adhesive effects (Glycotechnology)
– Promotes a healthy microbial balance in animals with keratoseborrheic conditions (Piroctone Olamine)

Available in:
8 fl oz (237 mL) SKU 002009
16 fl oz (473 mL) SKU 002017

NEW FOR PETS

ALLERDERM® Foaming Cleanser

- Micellar water solution adapted to use on any skin type, even sensitive skin
- Easy-to-use foam application
- Neutral pH, non-irritating formula
- Gently and quickly clean the pet's hair coat in between baths with no rinsing required
- Eco-Friendly Packaging: 100% recycled and recyclable bottle, excluding the pump

Available in:
6.76 oz SKU 13500

ALLERDERM OMEGADERM® Essential Fatty Acids Supplement

- A nutritional supplement containing omega-3 and omega-6 essential fatty acids
- Formulated for dogs and cats
- Once-daily supplement
- Ideal for maintaining healthy skin and hair coat
- Premeasured EZ-dose packets
- High palatability and product acceptance when poured over food

Available in: 28-count dispensers
4 mL for small dogs and cats < 20 lbs SKU 14149
8 mL for medium and large dogs > 20 lbs SKU 14186

EPI-SOOTHE® Cream Rinse

- Formulated for dry and sensitive skin in dogs, cats and horses of any age. This unique formula helps restore natural skin oils and moisture, makes the hair coat more manageable and helps prevent tangles while adding a high sheen to the hair coat.

Available in:
8 fl oz (237 mL) SKU 001808
16 fl oz (473 mL) SKU 001816

EPI-SOOTHE® Shampoo

- Natural oat-grain derivative, soap-free shampoo designed for soothing and cleansing dry and sensitive skin in dogs, cats and horses of any age. This shampoo is designed for soothing and cleansing sensitive skin.

Available in:
8 fl oz (237 mL) SKU 11708
16 fl oz (473 mL) SKU 11716

ALLERGROOM® Shampoo

- Gentle, soap-free moisturizing shampoo designed for frequent use on normal to dry skin to optimize the skin and hair coat of dogs, cats and horses of any age

Available in:
8 fl oz (237 mL) SKU 12208
16 fl oz (473 mL) SKU 12216

REBOUND® Recuperation Formula for Dogs

- Helps support pet's nutrition needs during recuperation
- Balanced, fortified nutrition in a low-calorie liquid formula
- Palatable and easy to administer
- No added preservatives or colorants
- Intended for intermittent or supplemental feeding
- For use in dogs

Available in:
Formula for Dogs: 5.1 fl oz (150 mL) SKU 10850

REBOUND® Recuperation Formula for Cats

- Helps support pet's nutrition needs during recuperation
- Balanced, fortified nutrition in a low-calorie liquid formula
- Palatable and easy to administer
- No added preservatives or colorants
- Intended for intermittent or supplemental feeding
- For use in cats

Available in:
Formula for Cats: 5.1 fl oz (150 mL) SKU 10851

TUMIL-K® (potassium gluconate) Tablets and TUMIL-K® (potassium gluconate) Powder

- For use as a supplement to support the health of the kidneys in cats and dogs with potassium deficiency

Available in:
Tablets in 100-count bottles SKU 845100
Powder: 4 oz SKU 846004

VETASYL® Fiber Capsules

- Natural fiber source — psyllium seed husks (95%)
- Provides gentle support, proper digestion and bowel health in dogs and cats
- Barley malt extract powder for flavor

Available in:
500 mg capsules in a 100-count bottle SKU VF410

ANADA 200-316, Approved by FDA

CLINTABS® Tablets

brand of clindamycin hydrochloride tablets, USP

DESCRIPTION

CLINTABS® Tablets contain clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by *Streptomyces lincolnensis var. lincolnensis*.

CLINTABS Tablets (For Use in Dogs Only):
25 mg Tablet, each white bisected tablet is marked "C" above the bisect and "25" below the bisect and contains clindamycin hydrochloride equivalent to 25 mg of clindamycin.
75 mg Tablet, each white bisected tablet is marked "C" above the bisect and "75" below the bisect and contains clindamycin hydrochloride equivalent to 75 mg of clindamycin.
150 mg Tablet, each white tablet is marked "C 150" on one side and contains clindamycin hydrochloride equivalent to 150 mg of clindamycin.

ACTIONS

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

MICROBIOLOGY: Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs in the United States are presented in Table 1. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS).

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-99[1]

Organism	Number of Isolates	MIC_{50}	MIC_{85}	MIC_{90}	Range
Soft Tissue/Wound[2]					
Staphylococcus aureus	17	0.5	0.5	≥4.0	0.25->4.0
Staphylococcus intermedius	28	0.25	0.5	≥4.0	0.125->4.0
Staphylococcus spp.	18	0.5	0.5	≥4.0	0.25->4.0
Beta-hemolytic streptococci	46	0.5	0.5	≥4.0	0.25->4.0
Streptococcus spp.	11	0.5	≥4.0	≥4.0	0.25->4.0
Osteomyelitis/Bone[3]					
Staphylococcus aureus	20	0.5	0.5	0.5	0.5[4]
Staphylococcus intermedius	15	0.5	≥4.0	≥4.0	0.25->4.0
Staphylococcus spp.	18	0.5	≥4.0	≥4.0	0.25->4.0
Beta-hemolytic streptococci	21	0.5	2.0	2.0	0.25->4.0
Streptococcus spp.	21	≥4.0	≥4.0	≥4.0	0.25->4.0
Dermal/Skin[5]					
Staphylococcus aureus	25	0.5	≥4.0	≥4.0	0.25->4.0
Staphylococcus intermedius	48	0.5	≥4.0	≥4.0	0.125->4.0
Staphylococcus spp.	32	0.5	≥4.0	≥4.0	0.25->4.0
Beta-hemolytic streptococci	17	0.5	0.5	0.5	0.25-0.5

[1] The correlation between the *in vitro* susceptibility data and clinical response has not been determined.
[2] Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass
[3] Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon
[4] No range, all isolates yielded the same value
[5] Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision, lip

PHARMACOLOGY

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract.

Dog Serum Levels: Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

Clindamycin Serum Concentrations
2.5 mg/lb (5.5 mg/kg) After B.I.D. Oral Dose
of Clindamycin Hydrochloride to Dogs



METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-dimethyl clindamycin and clindamycin sulfoxide.

ANIMAL SAFETY SUMMARY

Rat and Dog Data: One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride capsules to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gall bladder.

Safety in gestating bitches or breeding males has not been established.

INDICATIONS

CLINTABS® Tablets (brand of clindamycin hydrochloride) (for use in dogs only) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dogs: Skin infections (wounds and abscesses) due to: coagulase positive staphylococci (*Staphylococcus aureus* or *Staphylococcus intermedius*).

Deep wounds and abscesses due to Bacteroides *fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum* and *Clostridium perfringens.*

Dental infections due to *Staphyloccus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum* and *Clostridium perfringens.*

Osteomyelitis due to *Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum* and *Clostridium perfringens.*

CONTRAINDICATIONS

CLINTABS Tablets are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

WARNINGS

Keep out of reach of children. Not for human use.

PRECAUTIONS

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of clindamycin hydrochloride occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of CLINTABS Tablets should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see **CONTRAINDICATIONS**).

Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, CLINTABS Tablets should be used with caution in animals receiving such agents.

Safety in gestating bitches or breeding male dogs has not been established.

ADVERSE REACTIONS

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

To report adverse reactions or a suspected adverse reaction, call 1-800-338-3659.

DOSAGE AND ADMINISTRATION

Dogs:

Infected Wounds, Abscesses, and Dental Infections

Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with clindamycin hydrochloride products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Dosage Schedule:

Tablets
CLINTABS 25 mg, administer 1-6 tablets every 12 hours for each 10 pounds of body weight.
CLINTABS 75 mg, administer 1-6 tablets every 12 hours for each 30 pounds of body weight.
CLINTABS 150 mg, administer 1-6 tablets every 12 hours for each 60 pounds of body weight.

Dogs:

Osteomyelitis

Oral: 5.0-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with clindamycin hydrochloride is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

Dosage Schedule:

Tablets
CLINTABS 25 mg, administer 2-6 tablets every 12 hours for each 10 pounds of body weight.
CLINTABS 75 mg, administer 2-6 tablets every 12 hours for each 30 pounds of body weight.
CLINTABS 150 mg, administer 2-6 tablets every 12 hours for each 60 pounds of body weight.

HOW SUPPLIED

CLINTABS Tablets are available as:
25 mg - bottles of 400
75 mg - bottles of 200
150 mg - bottles of 100
ANADA #200-316, Approved by FDA

To report a suspected adverse reaction or to request a material safety data sheet (MSDS), call 1-800-338-3659.

Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Mfd. for
Virbac AH, Inc.
Fort Worth, TX 76137-4611, USA

Revised May 13 301617-05
CLINTABS is a registered trademark of Virbac AH, Inc.

CLOMICALM
(clomipramine hydrochloride)

Caution:
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description:
CLOMICALM® (clomipramine hydrochloride) tablets belong to the dibenzazepine class of tricyclic antidepressants. Clomipramine hydrochloride is 3-chloro-5[3-(dimethyl-amino)propyl]-10,11dihydro-5H dibenz[b,f]azepine monohydrochloride. CLOMICALM tablets are oblong, light brown in color and contain clomipramine hydrochloride formulated together with meat components. The molecular weight of clomipramine hydrochloride is 351.3. The structural formula is:



Clinical Pharmacology:
Clomipramine hydrochloride reduces the clinical signs of separation anxiety by affecting serotonergic and noradrenergic neuronal transmission in the central nervous system. While clomipramine hydrochloride can cause lethargy in dogs (see Adverse Reactions) its mode of action is not as a sedative. Clomipramine hydrochloride's capacity to inhibit re-uptake of serotonin in the central nervous system is believed to be the primary mechanism of action. Clomipramine hydrochloride is rapidly absorbed when administered orally. A single-dose crossover study involving 12 dogs evaluated clomipramine hydrochloride bioavailability after IV (2 mg/kg) and oral (4 mg/kg) administration in either a fed or fasted state. The administration of clomipramine hydrochloride in the presence of food resulted in an increase in the rate and extent of drug absorption as shown in the following table (mean ±SD):

	AUC0-inf (nmol hr/L)	Cmax (nmol/L)	Tmax (hr)	Absolute Bioavail-ability (F)
Fed	1670±575	601±286	1.18±0.32	0.21±0.07
Fasted	1350±447	379±154	1.31±0.32	0.17±0.05

The absolute bioavailability is approximately 25% greater in fed dogs. The apparent terminal plasma half-life ranges from approximately 2 to 9 hours in fed and 3 to 21 hours in fasted dogs. The difference and variability in apparent half-life estimates may be attributable to prolonged drug absorption in the fasted state. The relatively large volume of distribution (3.8±0.8 L/kg) suggests that the drug is widely distributed throughout the body. **Clomipramine is primarily metabolized in the liver.**

Indications and Usage: CLOMICALM tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. Inappropriate barking or destructive behavior, as well as inappropriate elimination (urination or defecation) may be alleviated by the use of CLOMICALM tablets in conjunction with behavior modification.

Separation anxiety is a complex behavior disorder displayed when the owner (or other attachment figure) leaves the dog. The signs of separation anxiety evaluated in controlled trials were vocalization, destructive behavior, excessive salivation, and inappropriate elimination. In the absence of the owner or attachment figure, dogs with separation anxiety may exhibit one or more of these clinical signs. Although the owner (attachment figure) may inadvertently misinterpret this behavior, which only happens in their absence, as spiteful, it is thought to be the result of anxiety experienced by the dog. Punishment is not considered appropriate for a dog with separation anxiety.

Proper recognition of clinical signs, including a complete patient history and assessment of the patient's household environment, is essential to accurately diagnose and treat separation anxiety.

The use of CLOMICALM tablets should not replace appropriate behavioral and environmental management but should be used to facilitate a comprehensive behavior management program.

Contraindications:
CLOMICALM tablets are contraindicated in dogs with known hypersensitivity to clomipramine or other tricyclic antidepressants. CLOMICALM tablets should not be used in male breeding dogs. Testicular hypoplasia was seen in dogs treated for 1 year at 12.5 times the maximum daily dose.

CLOMICALM tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz].

CLOMICALM tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold.

Human Warnings:
Not for use in humans. Keep out of reach of children. In case of accidental ingestion seek medical attention immediately. In children, accidental ingestion should be regarded as serious. There is no specific antidote for clomipramine. Overdose in humans causes anticholinergic effects including effects on the central nervous (e.g., convulsions) and cardiovascular (e.g., arrhythmia, tachycardia) systems. People with known hypersensitivity to clomipramine should administer the product with caution.

Precautions:
General: CLOMICALM tablets are not recommended for other behavior problems, such as aggression (see Adverse Reactions). Studies to establish the safety and efficacy of CLOMICALM tablets in dogs less than 6 months of age have not been conducted.

Diagnosis: It is critical to conduct a comprehensive physical examination, including appropriate laboratory tests, and to obtain a thorough history and assessment of the patient's household environment, to rule-out causes of inappropriate behavior unrelated to separation anxiety before prescribing CLOMICALM tablets. Periodic reassessment of hematological and serum biochemical data during the administration of this medication is advised. Veterinarians should be familiar with the risks and benefits of the treatment of behavioral disorders in dogs before initiating therapy. Inappropriate use of CLOMICALM tablets, i.e., in the absence of a diagnosis or without concurrent behavioral modification, may expose the animal to unnecessary adverse effects and may not provide any lasting benefit of therapy.

Drug Interactions: Recommendations on the interaction between clomipramine and other medications are extrapolated from data generated in humans. Plasma levels of tricyclic antidepressants have been reported to be decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin); therefore plasma concentrations of clomipramine may be decreased by the concomitant administration of phenobarbital. Plasma levels of closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine). Tricyclic antidepressants themselves may exhibit hepatic enzyme inhibition and possibly increase plasma levels of barbiturates (phenobarbital). Caution is advised in using clomipramine with anticholinergic or sympathomimetic drugs or with other CNS-active drugs, including general anesthetics and neuroleptics. Prior to elective surgery with general anesthetics, clomipramine should be discontinued for as long as clinically feasible.

Use in Concomitant Illness: Use with caution in dogs with cardiovascular disease. At 20 mg/kg/day (5X the maximum recommended dose), bradycardia and arrhythmias (atrioventricular node block and ventricular extrasystole) were observed in dogs. Because of its anticholinergic properties, clomipramine should be used with caution in patients with increased intraocular pressure, a history of narrow angle glaucoma, urinary retention or reduced gastrointestinal motility. Because clomipramine is principally metabolized in the liver, caution is advised in using this medication in the presence of preexisting liver disease.

Reproductive Safety: Safety studies to determine the effects of CLOMICALM tablets in pregnant or lactating female dogs have not been conducted. CLOMICALM tablets should not be used in breeding males (See Contraindications).

Efficacy:
Dose Establishment: A 12 week, placebo-controlled, multi-site clinical trial was conducted in the US and Europe to establish an effective dose of CLOMICALM (clomipramine hydrochloride) tablets in dogs. Treatment with CLOMICALM tablets, at 2 - 4 mg/kg/day divided twice daily, in conjunction with behavioral modification (desensitization and counterconditioning) was more effective than behavior modification alone in reducing the signs of separation anxiety in dogs.

Dose Confirmation: In another placebo-controlled, multi-site clinical trial, CLOMICALM tablets at 2 - 4 mg/kg/day given either once daily or divided twice daily showed significant improvement in resolving signs of separation anxiety when tested against behavioral modification alone (desensitization and counterconditioning). In this 8 week study, the rate of improvement of the dogs receiving CLOMICALM tablets with behavioral modification was significantly faster than the rate of improvement of the dogs receiving behavioral modification alone. After one week on trial, 47% of the dogs receiving CLOMICALM tablets once or twice (divided dose) daily in conjunction with behavioral modification showed clinical improvement compared to improvement in 29% of the dogs receiving behavioral modification alone.

Safety:
CLOMICALM tablets were demonstrated to be well-tolerated in dogs at the recommended label dose of 2-4 mg/kg/day. In a six month target animal safety study, beagle dogs were dosed daily at 4 (1X), 12 (3X), and 20 (5X) mg/kg/day. Emesis was seen in all groups including the dogs receiving placebo, but occurred more frequently in dogs receiving 12 and 20 mg/kg. Decreased activity was also seen in dogs receiving the 12 and 20 mg/kg. There were no apparent treatment-related alterations in the following: body weights, physical examination findings, electrocardiograph examinations, hematology or biochemistry parameters, ophthalmoscopic examinations, macroscopic or microscopic organ examinations and organ weights. Average food and water consumption over the 26 week period was similar for control and treated groups. In a one year study, pure bred dogs were dosed daily at 12.5 (3X), 50 (12.5X), and 100 (25X) mg/kg/day. Emesis and mydriasis were observed within 15 minutes to one hour after dosing in dogs receiving 12.5, 50, and 100 mg/kg/day and lethargy was observed within 1 hour of dosing in dogs receiving 50 and 100 mg/kg. Testicular hypoplasia was seen in dogs receiving 50 mg/kg. At 100 mg/kg/day (25X) convulsions and eventual death occurred in five out of the eight dogs.

Adverse Reactions: Frequency and category of adverse reactions observed in dogs dosed with CLOMICALM tablets or placebo were observed in multisite clinical studies as follows.

Adverse Reactions Reported in Placebo-Controlled Clinical Field Trials

	CLOMICALM N=180	Placebo N=88
Emesis	36 (20%)	8 (9%)
Lethargy	26 (14%)	7 (8%)
Diarrhea	17 (9%)	4 (5%)
Polydipsia	6 (3%)	0
Decreased Appetite	6 (3%)	3 (3%)
Aggression*	3 (2%)	1 (1%)
Seizure	2 (1%)	0
Dry Mouth	1 (0.5%)	1 (1%)
Tremors	1 (0.5%)	0
Constipation	1 (0.5%)	0
Anisocoria	1 (0.5%)	0
Polyuria	1 (0.5%)	0
Hyperthermia	1 (0.5%)	0

*These dogs displayed growling behavior towards either humans or other dogs.

Post-Approval Experience: Although not all adverse reactions are reported, the following adverse reactions are based on voluntary post-approval adverse drug experience reporting: lethargy/depression, anorexia, elevation in liver enzymes, vomiting and diarrhea. Hepatobiliary disease has occurred, especially in the presence of pre-existing conditions or with concurrent administration of drugs metabolized via the hepatic system. Additionally, in an overdose situation, the following signs have been reported: ataxia, convulsion(s), anticholinergic effects (e.g., mydriasis, bradycardia, tachycardia, and arrhythmia) and vocalization.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

Dosage and Administration:
The recommended daily dose of CLOMICALM tablets is 2 to 4 mg/kg/day (0.9 -1.8 mg/lb/day) (see dosing table below). It can be administered as a single daily dose or divided twice daily based on patient response and/or tolerance of the side effects. It may be prudent to initiate treatment in divided doses to minimize side effects by permitting tolerance to side effects to develop or allowing the patient time to adapt if tolerance does not develop. To reduce the incidence of vomiting that may be experienced by some dogs, CLOMICALM tablets may be given with a small amount of food.

Dog Weight (lbs.)	CLOMICALM per Day	No. Tablets per Day	Tablet Strength
2.75-5.5	5 mg	1	5 mg
5.6-10.9	10 mg	2	5 mg
11-22	20 mg	1	20 mg
22.1-44	40 mg	1	40 mg
44.1-88	80 mg	1	80 mg
88.1-176	160 mg	2	80 mg

The specific methods of behavioral modification used in clinical trials involved desensitization and counterconditioning techniques. Since the manifestation of separation anxiety can vary according to the individual dog, it is advised that a specific behavior modification plan be developed based on a professional assessment of each individual case.

Once the desired clinical effect is achieved and the owners have successfully instituted the appropriate behavioral modification, the dose of CLOMICALM tablets may be reduced to maintain the desired effect or discontinued. Withdrawal side effects were not reported in studies with CLOMICALM tablets in dogs. However, in clinical practice, it is recommended to taper the individual patient dose while continuing to monitor the dog's behavior and clinical status through the dose reduction or withdrawal period. Continued behavioral modification is recommended to prevent recurrence of the clinical signs.

The effectiveness and clinical safety of CLOMICALM tablets for long-term use (i.e., for more than 12 weeks) has not been evaluated.

Professional judgment should be used in monitoring the patient's clinical status, response to therapy and tolerance to side effects to determine the need to continue treatment with CLOMICALM tablets and to continue to rule-out physiological disorders which may complicate the diagnosis and treatment of separation anxiety.

Storage Conditions: Store in a dry place at controlled room temperature, between 59° and 77°F (15-25°C). Store unused tablets in the original closed container.

How Supplied: CLOMICALM tablets are available in 5, 20, 40 and 80 mg tablet strengths in color-coded packaging for oral administration to dogs.

Keep this and all drugs out of reach of children.

Manufactured for: Virbac AH, Inc.
P.O. Box 162059, Forth Worth, TX 76161, USA

Approved by FDA under NADA # 141-120.

11/21 - 01

Virbac

PRODUCT INSERTS/DISCLOSURES

Virbac

Cyclavance®
(cyclosporine oral solution) USP MODIFIED
100 mg/mL

CAUTION: Federal (USA) Law restricts this drug to use by or on the order of a licensed veterinarian. Keep this and all drugs out of reach of children.

DESCRIPTION: CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED is an oral form of cyclosporine that immediately forms a microemulsion in an aqueous environment. Cyclosporine, the active ingredient in CYCLAVANCE, is a cyclic polypeptide, immune modulating agent consisting of 11 amino acids. It is produced as a metabolite by the fungal species *Beauveria nivea.*

Chemically, cyclosporine A is designated Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl].



INDICATIONS: CYCLAVANCE is indicated for the control of atopic dermatitis in dogs weighing at least 4 lbs (1.8 kg) body weight.

DOSAGE AND ADMINISTRATION: Always Provide the Instructions for Assembling the Dispensing System and Preparing a Dose of CYCLAVANCE and the Information for Dog Owners with the prescription. The initial dose of CYCLAVANCE is 5 mg/kg/day as a single daily dose for 30 days. Following this initial daily treatment period, the dose of CYCLAVANCE may be tapered by decreasing the frequency of dosing to every other day or twice weekly, until a minimum frequency is reached which will maintain the desired therapeutic effect. CYCLAVANCE should be given at least one hour before or two hours after a meal. If a dose is missed, the next dose should be administered (without doubling) as soon as possible but dosing should be no more frequent than once daily. The dispensing system for the 5 and 15 mL vial sizes includes a 1 mL oral dosing syringe graduated in 0.05 mL increments. To dose the dog, administer 0.05 mL of CYCLAVANCE per 2.2 lbs of body weight. The dispensing system for the 30 and 50 mL vial sizes includes both a 1 mL oral dosing syringe graduated in 0.05 mL increments, and a 3 mL oral dosing syringe graduated in 0.1 mL increments. To dose the dog, administer 0.1 mL of CYCLAVANCE per 4.4 lbs of body weight. **Do not rinse or clean the oral dosing syringe between uses.** (See **Instructions for Assembling the Dispensing System and Preparing a Dose of CYCLAVANCE.**)

CONTRAINDICATIONS: CYCLAVANCE is contraindicated for use in dogs with a history of neoplasia. Do not use in dogs with a hypersensitivity to cyclosporine.

WARNINGS: CYCLAVANCE (cyclosporine oral solution) is a systemic immunosuppressant that may increase the susceptibility to infection and the development of neoplasia.

HUMAN WARNINGS: Not for human use. Keep this and all drugs out of reach of children. **For use only in dogs. Special precautions to be taken when administering CYCLAVANCE in dogs:** Do not eat, drink, smoke, or use smokeless tobacco while handling CYCLAVANCE. Wear gloves during administration. **Wash hands after administration.** In case of accidental ingestion, seek medical advice immediately and provide the package insert or the label to the physician. People with known hypersensitivity to cyclosporine should avoid contact with CYCLAVANCE.

PRECAUTIONS: The safety and effectiveness of cyclosporine has not been established in dogs less than 6 months of age or less than 4 lbs body weight. CYCLAVANCE is not for use in breeding dogs, pregnant or lactating bitches. As with any immunomodulation regimen, exacerbation of sub-clinical neoplastic and infectious conditions may occur. Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose (See *Animal Safety*).

CYCLAVANCE may cause elevated levels of serum glucose, and should be used with caution in cases with diabetes mellitus. If signs of diabetes mellitus develop following the use of CYCLAVANCE, consideration should be given to tapering or discontinuing the dose.

CYCLAVANCE should be used with caution with drugs that affect the P-450 enzyme system. Simultaneous administration of CYCLAVANCE with drugs that suppress the P-450 enzyme system, such as azoles (e.g. ketoconazole), may lead to increased plasma levels of cyclosporine.

Since the effect of cyclosporine use on dogs with compromised renal function has not been studied, CYCLAVANCE should be used with caution in dogs with renal insufficiency.

There have been reports of convulsions in human adult and pediatric patients receiving cyclosporine, particularly in combination with high dose methylprednisolone (See *Animal Safety*).

Killed vaccines are recommended for dogs receiving CYCLAVANCE because the impact of cyclosporine on the immune response to modified live vaccines is unknown (See *Animal Safety*).

ADVERSE REACTIONS: A total of 265 dogs were included in the field study safety analysis. One hundred and eleven (111) dogs were treated with placebo for the first 30 days. For the remainder of the study, all dogs received cyclosporine capsules.

Fourteen dogs withdrew from the study due to adverse reactions. Four dogs withdrew from the study after vomiting. One dog each withdrew from the study after diarrhea; vomiting, diarrhea and pruritus; vomiting, depression and lethargy; lethargy, anorexia and hepatitis; gingival hyperplasia, lethargy, polyuria/polydipsia and soft stool; seizure; sebaceous cyst; pruritus; erythema; or otitis externa.

Vomiting and diarrhea were the most common adverse reactions occurring during the study. In most cases, signs spontaneously resolved with continued dosing. In other cases, temporary dose modifications (brief interruption in dosing, divided dosing, or administration with a small amount of food) were employed to resolve signs.

Persistent otitis externa, urinary tract infections, anorexia, gingival hyperplasia, lymphadenopathy and lethargy were the next most frequent adverse events observed. Gingival hyperplasia regressed with dose tapering. Owners of four dogs reported seizures while dogs were receiving cyclosporine. In one dog, seizures were the result of a brain tumor diagnosed one month into the study. Another dog experienced seizures before and after the study.

Otitis externa, allergic otitis, or pinna erythema, with or without exudates, commonly accompanies atopy. Many dogs entered the study with otitis externa, which did not resolve without otic treatment. New cases of otitis externa, allergic otitis, or pinna erythema developed while dogs were receiving cyclosporine. However, the incidence rate was lower with cyclosporine compared to placebo. A change in the dose frequency was not necessary when new cases occurred.

Number of Dogs Displaying Each Clinical Observation in the Field Study

Clinical sign	% out of 265
Vomiting	30.9%
Diarrhea	20.0%
Persistent Otitis Externa	6.8%
Urinary Tract Infection	3.8%
Anorexia	3.0%
Lethargy	2.3%
Gingival Hyperplasia	2.3%
Lymphadenopathy	2.3%

The following clinical signs were reported in less than 2% of dogs treated with cyclosporine in the field study: constipation, flatulence, Clostridial organisms in the feces, nausea, regurgitation, polyuria/polydipsia, strong urine odor, proteinuria, pruritus, erythema/flushed appearance, pyoderma, sebaceous adenitis, crusty dermatitis, excessive shedding, coarse coat, alopecia, papillomas, histiocytoma, granulomatous mass or lesion, cutaneous cyst, epulis, benign epithelial tumor, multiple hemangioma, raised nodule on pinna, seizure, shaking/trembling, hind limb twitch, panting, depression, irritability, hyperactivity, quieter, increased light sensitivity, reluctance to go outside, weight loss, hepatitis.

The following clinical signs were observed in 1.5-4.5% of dogs while receiving the placebo: vomiting, diarrhea and urinary tract infection. The following clinical signs were observed in less than 1% of dogs receiving the placebo: anorexia, otitis externa, cutaneous cysts, corneal opacity, lymphadenopathy, erythema/flushed appearance.

Clinical Pathology Changes: During the study, some dogs experienced changes in clinical chemistry parameters while receiving cyclosporine, as described in the following table:

Clinical Chemistry	% Affected (out of 265)
Elevated Creatinine	7.8%
Hyperglobulinemia	6.4%
Hyperphosphatemia	5.3%
Hyperproteinemia	3.4%
Hypercholesterolemia	2.6%
Hypoalbuminemia	2.3%
Hypocalcemia	2.3%
Elevated BUN	2.3%

In addition, the following changes in clinical chemistry parameters were noted in less than 2% of dogs: hypernatremia; hyperkalemia, elevated ALT, elevated ALP, hypercalcemia and hyperchloremia. These clinical pathology changes were generally not associated with clinical signs.

POST-APPROVAL EXPERIENCE: The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are grouped by body system and are presented in decreasing order of reporting frequency.

Gastrointestinal: Emesis, diarrhea, gingival hyperplasia, hemorrhagic diarrhea, abdominal pain, hematemesis, digestive tract hemorrhage, hypersalivation, retching, flatulence, tenesmus, intestinal stasis, digestive tract hypermotility, melena, pancreatitis, involuntary defecation

General: Lethargy, anorexia, weight loss, polydipsia, hyperthermia, pale mucous membrane, general pain, collapse, dehydration, edema

Dermatologic: Pruritus, dermatitis and eczema, alopecia, erythema, papilloma, bacterial skin infection, skin lesion, skin and/or appendage neoplasm, pigmentation disorder, hair change, hyperkeratosis, histiocytoma, fungal skin infection, dermal cyst(s), desquamation

Behavioral: Hyperactivity, behavioral changes, anxiety, vocalization, aggression, inappropriate urination, disorientation

Neurologic: Muscle tremor, convulsion, ataxia, paresis

Respiratory: Tachypnea, dyspnea, cough

Urologic: Polyuria, urine abnormalities (hematuria, urinary tract infection, proteinuria, glucosuria, decreased urine concentration) urinary incontinence, cystitis, renal failure, renal insufficiency

Immune: Urticaria, anaphylaxis, allergic edema

Blood and lymphatic: Lymphadenopathy, anemia, hypoalbuminemia, leukopenia

Hepatic: Elevated Liver Enzymes, hepatopathy, hepatomegaly, hepatitis

Musculoskeletal: Lameness, limb weakness, myositis

Ear and labyrinth: Otitis externa

Cardio-vascular: Tachycardia

Endocrine: Diabetes mellitus, hyperglycemia
In some cases, death/euthanasia has been reported as an outcome of the adverse events listed above.

Neoplasms have been reported in dogs taking cyclosporine, including reports of lymphoma/lymphosarcoma and mast cell tumor. It is unknown if these were preexisting or developed de novo while on cyclosporine.

Diabetes mellitus has been reported; West Highland White Terriers are the most frequently reported breed.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

Information for Dog Owners

CYCLAVANCE is indicated for the control of atopic dermatitis in dogs weighing at least 4 lbs. (1.8 kg) body weight. Dogs with atopic dermatitis scratch, lick and chew their skin which can cause red, raised crusty bumps, open sores and/or hair loss.

Atopic dermatitis is a common skin disease in dogs and is caused by allergens such as house dust mites or pollens which stimulate an exaggerated immune response. The disease is chronic, recurrent, and requires lifelong management.

This summary contains important information about CYCLAVANCE. You should read this information before starting your dog on CYCLAVANCE. This sheet is provided only as a summary and does not take the place of instructions from your veterinarian. Talk to your veterinarian if you do not understand any of this information or you want to know more about CYCLAVANCE.

What is CYCLAVANCE?

CYCLAVANCE is an oral solution of cyclosporine that lowers the immune response.

CYCLAVANCE selectively acts on the immune cells involved in the allergic reaction.

CYCLAVANCE reduces the inflammation and itching associated with atopic dermatitis.

What kind of results can I expect when my dog takes CYCLAVANCE for the control of atopic dermatitis? CYCLAVANCE should be given daily until improvement is seen. This will generally be the case within 30 days. You should contact your veterinarian if you are not satisfied with your dog's response. Once the signs of atopic dermatitis are satisfactorily controlled, your veterinarian may reduce the frequency of administration of the product. Dose adjustment should only be carried out in consultation with your veterinarian. Your veterinarian will perform a clinical assessment at regular intervals and adjust the frequency of administration up or down according to the clinical response obtained.

What dogs should not take CYCLAVANCE?

Your dog should not be given CYCLAVANCE if s/he:

- Has a history of cancer or may possibly have cancer.
- Has a history of seizures, diabetes mellitus, and infections.
- Is hypersensitive to cyclosporine.

What to discuss with your veterinarian before giving CYCLAVANCE to your dog.

Tell your veterinarian about:

- Any digestive upset (vomiting or diarrhea) your dog has had
- Any history of lack of appetite and/or weight loss your dog has had
- Any serious disease or health conditions your dog has had
- Any allergies that your dog has now or has had
- Any medications, specifically any azoles (e.g. ketoconazole) and/or steroids that you are giving your dog or plan to give your dog, including those you can get without prescription (over the counter) and any dietary supplements
- If you plan to breed your dog, or if your dog is pregnant or nursing

Talk to your veterinarian about:

- What tests might be done before CYCLAVANCE is prescribed
- The potential side effects your dog may experience while taking CYCLAVANCE
- How often your dog may need to be examined by your veterinarian
- The risks and benefits of using CYCLAVANCE

What are the possible side effects that may occur in my dog during therapy with CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED?

CYCLAVANCE, like all other drugs, may cause some side effects in individual dogs. These are normally mild, but serious side effects have been reported in dogs taking CYCLAVANCE. Serious side effects can, in rare situations, result in death. It is important to stop the medication and contact your veterinarian immediately if you think your dog may have

a medical problem or side effect while on CYCLAVANCE. To report adverse effects, access medical information, or obtain additional product information call 1-800-338-3659.

In clinical studies, the most commonly reported side effect for cyclosporine was vomiting and diarrhea. In most cases, the vomiting and diarrhea stopped with continued use or dose modification. Persistent otitis externa, urinary tract infection, anorexia, lethargy, gingival hyperplasia and lymphadenopathy were the next most frequent side effects observed. Persistent, progressive weight loss may be associated with more serious side effects. You should monitor your dog's appetite and body weight. If you think that your dog is losing weight, you should contact your veterinarian. CYCLAVANCE may increase susceptibility to infection and to the development of tumors.

CYCLAVANCE should only be given to dogs.
People should not take CYCLAVANCE. Keep CYCLAVANCE and all medication out of reach of children. Call your physician immediately if you accidentally swallow CYCLAVANCE.

How to give CYCLAVANCE to your dog.
CYCLAVANCE should be given according to your veterinarian's instructions. Your veterinarian will tell you what amount of CYCLAVANCE is right for your dog. CYCLAVANCE should be given at least one hour before or two hours after a meal. Do not change the way you give CYCLAVANCE to your dog without first speaking with your veterinarian. If a dose is missed, the next dose should be administered (without doubling) as soon as possible, but dosing should be no more frequent than once daily. **Do not rinse or clean the oral dosing syringe between uses.**

Advice on Correct Administration.
See **Instructions for Assembling the Dispensing System and Preparing a Dose of CYCLAVANCE**. If your veterinarian has already assembled the dispensing system, skip the instructions for assembling the dispensing system and follow the instructions for preparing a dose of medicine.

How to Store CYCLAVANCE.
CYCLAVANCE should be stored and dispensed in the original container at temperatures between 68-86°F (20-30°C). Do not refrigerate because a precipitate may be observed below 68°F (20°C). **Once opened, use contents within 12 weeks.**

Special precautions to be taken when administering CYCLAVANCE.
Wear gloves during administration. Do not eat, drink, smoke, or use smokeless tobacco while handling CYCLAVANCE. **Wash hands after administration**. In case of accidental ingestion, seek medical advice immediately and show the package insert or the label to the physician.

People with known hypersensitivity to cyclosporine should avoid contact with CYCLAVANCE.

Can CYCLAVANCE be given with other medications?
CYCLAVANCE should not be given with other drugs that may lower the immune response. Cyclosporine has been safely used in conjunction with other common medications. However, interactions with certain medications are possible. Therefore, always tell your veterinarian about all medications that you have given your dog in the past and all medications that you are planning to give with CYCLAVANCE.

What can I do in case my dog gets more than the prescribed amount of CYCLAVANCE?
Contact your veterinarian immediately if your dog gets more than the prescribed amount of CYCLAVANCE.

What else should I know about CYCLAVANCE?
If your dog becomes seriously ill, consult your veterinarian who will recommend the appropriate treatment.

This sheet provides a summary of information about CYCLAVANCE. If you have any questions or concerns about CYCLAVANCE or atopic dermatitis in dogs, talk to your veterinarian. As with all prescribed medications, CYCLAVANCE should only be given to the dog for which it was prescribed. It should be given to your dog only for the condition for which it was prescribed, at the prescribed dose, and as directed by your veterinarian.

Approved by FDA under ANADA # 200-692

CLINICAL PHARMACOLOGY: Cyclosporine is a immunosuppressive agent that has been shown to work via suppression of T-helper and T-suppressor cells and inhibition of interleukin-2. It does not depress hematopoiesis or the function of phagocytic cells. A decrease in CD4 and CD8 cells was not seen in dogs receiving 20 mg/kg/day of cyclosporine for 56 days. Cyclosporine is not a corticosteroid or an antihistamine.

METABOLISM: Cyclosporine is extensively metabolized by the cytochrome P-450 enzyme system in the liver, and to a lesser degree in the gastrointestinal tract and the kidney. The metabolism of cyclosporine can be altered by the co-administration of a variety of agents (See *Precautions*).

EFFECTIVENESS FIELD STUDY: A multisite, placebo controlled, double masked, field study was conducted in the United States and Canada using 16 investigators. Two hundred sixty five (265) dogs aged 1-10 years, weighing 4-121 lbs received either cyclosporine capsules at 5 mg/kg/day or placebo capsules. After 30 days, placebo dogs were switched to cyclosporine capsules.

Dogs were treated with cyclosporine capsules for a total of 4 months. No additional therapy with antihistamines, corticosteroids or medicated shampoos was permitted. Evaluations for pruritus and for skin lesions to derive a Canine Atopic Dermatitis Extent and Severity Index (CADESI) score occurred at enrollment and at monthly intervals. One hundred ninety-two (192) dogs were included in the statistical analysis of effectiveness.

At the end of the 30 day placebo controlled period, CADESI scores of dogs treated with cyclosporine capsules improved by 45% from enrollment, while CADESI scores of dogs treated with placebo worsened by 9%. Seventy-four percent (74%) of cyclosporine capsule treated dogs showed improvement in their pruritus scores over the first 30 day period, while only 24% of the placebo treated dogs showed an improvement. Owner and Veterinary Global Assessment in response to treatment also demonstrated statistically significant ($p<0.0001$) improvement. After 4 weeks of therapy, Owner and Veterinary Global Assessments showed approximately twice as much improvement in the cyclosporine capsule treated dogs as compared to placebo treated dogs.

Improvements in pruritus accompanied by 50% or 75% improvements in CADESI scores resulted in dose reductions to every other day or twice weekly respectively. Not all dogs were able to decrease to twice weekly dosing. Some animals required upward or downward dosage adjustments during the study. Such adjustments should be expected during therapy of this disease. Dogs unable to decrease from once daily dosing after 60 days were considered dose reduction failures for the purposes of the study.

The results of dose assignments, based on the study criteria, for each 4-week dosing period, are shown in the graph below.
Analysis of blood levels of cyclosporine drawn during the study demonstrated no correlation between blood cyclosporine levels and CADESI scores or pruritus; therefore monitoring blood cyclosporine levels is not an appropriate predictor of effectiveness.

ANIMAL SAFETY: In a 52-week oral study with dose levels of 0, 1, 3, and 9 times the target initial daily dose, emesis, diarrhea and weight loss were seen in all cyclosporine treated



groups with increasing frequency as the dose increased.

Multilocular papilloma-like lesions of the skin were observed in 5 out of 8 high dose animals between weeks 20 and 40. These changes regressed spontaneously after drug was withdrawn.

Other findings in the mid and high dose animals included swollen gums due to chronic gingivitis and periodontitis, lower serum albumin and higher cholesterol, triglyceride, IgA and IgG. Hematological findings consisted of anemia and decreased leukocyte counts in a few high dose animals. Erythrocyte sedimentation rates were increased at all dose levels in a dose dependent fashion. Notable histopathological findings were limited to lymphoid atrophy, hypertrophic gums (from gingivitis) and slight regenerative changes of the renal tubular epithelium in high dose animals. The findings were shown to be reversible during a 12-week recovery phase of the study.

In a 90-day study with cyclosporine, dogs were dosed in one of two patterns: either 1, 3, or 5X the maximum recommended target initial daily dose for 90 days, or 1, 3, or 5X the maximum recommended target initial daily dose for 30 days followed by tapering to mimic the recommended clinical dosing pattern. The maximum recommended dose, when administered for 90 days causes callus-like lesions on the footpads, red/swollen pinnae, mild to moderate gingival proliferation, hyperkeratotic areas on the integument, hair loss, salivation, vomiting, and diarrhea/ abnormal stools. These clinical signs lessened in severity or resolved as the drug was tapered to a lower dose. Increased erythrocyte sedimentation rate, hyperproteinemia, hyperglobulinemia, hypoalbuminemia, hypocalcemia, hypophosphatemia, and hypomagnesemia were observed at three and five times the maximum recommended dose. These resolved as the dose was tapered.

When administered at higher than the maximum recommended dose, raised skin lesions, papilloma-like areas on the integument, popliteal lymph node enlargement, and weight loss were also seen. There were no cyclosporine related changes in urinalysis, ECG, blood pressure, or ophthalmologic exams.

Gross necropsy revealed epithelial changes consistent with those seen on physical examination. Proliferation of gingiva and toe pad epithelium was seen in all cyclosporine dosed groups, and was seen in a dose dependent fashion. The degree of the proliferation was greater in dogs in the non-tapered groups as compared to the tapered groups. Similar changes were noted on histopathologic examination of the cutaneous changes seen on physical examination. These lesions were characterized by epidermal hyperplasia, chronic dermatitis and hyperkeratosis.

Methylprednisolone combination: Twenty-four dogs were administered 1 mg/kg/day methylprednisolone alone for 14 days followed by 20 mg/kg/day cyclosporine either alone or in combination with methylprednisolone, or placebo for 14 days. There was no evidence of seizures/convulsions or neurological signs.

Vaccination effect: The effect of cyclosporine administration on the immunological response to vaccination was evaluated in a study in which 16 dogs were dosed with either cyclosporine at 20 mg/kg/day (4X the initial daily dose) or placebo for 56 days. All dogs were vaccinated on Day 27 with a killed commercial rabies virus and a multivalent vaccine (DHLPP) which included a modified live virus. Antibody titers for rabies, canine distemper, canine adenovirus type 2, parainfluenza, parvovirus, *Leptospira canicola*, and *Leptospira icterohaemmorrhagiae* were examined on Days 0, 27 (prior to vaccination), 42 and 56. Quantification of CD4, CD8, and CD3 T-lymphocytes was analyzed.

Clinical changes included soft stool and dermatologic changes consistent with those seen in previous studies. Antibody titers did not rise in dogs treated with cyclosporine or the placebo for any component of the multivalent vaccine which included a modified live virus while all animals demonstrated a significant increase in antibody rabies titer by Day 42 or 15 days post-revaccination. No effect was seen on T-lymphocytes.

STORAGE INFORMATION: CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED should be stored and dispensed in the original container at temperatures between 68-86°F (20-30°C).
Do not refrigerate because a precipitate may be observed below 68°F (20°C). **Once opened, use contents within 12 weeks.**

HOW SUPPLIED: CYCLAVANCE is supplied in glass amber vials of 5, 15, 30 and 50 mL at 100 mg/mL.
- 5 and 15 mL vials are supplied with a 1 mL Luer-Lok® oral dosing syringe.
- 30 and 50 mL vials are supplied with a 1 mL and 3 mL Luer-Lok® oral dosing syringes.

Instructions for Assembling the Dispensing System and Preparing a Dose of CYCLAVANCE® (cyclosporine oral solution) USP MODIFIED.



Assembling the Dispensing System

The dispensing system consists of three parts:
1. A vial containing the medicine sealed with a rubber stopper
2. A plastic adapter (dispensing system) that you will push onto the top of the vial. The adapter must always remain on the vial after first use.
3. An oral dosing syringe that fits into the top of the plastic adapter to withdraw the prescribed dose of medicine from the vial. (1 mL syringe with the 5 and 15 mL vial sizes; 1 and 3 mL syringes with the 30 and 50 mL vial sizes)

Fitting the Plastic Adapter into the New Bottle of Medicine

1. Remove the plastic lid from the top of the vial.
2. Hold the vial upright on a table and align the stylet straight up and down over the center ring in the vial stopper. Push the plastic adapter firmly straight down onto the top of the vial until it is firmly and evenly seated.

Note: To prepare a dose, carefully follow the instructions for **Preparing a Dose of Medicine.**

Preparing a Dose of Medicine

1. Check that the plunger of the oral dosing syringe is pushed all the way down.
2. Keep the vial upright and push the oral dosing syringe firmly into the plastic adapter while turning the syringe clockwise to secure the dispensing system.
3. Turn the vial with the attached dosing syringe upside down and slowly pull the plunger down so that the oral dosing syringe fills with the medicine.
4. **Expel any large bubbles by pushing and pulling the plunger a few times. The presence of a few tiny bubbles is not important for dosing accuracy.**
5. Withdraw the dose of medicine prescribed by your veterinarian using the flange of the barrel to align with the marks on the plunger. These marks are in milliliters (mL).

Note: If the prescribed dose is more than the maximum volume marked on the oral dosing syringe, you will need to reload the syringe to withdraw the full dose.
6. Return the vial to its upright position and remove the oral dosing syringe by twisting it counterclockwise out of the plastic dispenser.

You can now introduce the syringe into the mouth of the dog according to your veterinarian's instructions, and push the medicine out of the syringe.

See **Information for Dog Owners** for complete administration instructions. To view an instructional video on Assembling the Dispensing System and Preparing a Dose of CYCLAVANCE, please go to https://vet-us.virbac.com/cyclavance

Do not rinse or clean the oral dosing syringe between uses.
Store the medication and the dosing syringe securely.
CYCLAVANCE should be stored and dispensed in the original container at temperatures between 68-86°F (20-30°C).
Do not refrigerate because a precipitate may be observed below 68°F (20°C). **Once opened, use contents within 12 weeks.**

Keep out of reach of children

Approved by FDA under ANADA # 200-692

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059
Fort Worth, TX 76161
1-800-338-3659
us.virbac.com

02026053
Rev. 08/2022

PRODUCT INSERTS/DISCLOSURES

easOtic®

(hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate)
Otic Suspension for Dogs
Anti-inflammatory, antifungal, and antibacterial

Rx
For Otic Use in Dogs Only

CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION
EASOTIC® Otic Suspension contains 1.11 mg/mL hydrocortisone aceponate, 17.4 mg/mL miconazole nitrate and 1.5 mg/mL gentamicin (as sulfate). The inactive ingredient is a semi-liquid petroleum jelly.

INDICATIONS
EASOTIC Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Staphylococcus pseudintermedius*).

DOSAGE AND ADMINISTRATION
Verify that the tympanic membrane is intact. **Shake well before each use.**

Priming the canister: Prior to the first use of the dosing container, press firmly on the pump several times until the product fills the nozzle (canula tip) with a full dose of product.

Carefully insert the canula into the affected external ear canal(s) and apply 1 mL (a single pump) of Otic Suspension once per day for 5 days. Wash hands after usage.

CONTRAINDICATIONS
Do not use in dogs with known tympanic membrane perforation.

EASOTIC Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics.

WARNINGS
Human Warnings: Not for use in humans. Keep this and all drugs out of reach of children. In case of accidental skin contact, wash area thoroughly with water. Avoid contact with eyes.

Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product.

In case of accidental ingestion by humans, contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.

Animal Warnings: As a class, aminoglycoside antibiotics are associated with ototoxicity, vestibular dysfunction and renal toxicity. The use of EASOTIC Otic Suspension in a dog with a damaged tympanic membrane can result in damage to the structures of the ear associated with hearing and balance or in transmission of the infection to the middle or inner ear. Immediately discontinue use of EASOTIC Otic Suspension if hearing loss or signs of vestibular dysfunction are observed during treatment (see **ADVERSE REACTIONS**).

PRECAUTIONS
Do not administer orally.

Concurrent administration of potentially ototoxic drugs should be avoided.

Use with caution in dogs with impaired hepatic or renal function (see **ANIMAL SAFETY**).

Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see **ANIMAL SAFETY**).

The safe use of EASOTIC Otic Suspension in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

ADVERSE REACTIONS
In a field study conducted in the United States (see **EFFECTIVENESS**), there were no adverse reactions reported in 145 dogs administered EASOTIC Otic Supsension.

In foreign market experience, reports of hearing loss and application site erythema have been received. In most reported cases, the hearing loss and erythema were transient and resolved with discontinuation of EASOTIC® suspension.

To report suspected adverse drug events, contact Virbac AH, Inc at 1-800-338-3659 or the FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

For technical assistance or to obtain a Safety Data Sheet, call Virbac at 800-338-3659 or visit us at us.virbac.com.

PHARMACOLOGY
Hydrocortisone aceponate is a glucocorticoid with anti-inflammatory effects. Miconazole nitrate is an imidazole antifungal. Gentamicin sulfate is an aminoglycoside antibiotic.

In the target animal safety study, hydrocortisone aceponate, miconazole and gentamicin were shown to be systemically absorbed from the ears of healthy dogs (see **ANIMAL SAFETY**); increased systemic absorption may be observed in inflamed ears.

MICROBIOLOGY
The compatibility and additive effect of each of the components in EASOTIC® Otic Suspension was demonstrated in a component effectiveness and non-interference study. An in vitro study of organisms collected from clinical cases of otitis externa in dogs and from dogs enrolled in the clinical effectiveness study for EASOTIC Otic Suspension determined that miconazole nitrate and gentamicin sulfate inhibit the growth of bacteria and yeast commonly associated with otitis externa in dogs. No consistent synergistic or antagonistic effect of the two antimicrobials was demonstrated. The addition of hydrocortisone aceponate to the combination did not impair antimicrobial activity to any clinically-significant extent.

In a field study (see **EFFECTIVENESS**), the minimum of 10 isolates from successfully treated cases was met for *S. pseudintermedius* and *M. pachydermatis*.

EFFECTIVENESS
The effectiveness of this drug was evaluated in 157 dogs with otitis externa. The study was a double-masked field study with a placebo control. One hundred and four dogs were treated with EASOTIC Otic Suspension and 53 dogs were treated with the placebo control. Treatment was administered once daily for 5 consecutive days to the affected ear(s). The dogs were evaluated at 4 different intervals over the course of 1 month to determine response to therapy. The 6 clinical signs evaluated were: malodor, aural discharge, pruritus, erythema, swelling and pain. The individual clinical scores were assigned based on the severity of each sign. Success was based on clinical improvement at Day 28 ±2 days. The success rates of the 2 groups were significantly different ($p=0.0179$); 68.5% of dogs administered EASOTIC Otic Suspension were successfully treated, compared to 21.8% of the dogs in the placebo control group.

ANIMAL SAFETY
In the target animal safety study, EASOTIC Otic Suspension was administered at 0X, 1X, 3X and 5X the recommended dose for 15 consecutive days (3 times the recommended treatment duration) in laboratory Beagles, with 8 dogs per group. Hypersensitivity reactions in the external ear canal and inner pinnae were seen in all EASOTIC Otic Suspension groups and included mild to severe aural erythema (3X group), papules and ulceration (1X and 5X groups), otitis externa (3X and 5X groups), and otitis media (5X group). Renal tubular crystals were present in the cortex and medulla (0X, 1X, 3X, and 5X groups) and mild renal tubular basophilia and atrophy were present in one 5X group dog. Baseline cortisol values and the cortisol response to ACTH stimulation were lower in treated dogs compared to the control dogs. The ACTH stimulation test results are consistent with systemic absorption of topical corticosteroids causing suppression of the hypothalamic-pituitary-adrenal axis. Dogs in the 3X and 5X groups demonstrated elevations in AST and ALP, while dogs in the 1X, 3X, and 5X groups had elevated cholesterol, total protein, and albumin levels. Dogs in the 3X and 5X groups also had higher liver weights and greater food consumption.

STORAGE INFORMATION: Store at temperatures between 20° C-25° C (68° F-77° F), with excursions permitted between 15° C-30° C (59° F-86° F).

HOW SUPPLIED: EASOTIC Otic Suspension is supplied in a polyethylene canister, with a soft applicator canula.

Each canister contains ten 1 mL doses.Made in the U.S.A.

Distributed by:
Virbac AH, Inc.
P.O. Box 162059
Fort Worth, TX 76161 USA

Approved by FDA under NADA # 141-330

Revision Date 04/2020

302076-04

Approved by FDA under ANADA # 200-071

0234
0302086-04

PRODUCT INFORMATION

EUTHASOL®

(pentobarbital sodium and phenytoin sodium)
Euthanasia Solution

FOR DOGS ONLY

CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION A non-sterile solution containing pentobarbital sodium and phenytoin sodium as the active ingredients. Rhodamine B, a bluish-red fluorescent dye, is included in the formulation to help distinguish it from parenteral drugs intended for therapeutic use. Although the solution is not sterile, benzyl alcohol, a bacteriostat, is included to retard the growth of microorganisms.

Each mL contains: Active ingredients: 390 mg pentobarbital sodium (barbituric acid derivative), 50 mg phenytoin sodium; *Inactive ingredients:* 10% ethyl alcohol, 18% propylene glycol, 0.003688 mg rhodamine B, 2% benzyl alcohol (preservative), water for injection q.s. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH.

ACTIONS EUTHASOL® Euthanasia Solution contains two active ingredients which are chemically compatible but pharmacologically different. Each ingredient acts in such a manner so as to cause humane, painless, and rapid euthanasia. Euthanasia is due to cerebral death in conjunction with respiratory arrest and circulatory collapse. Cerebral death occurs prior to cessation of cardiac activity.

When administered intravenously, pentobarbital sodium produces rapid anesthetic action. There is a smooth and rapid onset of unconsciousness. At the lethal dose, there is depression of vital medullary respiratory and vasomotor centers.

When administered intravenously, phenytoin sodium produces toxic signs of cardiovascular collapse and/or central nervous system depression. Hypotension occurs when the drug is administered rapidly.

Pharmacodynamic Activity The sequence of events leading to humane, painless, and rapid euthanasia following intravenous injection of EUTHASOL® Euthanasia Solution is similar to that following intravenous injection of pentobarbital sodium or other barbituric acid derivatives. Within seconds, unconsciousness is induced with simultaneous collapse of the dog. This stage rapidly progresses to deep anesthesia with concomitant reduction in the blood pressure. A few seconds later, breathing stops, due to depression of the medullary respiratory center; encephalographic activity becomes isoelectric, indicating cerebral death; and then cardiac activity ceases.

Phenytoin sodium exerts its effect during the deep anesthesia stage caused by the pentobarbital sodium. This ingredient, due to its cardiotoxic properties, hastens the stoppage of electrical activity in the heart.

INDICATIONS For use in dogs for humane, painless, and rapid euthanasia.

WARNING For canine euthanasia only. Must not be used for therapeutic purposes. Do not use in animals intended for food.

ENVIRONMENTAL HAZARD: This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with state and local laws, to prevent consumption of carcass material by scavenging wildlife.

HUMAN WARNING Caution should be exercised to avoid contact of the drug with open wounds or accidental self-inflicted injections. Keep out of reach of children. If eye contact, flush eyes with water and seek medical attention.

PRECAUTIONS Euthanasia may sometimes be delayed in dogs with severe cardiac or circulatory deficiencies. This may be explained by the impaired movement of the drug to its site of action. An occasional dog may elicit reflex responses manifested by motor movement; however, an unconscious animal does not experience pain, because the cerebral cortex is not functioning.

When restraint may cause the dog pain, injury, or anxiety, or danger to the person making the injection, prior use of tranquilizing or immobilizing drugs may be necessary.

DOSAGE AND ADMINISTRATION

Dosage: Dogs, 1 mL for each 10 pounds of body weight.

Administration: Intravenous injection is preferred. Intracardiac injection may be made when intravenous injection is impractical, as in a very small dog or in a comatose dog with impaired vascular functions. Good injection skill is necessary for intracardiac injection.

The calculated dose should be given in a single bolus injection.

For intravenous injection, a needle of sufficient gauge to ensure intravenous placement of the entire dose should be used.

The use of a Luer-Lok® syringe is recommended to prevent accidental exposure due to needle/syringe separation.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

HOW SUPPLIED EUTHASOL® Euthanasia Solution is available in 100 mL multiple dose vials.

STORAGE Store at controlled room temperature of between 20˚ and 25˚C (68˚ and 77˚F), with excursions permitted between 15° to 30°C (59° to 86°F).

Manufactured by a nonsterilizing process.

Manufactured for **Virbac AH, Inc.**, P.O. Box 162059, Fort Worth, TX 76161

PRODUCT INSERTS/DISCLOSURES

GENESIS®

TOPICAL SPRAY

Solution of 0.015% triamcinolone acetonide

FOR TOPICAL USE IN DOGS ONLY

CAUTION: Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION
GENESIS® Topical Spray contains 0.015% triamcinolone acetonide for dermatologic use. Each mL of GENESIS Topical Spray contains 0.15 mg triamcinolone acetonide in an aqueous solution containing propylene glycol, specially denatured alcohol, and DMDM hydantoin.

PHARMACOLOGY
Triamcinolone acetonide is highly potent synthetic glucocorticoid, which is primarily effective because of its anti-inflammatory activity. Topical corticosteroids can be absorbed from normal intact skin. Studies have demonstrated that topical preparations of triamcinolone have decreased plasma cortisol levels and suppressed the response to ACTH.

INDICATIONS
GENESIS Topical Spray is indicated for the control of pruritus associated with allergic dermatitis in dogs.

DOSAGE AND ADMINISTRATION
Apply sufficient pump sprays to uniformly and thoroughly wet the affected areas while avoiding run-off of excess product. Avoid getting the spray in dog's eyes. GENESIS Topical Spray should be administered twice daily for seven days, once daily for the next seven days, then every other day for an additional 14 days (28 days total).

DOSAGE AND ADMINISTRATION
Apply sufficient pump sprays to uniformly and thoroughly wet the affected areas while avoiding run-off of excess product. Avoid getting the spray in dog's eyes. GENESIS Topical Spray should be administered twice daily for seven days, once daily for the next seven days, then every other day for an additional 14 days (28 days total). To avoid overdosing the product, use the following table to determine the maximum number of pump sprays per treatment application. For mild pruritus or for small treatment surface areas, the number of pumps used should be less than this maximum amount.

Table 1. Maximum allowable dosage

Dog weight		Maximum number of pumps per single application*	Total maximum volume (mL) per 28 day treatment regimen
lb	kg		
11	5	4	101
22	10	7	176
33	15	11	277
44	20	15	378
55	25	19	478 (one 16-oz bottle)
66	30	22	554
77	35	26	655
88	40	30	756
99	45	33	832
110	50	37	932 (two 16-oz bottles)

*Using the recommended dosing regimen, there are two applications per day for the first week, one application per day for the second week and one application every other day for the last two weeks of treatment.

WARNINGS
User Safety: Wear gloves when applying the product. Spray in a well ventilated area. If the spray causes irritation to mucous membranes, discontinue use.

Keep this and all drugs out of reach of children.

Animal Safety: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palates in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies including deformed forelegs, phocomelia, and anasarca.

PRECAUTIONS
The safety of this product for dogs less than eight pounds or for dogs less than one year of age has not been evaluated. The safety of this product in breeding, pregnant or lactating dogs has not been evaluated (see **WARNINGS**). The safety of long term or repeated use of this product (greater than 28 days) has not been evaluated.

Prolonged use or overdosage of any corticosteroid may produce adverse effects.

Because absorption of triamcinolone acetonide through topical application on the skin and by licking may occur, dogs receiving triamcinolone acetonide therapy should be observed closely for evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression. When the product was applied at approximately 6 times the maximum allowable dose (100 mL) once daily to normal skin of two dogs for five days, plasma cortisol levels were decreased after the first treatment and response to ACTH was reduced.

If adverse clinical signs are observed, treatment should be discontinued. Once the signs have disappeared, treatment can be resumed at a lower dose or frequency of application. If hypersensitivity to the product occurs, treatment should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

ADVERSE REACTIONS
In a field study with GENESIS Topical Spray, polyuria was reported in 3 of 57 dogs (5.3%) and polyphagia in 1 of 57 dogs (1.8%). Mild (within reference range) decreases in total leukocyte, lymphocyte and eosinophil counts were also reported. The following local reactions were reported in ≤ 3.6% of 110 dogs treated with GENESIS Topical Spray or the product vehicle: aversion/discomfort, sneezing and watery eyes.

EFFECTIVENESS
In a 28-day field study to demonstrate the effectiveness of GENESIS Topical Spray in controlling pruritus associated with allergic dermatitis in dogs under field conditions, 105 dogs with atopy, unspecified allergic dermatitis, flea allergy, and food allergy were treated with GENESIS Topical Spray at the recommended use level or placebo. Results are shown in Table 2.

Table 2. Percent of cases considered treatment successes

Treatment	Percent success[1]
GENESIS Topical Spray	35/54 = 64.8%*
Placebo	12/51 = 23.5%

[1]Success = reduction in the level of severity by two or more grades in the investigator's overall evaluation from the pre-treatment to the post-treatment evaluation period.
*Significantly different from placebo at $p < 0.05$

STORAGE CONDITIONS
Store at room temperature, 15° - 30° C (59° - 86° F).

HOW SUPPLIED
GENESIS Topical Spray is supplied in 8 ounce (237 mL) and 16 ounce (478 mL) bottles with spray applicators.

For technical information or to report adverse reactions, please call 1-800-338-3659.

Approved by FDA under NADA # 141-210.

Distributed by:
Virbac AH, Inc.
Fort Worth, TX 76161

Rev. 10/21

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

PRODUCT INSERTS/DISCLOSURES

1608247D
11605

Itrafungol®
(itraconazole oral solution)
10 mg/mL

Antifungal for oral use in cats only

Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description
ITRAFUNGOL (itraconazole oral solution) is a yellow to slightly amber, clear solution containing the active ingredient, itraconazole, at 10 mg/mL.

Indication
ITRAFUNGOL is indicated for the treatment of dermatophytosis caused by *Microsporum canis* in cats.

Dosage and Administration
The solution should be administered orally using the enclosed graduated dosing syringe.
The daily dosage is 5 mg/kg (0.5 mL/kg) body weight administered once daily on alternating weeks for 3 treatment cycles. Cats are treated during weeks 1, 3, and 5, and left untreated during weeks 2 and 4.

7 days	7 days	7 days	7 days	7 days
Daily treatment	No treatment	Daily treatment	No treatment	Daily treatment

Each line on the dosing syringe represents 0.05 mL of oral solution.

Table 1: Dose Table for ITRAFUNGOL

Weight of Cat	Volume of ITRAFUNGOL
lb 0.5	mL 0.1
lb 1	mL 0.2
lb 1.5	mL 0.35
lb 2	mL 0.45
lb 2.5	mL 0.55
lb 3	mL 0.7
lb 3.5	mL 0.8
lb 4	mL 0.9
lb 4.5	mL 1
lb 5	mL 1.15
lb 6	mL 1.35
lb 7	mL 1.6
lb 8	mL 1.8
lb 9	mL 2
lb 10	mL 2.25
lb 11	mL 2.5
lb 12	mL 2.7
lb 13	mL 3

The solution should be administered orally using the enclosed graduated dosing syringe. Keep the bottle upright and insert the dosing syringe through the opening of the top of the bottle (Figure 1). Do not invert the bottle (Figure 2). Fill the syringe by pulling the plunger until it reaches the graduation corresponding to the correct mL dose as indicated at the top of the syringe ring (Figure 3). Treat the cat by slowly and gently administering the liquid into the mouth, allowing the cat to swallow the product (Figure 4). For cats weighing more than 13.0 lbs, the total dose will need to be calculated and given over two doses as the dosing syringe only holds 3.0 mL of solution.

Fig 1



Fig 2

Fig 3

Fig 4

After dosing, do not replace syringe in the bottle. Rinse and dry the syringe. The bottle cap should be screwed back on tightly.

Contraindications
Do not administer to cats with hypersensitivity to itraconazole.

Warnings

User Safety Warnings
Not for use in humans. Keep this and all medications out of reach of children. Wash hands and exposed skin after use. In case of accidental contact with eyes, rinse thoroughly with water. In case of pain or irritation, seek medical advice. In case of accidental ingestion, rinse mouth with water and seek medical advice.
Special precautions for person administering the veterinary product to the animal:
Microsporum canis dermatophytosis is a zoonotic disease (a disease that can be transmitted from animals to humans); therefore consult a physician if a suspected lesion occurs on a human. Wear protective gloves when handling the animal during treatment or when cleaning the syringe. Wash hands and exposed skin after handling the animal.

ITRAFUNGOL (itraconazole oral solution) has not been shown to be sporicidal; therefore in order to reduce zoonotic potential, environmental contamination, and to decrease course of the disease, topical and environmental treatment should also be utilized.

Animal Safety Warnings
ITRAFUNGOL has not been shown to be safe in pregnant cats (see *Animal Safety*).
ITRAFUNGOL should only be used in pregnant or lactating cats when the benefits outweigh the potential risks.

Keep ITRAFUNGOL in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Precautions
ITRAFUNGOL has been associated with renal changes found on histopathology that were not noted after an eight week recovery period (see *Animal Safety*). Use with caution in cats with renal dysfunction.

ITRAFUNGOL is metabolized by the liver (mainly CYP3A) and can cause elevated liver enzymes (see *Animal Safety*). Use with caution in cats with impaired liver function. If clinical signs suggestive of liver dysfunction develop, treatment should be discontinued.

ITRAFUNGOL is a cytochrome p-450 inhibitor and may increase or prolong plasma concentrations of other drugs metabolized by this pathway, such as amitriptyline, amlodipine, benzodiazepines, buspirone, cisapride, corticosteroids, cyclosporine, ivermectin, and macrolide antibiotics.

Negative inotropic effects have been reported in literature when itraconazole was administered intravenously to dogs and healthy human volunteers. Cats suffering from heart disease should be carefully monitored during treatment.

Adverse Reactions
In the laboratory effectiveness study, adverse reactions related to exposure to ITRAFUNGOL were primarily related to the gastrointestinal tract. Two ITRAFUNGOL-treated cats experienced transient hypersalivation during the dosing period. Vomiting was observed in 5 ITRAFUNGOL-treated cats (12.5%) during the dosing period compared to four cats (10%) in the control group. Diarrhea was observed in 9 ITRAFUNGOL-treated cats (22.5%) during the dosing period as compared to 7 cats (17.5%) in the control group.
One ITRAFUNGOL-treated cat showed mild increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at the end of the dosing period. No related clinical signs were observed, and these values returned to normal by the end of the follow-up period. One cat in the ITRAFUNGOL-treated group was noted to have lip erythema and lip induration once during the study.

Field safety was evaluated in 266 cats randomized to receive itraconazole oral solution. Of the 266 cats that received at least one dose of itraconazole oral solution, adverse reactions included 35 cases (13%) of one or more elevated hepatic enzymes and 8 cases (3%) of gastrointestinal upset, including decreased appetite, vomiting and/or diarrhea. Other infrequent adverse reactions included less than 3 cases each of somnolence, depression, and increased salivation.

Contact Information
To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

Clinical Pharmacology
The mode of action of itraconazole is based on its highly selective binding ability to fungal cytochrome p-450 iso-enzymes. This inhibits the synthesis of ergosterol and affects membrane-bound enzyme function and membrane permeability. This effect is irreversible and causes structural degeneration of the fungal organism.

Itraconazole was absorbed rapidly following oral administration of ITRAFUNGOL (itraconazole oral solution) to laboratory cats. Compared to the fasted state, administration of ITRAFUNGOL with food results in slightly higher (1.3 fold) mean total itraconazole exposure (AUC), delay in median T_{max} (Fed 4 hours vs. Fasted 2 hours) and significant decrease (approximately 0.55 fold) in maximum plasma concentration (C_{max}). ITRAFUNGOL can be administered with or without food. Itraconazole oral solution binds extensively to plasma proteins (> 99%), and distributes well to tissues. More than 30 metabolites are formed. Hydroxy-itraconazole is the parent metabolite and has antifungal activity. Excretion is rapid and primarily via the feces.

In cats, a single oral dose of 5 mg/kg results in a C_{max} of 0.525 µg/mL post dose at 2 hours (T_{max}). The $AUC_{0\text{-}24h}$ is 5.09 µg.h/mL and the half-life in plasma is 12.1 hours. After repeated daily administration for seven days at 5 mg/kg/day, the C_{max} is doubled (1.05 µg/mL), the $AUC_{0\text{-}24h}$ is increased 3-fold (15.4 µg.h/mL) and the plasma half-life is increased to 36 hours.

In the therapeutic treatment schedule, itraconazole is almost completely cleared from plasma after each wash-out period. The hydroxy-itraconazole remains near or below the quantification limit in feline plasma after a single dose of itraconazole oral solution at 5 mg/kg. However, after repeated daily doses of itraconazole oral solution at 5 mg/kg for one week, the hydroxy-itraconazole C_{max} of 0.059 µg/mL was reached at 2 hours (T_{max}). Itraconazole concentrations in cat's hair vary; an increase occurs during treatment to a median value of 3.0 µg/g (mean 5.2 µg/g) at the end of the third dosing week and concentrations drop slowly to 1.5 µg/g (mean 1.9 µg/g) at 14 days after final dosing. Concentrations of hydroxy-itraconazole in hair are insignificant.

Effectiveness
Laboratory Study
Effectiveness was demonstrated using ITRAFUNGOL in a masked, placebo controlled laboratory study. Eighty cats were experimentally infected with *Microsporum canis* and treated with either ITRAFUNGOL or sterile water (control product) for the proposed therapeutic treatment schedule followed by a 4-week follow-up period. No topical therapy was used during this study. A statistical difference (P =0.0003) in mycological cure rate (defined as two consecutive negative mycological cultures) was demonstrated between cats treated with ITRAFUNGOL (24/40 or 60%) versus control (1/40 or 2.5%). Ninety percent of ITRAFUNGOL-treated cats (36/40) achieved at least one negative culture by the end of the study. Improvement was seen in inoculation site erythema and skin thickening by Day 7 and in crusts and scales by Day 14. By the end of the study, 98% of ITRAFUNGOL-treated cats had complete resolution of all clinical lesions, compared to 15% in the control group. Wood's lamp cure (defined as no fluorescence at the base and mid-shaft of the hair) in the ITRAFUNGOL-treated group (39/40 or 97.5%) was higher compared to the control group (6/40 or 15%). Itraconazole MICs indicative of susceptibility were obtained in *M. canis* isolates from the two cats unsuccessfully treated with ITRAFUNGOL.

Field Study
A masked, positive-controlled, multi-site field study was conducted in client-owned cats in Europe. In this study, 514 cats diagnosed with dermatophytosis were randomly administered itraconazole oral solution or an active control. Cats received a daily dose of either itraconazole oral solution for three alternating weeks plus a placebo tablet once daily for 5 consecutive weeks, or a placebo solution for three alternating weeks plus the active control once daily for five weeks. Success was evaluated on clinical cure, which was noted with a complete resolution of all clinical lesions. Four weeks after the end of treatment, 175 (83%) out of 207 cats treated with itraconazole oral solution were clinically cured.

Animal Safety
Margin of Safety Study with Recovery
In a margin of safety study, ITRAFUNGOL (itraconazole oral solution) was administered orally to 9-10 week old healthy kittens once daily at 0X (saline control), 1X (5 mg/kg), 3X (15 mg/kg), and 5X (25 mg/kg) the therapeutic dose for 17 alternating weeks (9 total weeks of dosing) followed by an 8 week recovery period. Hypersalivation during or immediately following dosing, vomiting, and loose stool were the most frequent abnormal clinical observations related to treatment with ITRAFUNGOL. Hypersalivation was limited to the 3X and 5X groups and was observed in every dosing cycle. Vomiting was noted at similar levels in the control, 1X and 3X groups; however, it occurred approximately twice as often in the 5X group. Mild gingival bleeding and perioral irritation (patchy alopecia and erythema) was noted in cats in the 3X and 5X groups. Food consumption was consistently higher throughout the study in the control group than the ITRAFUNGOL group. The control group gained more weight during the study than the groups administered ITRAFUNGOL. Mild elevations in ALT were sporadically noted in all groups; however, the number of affected cats increased with the higher doses (two cats in the control group, two cats in the 1X group, three cats in the 3X group, and four cats in the 5X group). In most cats, ALT values peaked just above the upper limit of the reference range and were continuing to trend upward or were elevated yet stable at the end of the study. One cat in the 5X group exhibited inappetence progressing to anorexia, dehydration and vomiting during the first dosing cycle. This cat had repeated episodes of inappetence during the second and third dosing cycles. This cat also had markedly elevated ALT and AST values on Day 36 (693 U/L and 283 U/L, respectively), was treated with minimal supportive care and recovered to complete the study.

Margin of Safety Study
In a margin of safety study, ITRAFUNGOL was administered orally to healthy adult cats once daily at 0X (saline control), 1X (5 mg/kg), 3X (15 mg/kg), and 5X (25 mg/kg) the therapeutic dose for 17 alternating weeks (9 total weeks of dosing) with no recovery period. Hypersalivation was the most frequent abnormal clinical observation related to treatment with ITRAFUNGOL and the incidence increased with the higher doses. One cat in group 4 (5X; Cat #26302) lost 22% of its body weight and had a number of episodes of vomiting, salivation, and anorexia during the treatment period. This cat also had renal lesions found on histopathology. Increasing trends were noted in ALT, AST, and creatinine values in some cats administered ITRAFUNGOL as compared to baseline values. Abnormal renal findings included proximal convoluted tubule acute degeneration in 3 cats in the 1X group and 3 cats in the 5X group; one 5X cat (cat #26302) also had proximal convoluted tubule marked pallor and focal mononuclear cell infiltration in the kidneys. In the lungs, one 3X group cat and five 5X cats had intra-alveolar foamy macrophages; five 5X group cats had intra-alveolar syncytial cells.

These histopathology findings are likely related to exposure to ITRAFUNGOL, specifically the vehicle component hydroxypropyl- -cyclodextrin (HP CD). There were no corresponding adverse clinical effects noted on observation or on clinical pathology analysis. In addition, similar changes have been described in literature in other species exposed to HP CD and have been reported to be reversible.

Reproductive Safety
In a study of 16 pregnant queens administered itraconazole oral solution at 5 mg/kg bodyweight for a total of 21 days (7 days on alternate weeks) during gestation or lactation, there was a high frequency of fetal resorption (partial and total), abnormal fetuses, and abnormal maternal behaviors. Confounding factors, such as infectious disease (*Chlamydia psittaci*) in some cats made it difficult to establish a definitive relationship between administration of itraconazole and the abnormal findings. However, the results of this study reveal potential reproductive safety risks and do not support the safe of use of ITRAFUNGOL in pregnant queens.

Storage conditions
Store at 68-77°F (20-25°C). Excursions permitted between 59-86°F (15-30°C).

How supplied
ITRAFUNGOL is available in a glass bottle containing 52 mL of oral solution, closed with a child resistant screw cap and packaged in a cardboard box that includes a package insert and a graduated dosing syringe.

Approved by FDA under NADA # 141-474

Manufactured for Virbac AH, Inc.
P.O. Box 162059
Fort Worth, TX 76161

Version Date: April 2022
1608247D-01

IVERHART MAX®
Chew
(ivermectin/pyrantel pamoate/praziquantel)

For oral use in dogs only.

Caution: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Description: IVERHART MAX® Chew is a combination of three anthelmintics (ivermectin/pyrantel pamoate/praziquantel). The chews are available in four sizes in color-coded packages for oral administration to dogs according to their weight **(see Dosage and Administration)**.

Indications: For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (*Dirofilaria immitis*) for a month (30 days) after infection and for the treatment and control of roundworms (*Toxocara canis, Toxascaris leonina*), hookworms (*Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense*), and tapeworms (*Dipylidium caninum, Taenia pisiformis*).

Dosage and Administration: IVERHART MAX Chew should be administered orally at monthly intervals and the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb), 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb) and 5 mg of praziquantel per kg (2.27 mg/lb) of body weight, as follows:

Dog Weight Pounds	Chew per Month	Chew Size	Ivermectin Content	Pyrantel Pamoate Content	Praziquantel Content
6.0 to 12	1	Toy	34 mcg	28.5 mg	28.5 mg
12.1 to 25	1	Small	68 mcg	57 mg	57 mg
25.1 to 50	1	Medium	136 mcg	114 mg	114 mg
50.1 to 100	1	Large	272 mcg	228 mg	228 mg

IVERHART MAX Chew is recommended for dogs 8 weeks of age or older. For dogs over 100 lbs, use the appropriate combination of these soft chews.

Remove only one dose at a time from the packaging. Return the remaining chew(s) to their box to protect from light. The chew can be offered to the dog by hand or added, intact, to a small amount of dog food. Care should be taken to ensure that the dog consumes the complete dose. The treated dog should be observed for a few minutes after administration to confirm that none of the dose has been lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

IVERHART MAX Chew should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog's first exposure to mosquitoes. The final dose must be given within a month (30 days) after the dog's last exposure to mosquitoes.

When replacing another heartworm preventative product in a heartworm disease prevention program, the first dose of IVERHART MAX Chew must be given within a month (30 days) after the last dose of the former medication. A heartworm test should be performed prior to and 6 months after switching heartworm preventative products.

If the interval between doses exceeds a month (30 days), the effectiveness of ivermectin can be reduced. Therefore, for optimal performance, the chew must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with IVERHART MAX Chew and resumption of the recommended dosing regimen will minimize the opportunity for the development of adult heartworms.

Warnings:
For use in dogs only. Keep this and all drugs out of reach of children and pets. In safety studies with ivermectin/pyrantel pamoate/praziquantel tablets, testicular hypoplasia was observed in some dogs receiving 3 and 5 times the maximum recommended dose monthly for 6 months (see Animal Safety).

In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.

Precautions: Use with caution in sick, debilitated, or underweight animals and dogs weighing less than 10 lbs (see Animal Safety). The safe use of this drug has not been evaluated in pregnant or lactating bitches.

All dogs should be tested for existing heartworm infection before and 6 months after starting treatment with IVERHART MAX Chew, which is not effective against adult *Dirofilaria immitis*. Infected dogs should be treated to remove adult heartworms and microfilariae before initiating a heartworm prevention program.

While some microfilariae may be killed by the ivermectin in IVERHART MAX® Chew at the recommended dose level, IVERHART MAX Chew is not effective for microfilariae clearance. A mild hypersensitivity-type reaction, presumably due to dead or dying microfilariae and particularly involving a transient diarrhea, has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microfilariae.

Adverse Reactions: In a field study with IVERHART MAX Chew, self-limiting adverse reactions, including vomiting, diarrhea, lethargy, difficulty swallowing, excessive salivation, increased water consumption, and coughing were reported. Self-limiting adverse reactions, including lethargy, limpness, salivation, shaking, diarrhea, decreased appetite, licking lips, and belching were reported between 20 minutes and 72 hours following treatment in a field study with ivermectin/pyrantel pamoate/praziquantel tablets.

In field studies with ivermectin/pyrantel/praziquantel pamoate tablets, vomiting or diarrhea within 24 hours of dosing was rarely observed (1.1% of administered doses). The following adverse reactions have been reported in dogs following the use of ivermectin products: depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions, and hypersalivation.

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact the FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

Effectiveness: Prevention of the tissue larval stage of heartworm (*Dirofilaria immitis*) and the elimination of the adult stage of hookworm (*Ancylostoma caninum, Uncinaria stenocephala, Anyclostoma braziliense*), roundworm (*Toxocara canis, Toxascaris leonina*), and tapeworm (*Dipylidium caninum, Taenia pisiformis*) infections in dogs was demonstrated in well-controlled laboratory studies.

Palatability: In a field study of 132 dogs, IVERHART MAX Chew was offered once monthly for 3 months. The dogs voluntarily consumed 86.3% of the doses from the owner's hand or from a bowl within 5 minutes, 13.0% accepted the dose when it was offered in food or administered by placing in the back of the dog's tongue (pilling), and 0.7% of the doses were unable to be administered.

Animal Safety: Studies with ivermectin indicate that certain dogs of the Collie breed are more sensitive to the effects of ivermectin administered at elevated dose levels (more than 16 times the target dose level of 6 mcg/kg) than dogs of other breeds. At elevated doses, sensitive dogs showed more adverse reactions which included mydriasis, depression, ataxia, tremors, drooling, paresis, recumbency, excitability, stupor, coma and death. No signs of toxicity were seen at 10 times the recommended dose (27.2 mcg/lb) in sensitive Collies. Data from these studies support the safety of ivermectin products in dogs, including Collies, when used at the label recommended dose.

Because ivermectin and praziquantel are approximately 30% more bioavailable in the IVERHART MAX Chew than in the ivermectin/pyrantel pamoate/praziquantel tablets used in the following target animal safety studies, the margin of safety is narrower than reported in these studies. The potential for adverse reactions may be greater in individual dogs administered IVERHART MAX Chew than ivermectin/pyrantel pamoate/praziquantel tablets.

In a target animal safety study using ivermectin/pyrantel pamoate/praziquantel tablets, doses were administered to 8 week old Beagle puppies at one, three, and five times the maximum recommended dose of 12.5 mcg/kg ivermectin, 10.47 mg/kg pyrantel and 10.47 mg/kg praziquantel. The dogs were treated every 30 days for 6 months. Vomiting within 6 hours of dosing and soft or watery feces within 24 hours of dosing were observed. Other observations during the study were: ano-genital swelling, lethargy, head movements, shallow, audible or difficult breathing, and salivation. One dog in the 5X group had tremors and decreased activity. All of these signs were transient. No treatment was required. Histopathology showed testicular hypoplasia in the 3X and 5X groups **(see Warnings)**.

In a laboratory safety study using ivermectin/pyrantel pamoate/praziquantel tablets, 12-week-old Beagle puppies receiving 3 and 5 times the recommended dose once weekly for 13 weeks demonstrated a dose-related decrease in testicular maturation compared to controls. In this study, all treated puppies had significantly higher cholesterol levels compared to untreated controls.

In a reproductive safety study, adult males were treated at 37.5 mcg/kg ivermectin, 31.4 mg/kg pyrantel and 31.4 mg/kg praziquantel every 14 days during two full spermatogenic cycles (112 days). The quality of semen and reproductive health were not affected by treatment. Treatment related vomiting and soft feces were reported during this study.

In a study of the effectiveness of ivermectin/pyrantel pamoate/praziquantel tablets for the treatment of *Toxocara canis*, one 8.1 lb, 72-day-old puppy died 6 days after administration of the label dose. This puppy and many other puppies in the study had high worm burdens and were reported to have diarrhea, sometimes bloody, frequently before and after treatment. Dehydration and signs of anemia (pale mucous membranes) were the only abnormal gross necropsy finding observed. No definitive cause was determined. In a 90-day field study using ivermectin/pyrantel pamoate/praziquantel tablets, the most serious adverse reactions (lethargy, limpness, and salivation) were seen in dogs weighing less than 10 lbs **(see Precautions)**.

Storage Information: Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F to 86°F). Protect product from light.

How Supplied: IVERHART MAX Chew is available in four dosage strengths **(see Dosage and Administration)** for dogs of different weights. Each strength comes in a package of 6 chews.

Approved by FDA under NADA # 141-441

Manufactured by:

Virbac AH, Inc.
Fort Worth, TX 76137 USA
Phone: 1-800-338-3659

302143-04
10/2020

Virbac **Shaping** the future of **animal health**

PRODUCT INSERTS/DISCLOSURES

IVERHART PLUS®
(ivermectin/pyrantel)
Flavored Chewables

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS: For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae *(Dirofilaria immitis)* for a month (30 days) after infection and for the treatment and control of ascarids *(Toxocara canis, Toxascaris leonina)* and hookworms *(Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense)*.

DOSAGE: *IVERHART* PLUS® (ivermectin/pyrantel) *Flavored Chewables* should be administered orally at monthly intervals at the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb) and 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb) of body weight. The recommended dosing schedule for prevention of canine heartworm disease and for the treatment and control of ascarids and hookworms is as follows:

Dog Weight	Flavored Chewable Per Month	Ivermectin Content	Pyrantel Content
Up to 25 lbs	1	68 mcg	57 mcg
26 to 50 lbs	1	136 mcg	114 mcg
51 to 100 lbs	1	272 mcg	227 mcg

IVERHART PLUS *Flavored Chewables* are recommended for dogs 6 weeks of age and older. For dogs over 100 lbs use the appropriate combination of these flavored chewables.

ADMINISTRATION: Remove only one chewable at a time from the foil-backed blister card. Return the card with the remaining chewables to its box to protect the product from light. Because most dogs find *IVERHART* PLUS *Flavored Chewables* palatable, the product can be offered to the dog by hand. Alternatively, it may be added intact to a small amount of dog food. The chewable should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole.

Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after administration to ensure that part of the dose is not lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

IVERHART PLUS *Flavored Chewables* should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog's first exposure to mosquitoes. The final dose must be given within a month (30 days) after the dog's last exposure to mosquitoes.

When replacing another heartworm preventive product in a heartworm disease preventive program, the first dose of *IVERHART* PLUS *Flavored Chewables* must be given within a month (30 days) of the last dose of the former medication.

If the interval between doses exceeds a month (30 days), the efficacy of ivermectin can be reduced. Therefore, for optimal performance, the flavored chewable must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with *IVERHART* PLUS *Flavored Chewables* and resumption of the recommended dosing regimen will minimize the opportunity for the development of adult heartworms.

Monthly treatment with *IVERHART* PLUS *Flavored Chewables* also provides effective treatment and control of ascarids (*T. canis, T. leonina*) and hookworms (*A. caninum, U. stenocephala, A. braziliense*). Clients should be advised of measures to be taken to prevent reinfection with intestinal parasites.

EFFICACY: *IVERHART* PLUS *Flavored Chewables*, given orally using the recommended dose and regimen, are effective against the tissue larval stage of *D. immitis* for a month (30 days) after infection and, as a result, prevent the development of the adult stage. *IVERHART* PLUS *Flavored Chewables* are also effective against canine ascarids (*T. canis, T. leonina*) and hookworms (*A. caninum, U. stenocephala, A. braziliense*).

ACCEPTABILITY: In a trial in client-owned dogs, *IVERHART* PLUS *Flavored Chewables* were shown to be a palatable oral dosage form consumed at first offering by the majority of dogs.

PRECAUTIONS: All dogs should be tested for existing heartworm infection before starting treatment with *IVERHART* PLUS *Flavored Chewables*, which are not effective against adult *D. immitis*. Infected dogs must be treated to remove adult heartworms and microfilariae before initiating a program with *IVERHART* PLUS *Flavored Chewables*.

While some microfilariae may be killed by the ivermectin in *IVERHART* PLUS *Flavored Chewables* at the recommended dose level, *IVERHART* PLUS *Flavored Chewables* are not effective for microfilariae clearance. A mild hypersensitivity-type reaction, presumably due to dead or dying microfilariae and particularly involving a transient diarrhea, has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microfilariae.

Keep this and all drugs out of the reach of children.
In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.

Store at 20°C - 25°C (68°F - 77°F), excursions permitted between 15°C - 30°C (59°F - 86°F). Protect product from light.

Warnings: Use product on or before its expiration date.
Discard or return unused tablets.

ADVERSE REACTIONS: In clinical trials with ivermectin/pyrantel, vomiting or diarrhea within 24 hours of dosing was rarely observed (1.1% of administered doses). The following adverse reactions have been reported following the use of ivermectin: Depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions and hypersalivation.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

SAFETY: Studies with ivermectin indicate that certain dogs of the Collie breed are more sensitive to the effects of ivermectin administered at elevated dose levels (more than 16 times the target use level of 6 mcg/kg) than dogs of other breeds. At elevated doses, sensitive dogs showed adverse reactions which included mydriasis, depression, ataxia, tremors, drooling, paresis, recumbency, excitability, stupor, coma and death. Ivermectin demonstrated no signs of toxicity at 10 times the recommended dose (60 mcg/kg) in sensitive Collies. Results of these trials and bioequivalency studies, support the safety of ivermectin products in dogs, including Collies, when used as recommended.

Ivermectin/pyrantel has shown a wide margin of safety at the recommended dose level in dogs, including pregnant or breeding bitches, stud dogs and puppies aged 6 or more weeks. In clinical trials, many commonly used flea collars, dips, shampoos, anthelmintics, antibiotics, vaccines and steroid preparations have been administered with ivermectin/pyrantel in a heartworm disease preventive program.

In one trial, where some pups had parvovirus, there was a marginal reduction in efficacy against intestinal nematodes, possibly due to a change in intestinal transit time.

HOW SUPPLIED: *IVERHART* PLUS *Flavored Chewables* are available in three dosage strengths (See DOSAGE section) for dogs of different weights. Each strength comes in a box of 6 tablets, packed 10 boxes per display box.

Approved by FDA under ANADA # 200-302

Manufactured by: Virbac AH, Inc.
Fort Worth, TX 76161, USA
301732-06
07/21

Virbac

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

MILBEHART™
(milbemycin oxime)
Flavored Tablets

INFORMATION FOR DOSING DOGS

The once-a-month tablet that prevents heartworm disease, controls adult hookworm, and removes and controls adult roundworm and whipworm infections in dogs and puppies.

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Keep this and all drugs out of the reach of children.

Description: MILBEHART™ (milbemycin oxime) Flavored Tablets are available in four tablet sizes in color-coded packages for oral administration to dogs and puppies. Each tablet is formulated to provide a minimum of 0.23 mg/lb (0.5 mg/kg) body weight of milbemycin oxime. Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A[4] ($C_{32}H_{46}NO_7$, MW 555.71) and 20% A[3] ($C_{31}H_{43}NO_7$, MW 541.68).

Package color	Milbemycin oxime tablet
Yellow	2.3 mg*
Blue	5.75 mg
Purple	11.5 mg
Red	23.0 mg

*for dogs only

Indications: MILBEHART™ Flavored Tablets are indicated for use in the prevention of heartworm disease caused by *Dirofilaria immitis*, the control of adult *Ancylostoma caninum* (hookworm), and the removal and control of adult *Toxocara canis* and *Toxascaris leonina* (roundworms) and *Trichuris vulpis* (whipworm) infections in dogs and in puppies four weeks of age or greater and two pounds body weight or greater.

Dosage: MILBEHART™ Flavored Tablets are given orally, once a month, at the recommended minimum dosage rate of 0.23 mg milbemycin oxime per pound of body weight (0.5 mg/kg).

Recommended Dosage Schedule for Dogs

Body Weight	MILBEHART™ Flavored Tablets
2-10 lbs.	One tablet (2.3 mg)
11-25 lbs.	One tablet (5.75 mg)
26-50 lbs.	One tablet (11.5 mg)
51-100 lbs.	One tablet (23.0 mg)

Dogs over 100 lbs. are provided the appropriate combination of tablets.

Administration: MILBEHART™ Flavored Tablets are dual-purpose and may be offered in food or administered as other tablet medications. Watch the dog closely following dosing to be sure the entire dose has been consumed. If it is not entirely consumed, redose once with the full recommended dose as soon as possible.

MILBEHART™ Flavored Tablets must be administered monthly, preferably on the same date each month. The first dose should be administered within one month of the dog's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. If a dose is missed and a 30-day interval between dosing is exceeded, administer MILBEHART™ Flavored Tablets immediately and resume the monthly dosing schedule.

If MILBEHART™ Flavored Tablets replaces diethylcarbamazine (DEC) for heartworm prevention, the first dose must be given within 30 days after the last dose of DEC.

Precautions: Do not use in puppies less than four weeks of age or less than two pounds of body weight. Prior to initiation of the MILBEHART™ Flavored Tablets treatment program, dogs should be tested for existing heartworm infections. Infected dogs should be treated to remove adult heartworms and microfilariae prior to initiating treatment with MILBEHART™ Flavored Tablets. Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy, have been noted in some treated dogs carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.

Adverse Reactions: The following adverse reactions have been reported following the use of MILBEHART™ Flavored Tablets: Depression/lethargy, vomiting, ataxia, anorexia, diarrhea, convulsions, weakness and hypersalivation.

Efficacy: MILBEHART™ Flavored Tablets eliminate the tissue stage of heartworm larvae and the adult stage of hookworm (*Ancylostoma caninum*), roundworms (*Toxocara canis, Toxascaris leonina*) and whipworm (*Trichuris vulpis*) infestations when administered orally according to the recommended dosage schedule. The anthelmintic activity of milbemycin oxime is believed to be a result of interference with invertebrate neurotransmission.

Safety: Milbemycin oxime has been tested safely in over 75 different breeds of dogs, including collies, pregnant females, breeding males and females, and puppies over two weeks of age. In well-controlled clinical field studies, 786 dogs completed treatment with milbemycin oxime. Milbemycin oxime was used safely in animals receiving frequently used veterinary products such as vaccines, anthelmintics, antibiotics, steroids, flea collars, shampoos and dips.

Two studies in heartworm-infected dogs were conducted which demonstrated mild, transient hypersensitivity reactions in treated dogs with high microfilaremia counts (see Precautions for reactions observed). Safety studies in pregnant dogs demonstrated that high doses (1.5 mg/kg =3X) of milbemycin oxime given in an exaggerated dosing regimen (daily from mating through weaning), resulted in measurable concentrations of the drug in milk. Puppies nursing these females which received exaggerated dosing regimens demonstrated milbemycin-related effects. These effects were directly attributable to the exaggerated experimental dosing regimen. The product is normally intended for once-a-month administration only. Subsequent studies included using 3X daily from mating to one week before weaning and demonstrated no effects on the pregnant females or their litters. A second study where pregnant females were dosed once at 3X the monthly use rate either before, on the day of or shortly after whelping resulted in no effects on the puppies.

Some nursing puppies, at 2, 4, and 6 weeks of age, given greatly exaggerated oral milbemycin oxime doses (9.6 mg/kg = 19X) exhibited signs typified by tremors, vocalization and ataxia. These effects were all transient and puppies returned to normal within 24 to 48 hours. No effects were observed in puppies given the recommended dose of milbemycin oxime (0.5 mg/kg). This product has not been tested in dogs less than 1 kg weight.

A rising-dose safety study conducted in rough-coated collies, manifested a clinical reaction consisting of ataxia, pyrexia and periodic recumbency, in one of fourteen dogs treated with milbemycin oxime at 12.5 mg/kg (25X monthly use rate). Prior to receiving the 12.5 mg/kg dose (25X monthly use rate) on day 56 of the study, all animals had undergone an exaggerated dosing regimen consisting of 2.5 mg/kg milbemycin oxime (5X monthly use rate) on day 0, followed by 5.0 mg/kg (10X monthly use rate) on day 14 and 10.0 mg/kg (20X monthly use rate) on day 32. No adverse reactions were observed in any of the collies treated with this regimen up through the 10.0 mg/kg (20X monthly use rate) dose.

How supplied: MILBEHART™ Flavored Tablets are available in four tablet sizes (see Dosage section), formulated according to the weight of the dog. Each tablet size is available in color-coded packages of 6 tablets each, which are packaged 10 per display carton.

Storage conditions: MILBEHART™ Flavored Tablets should be stored at room temperature, between 68° and 77°F (20-25°C).

INFORMATION FOR DOSING CATS

The once-a-month tablet that prevents heartworm disease and removes adult roundworms and hookworms in cats and kittens.

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Keep this and all drugs out of the reach of children.

Description: MILBEHART™ Flavored Tablets for Cats are available in three tablet sizes in color-coded packages for oral administration to cats and kittens. Each tablet is formulated to provide a minimum of 0.9 mg/lb (2.0 mg/kg) body weight of milbemycin oxime. Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A[4] ($C_{32}H_{46}NO_7$, MW 555.71) and 20% A[3] ($C_{31}H_{43}NO_7$, MW 541.68).

Package color	Milbemycin oxime tablet
Blue	5.75 mg
Purple	11.5 mg
Red	23.0 mg

Indications: MILBEHART™ Flavored Tablets for Cats are indicated for use in the prevention of heartworm disease caused by *Dirofilaria immitis*, and the removal of adult *Ancylostoma tubaeforme* (hookworm) and *Toxocara cati* (roundworm) in cats and kittens six weeks of age or greater and 1.5 lbs. body weight or greater.

Dosage: MILBEHART™ Flavored Tablets for Cats are given orally, once a month, at the recommended minimum dosage rate of 0.9 mg milbemycin oxime per pound of body weight (2.0mg/kg).

Recommended Dosage Schedule for Cats

Body Weight	MILBEHART™ Flavored Tablets
1.5-6 lbs.	One tablet (5.75 mg)
6.1-12 lbs.	One tablet (11.5 mg)
12.1-25 lbs.	One tablet (23.0 mg)

Cats over 25 lbs. are provided the appropriate combination of tablets.

Administration: MILBEHART™ Flavored Tablets for Cats may be offered in food or administered as other tablet medications. The tablets can be broken for ease of administration. Watch the cat closely following dosing to be sure the entire dose has been consumed. If it is not entirely consumed, redose once with the full recommended dose as soon as possible.

MILBEHART™ Flavored Tablets for Cats must be administered monthly, preferably on the same date each month. The first dose should be administered within one month of the cat's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. If a dose is missed and a 30-day interval between dosing is exceeded, administer MILBEHART™ Flavored Tablets for Cats immediately and resume the monthly dosing schedule. It is recommended that cats be tested for existing heartworm infection prior to starting treatment with MILBEHART™ Flavored Tablets for Cats (See Precautions).

Precautions: Do not use in kittens less than six weeks of age or less than 1.5 lbs. body weight. Safety in heartworm positive cats has not been established. Safety in breeding, pregnant, and lactating queens and breeding toms has not been established.

Efficacy: MILBEHART™ Flavored Tablets for Cats eliminate the tissue stage of heartworm larvae and hookworm (*Ancylostoma tubaeforme*) and roundworm (*Toxocara cati*) infections when administered orally according to the recommended dosage schedule. The anthelmintic activity of milbemycin oxime is believed to be a result of interference with invertebrate neurotransmission.

Safety: Milbemycin oxime has been tested safely in over 8 different breeds of cats. In well-controlled clinical field studies 141 cats completed treatment with milbemycin oxime. Milbemycin oxime was used safely in animals receiving frequently used veterinary products such as vaccines, anthelmintics, anesthetics, antibiotics, steroids, flea collars, shampoos and dips.

Safety studies were conducted in young cats and kittens and doses of 1X, 3X and 5X the minimum recommended dose of 2.0 mg/kg demonstrated no drug-related effects. Tolerability studies at exaggerated doses of 10X also demonstrated no drug-related adverse effects in kittens and young adult cats.

How supplied: MILBEHART™ Flavored Tablets for Cats are available in three tablet sizes (see Dosage section), formulated according to the weight of the cat. Each tablet size is available in color-coded packages of 6 tablets each, which are packaged 10 per display carton.

Storage conditions: MILBEHART™ Flavored Tablets for Cats should be stored at room temperature, between 68° and 77°F (20-25°C).

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059
Fort Worth, TX 76161
Phone: 1-800-338-3659

Made in Canada.

Approved by FDA under ANADA # 200-629

D86910E 08-A1-V2

PRODUCT INSERTS/DISCLOSURES

MOVODYL™ Chewable Tablets
(carprofen)
Non-steroidal anti-inflammatory drug
For oral use in dogs only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:
MOVODYL Chewable Tablets are a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen. Carprofen is the nonproprietary designation for a substituted carbazole, 6-chloro-α-methyl-9H-carbazole-2-acetic acid. The empirical formula is $C_{15}H_{12}ClNO_2$ and the molecular weight 273.72. The chemical structure of carprofen is:



Carprofen is a white, crystalline compound. It is freely soluble in ethanol, but practically insoluble in water at 25°C.

CLINICAL PHARMACOLOGY:
Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models[1].

The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals[2]. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. The specificity of a particular NSAID for COX-2 versus COX-1 may vary from species to species[3]. In an *in vitro* study using canine cell cultures, carprofen demonstrated selective inhibition of COX-2 versus COX-1.[4] Clinical relevance of these data has not been shown. Carprofen has also been shown to inhibit the release of several prostaglandins in two inflammatory cell systems: rat polymorphonuclear leukocytes (PMN) and human rheumatoid synovial cells, indicating inhibition of acute (PMN system) and chronic (synovial cell system) inflammatory reactions[1].

Several studies have demonstrated that carprofen has modulatory effects on both humoral and cellular immune responses[5-9]. Data also indicate that carprofen inhibits the production of osteoclast-activating factor (OAF), PGE_1, and PGE_2 by its inhibitory effect in prostaglandin biosynthesis[1].

Based upon comparison with data obtained from intravenous administration, carprofen is rapidly and nearly completely absorbed (more than 90% bioavailable) when administered orally[10]. Peak blood plasma concentrations are achieved in 1-3 hours after oral administration of 1, 5, and 25 mg/kg to dogs. The mean terminal half-life of carprofen is approximately 8 hours (range 4.5-9.8 hours) after single oral doses varying from 1-35 mg/kg of body weight. After a 100 mg single intravenous bolus dose, the mean elimination half-life was approximately 11.7 hours in the dog. MOVODYL is more than 99% bound to plasma protein and exhibits a very small volume of distribution.

Carprofen is eliminated in the dog primarily by biotransformation in the liver followed by rapid excretion of the resulting metabolites (the ester glucuronide of carprofen and the ether glucuronides of 2 phenolic metabolites, 7-hydroxy carprofen and 8-hydroxy carprofen) in the feces (70-80%) and urine (10-20%). Some enterohepatic circulation of the drug is observed.

INDICATIONS:
MOVODYL Chewable Tablets are indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

CONTRAINDICATIONS:
MOVODYL Chewable Tablets should not be used in dogs exhibiting previous hypersensitivity to carprofen.

WARNINGS:
Keep out of reach of children. Not for human use. Consult a physician in cases of accidental ingestion by humans. **For use in dogs only**. Do not use in cats.

All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. **Owners should be advised to observe for signs of potential drug toxicity (see Information for Dog Owners, Adverse Reactions, Animal Safety and Post-Approval Experience).**

PRECAUTIONS:
As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachidonic acid[11-14]. When NSAIDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients[12,14]. NSAID therapy could unmask occult disease which has previously been undiagnosed due to the absence of apparent clinical signs. Patients with underlying renal disease for example, may experience exacerbation or decompensation of their renal disease while on NSAID therapy[11-14]. The use of parenteral fluids during surgery should be considered to reduce the potential risk of renal complications when using NSAIDs perioperatively.

Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be approached cautiously, with appropriate monitoring. Concomitant use of MOVODYL Chewable Tablets with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided because of the potential increase of adverse reactions, including gastrointestinal ulcerations and/or perforations. Sensitivity to drug-associated adverse reactions varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Carprofen treatment was not associated with renal toxicity or gastrointestinal ulceration in well-controlled safety studies of up to ten times the dose in healthy dogs.

MOVODYL Chewable Tablets are not recommended for use in dogs with bleeding disorders (e.g., Von Willebrand's disease), as safety has not been established in dogs with these disorders. The safe use of MOVODYL Chewable Tablets in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established. Studies to determine the activity of MOVODYL Chewable Tablets when administered concomitantly with other protein-bound or similarly metabolized drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring additional therapy. Such drugs commonly used include cardiac, anticonvulsant and behavioral medications. It has been suggested that treatment with carprofen may reduce the level of inhalant anesthetics needed[15].

If additional pain medication is warranted after administration of the total daily dose of MOVODYL Chewable Tablets, alternative analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroids use to NSAID use.

Due to the flavoring contained in MOVODYL Chewable Tablets, store out of the reach of dogs and in a secured area. Severe adverse reactions may occur if large quantities of tablets are ingested. If you suspect your dog has consumed MOVODYL Chewable Tablets above the labeled dose, please call your veterinarian for immediate assistance and notify Virbac AH, Inc. (1-800-338-3659).

INFORMATION FOR DOG OWNERS:
MOVODYL Chewable Tablets, like other drugs of its class, are not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. **Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death (see Adverse Reactions). Owners should be advised to discontinue MOVODYL Chewable Tablets therapy and contact their veterinarian immediately if signs of intolerance are observed.** The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.

ADVERSE REACTIONS:
During investigational studies for the caplet formulation with twice daily administration of 1 mg/lb, no clinically significant adverse reactions were reported. Some clinical signs were observed during field studies (n=297) which were similar for carprofen caplet- and placebo-treated dogs. Incidences of the following were observed in both groups: vomiting (4%), diarrhea (4%), changes in appetite (3%), lethargy (1.4%), behavioral changes (1%), and constipation (0.3%). The product vehicle served as control.

There were no serious adverse events reported during clinical field studies with once daily administration of 2 mg/lb. The following categories of abnormal health observations were reported. The product vehicle served as control.

Percentage of Dogs with Abnormal Health Observations Reported in Clinical Field Study (2mg/lb once daily)

Observation	Carprofen (n=129)	Placebo (n=132)
Inappetence	1.6	1.5
Vomiting	3.1	3.8
Diarrhea/Soft stool	3.1	4.5
Behavior change	0.8	0.8
Dermatitis	0.8	0.8
PU/PD	0.8	-
SAP increase	7.8	8.3
ALT increase	5.4	4.5
AST increase	2.3	0.8
BUN increase	3.1	1.5
Bilirubinuria	16.3	12.1
Ketonuria	14.7	9.1

Clinical pathology parameters listed represent reports of increases from pre-treatment values; medical judgment is necessary to determine clinical relevance.

During investigational studies of surgical pain for the caplet formulation, no clinically significant adverse reactions were reported. The product vehicle served as control.

Percentage of Dogs with Abnormal Health Observations Reported in Surgical Pain Field Studies with Caplets (2 mg/lb once daily)

Observation*	Carprofen (n=148)	Placebo (n=149)
Vomiting	10.1	13.4
Diarrhea/soft stool	6.1	6.0
Ocular disease	2.7	0
Inappetence	1.4	0
Dermatitis/Skin lesion	2.0	1.3
Dysrhythmia	0.7	0
Apnea	1.4	0
Oral/Periodontal disease	1.4	0
Pyrexia	0.7	1.3
Urinary tract disease	1.4	1.3
Wound drainage	1.4	0
*A single dog may have experienced more than one occurrence of an event		

During investigational studies for the chewable tablet formulation, gastrointestinal signs were observed in some dogs. These signs included vomiting and soft stools.

Post-Approval Experience:
Although not all adverse reactions are reported, the following adverse reactions are based on voluntary post-approval adverse drug experience reporting. The categories of adverse reactions are listed in decreasing order of frequency by body system.

Gastrointestinal: *Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis.*

Hepatic: *Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function test(s), hyperbilirubinemia, bilirubinuria, hypoalbuminemia. Approximately one-fourth of hepatic reports were in Labrador Retrievers.*

Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, disorientation.

Urinary: *Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glucosuria.*

Behavioral: *Sedation, lethargy, hyperactivity, restlessness, aggressiveness.*

Hematologic: *Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis.*

Dermatologic: *Pruritus, increased shedding, alopecia, pyotraumatic moist dermatitis (hot spots), necrotizing panniculitis/vasculitis, ventral ecchymosis.*

Immunologic or hypersensitivity: *Facial swelling, hives, erythema.*

In rare situations, death has been associated with some of the adverse reactions listed above.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac

PRODUCT INSERTS/DISCLOSURES

AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION:
Always provide Client Information Sheet with prescription. Carefully consider the potential benefits and risk of MOVODYL Chewable Tablets and other treatment options before deciding to use MOVODYL Chewable Tablets. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage for oral administration to dogs is 2 mg/lb of body weight daily. The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure. MOVODYL Chewable Tablets are scored and dosage should be calculated in half-tablet increments. Tablets can be halved by placing the tablet on a hard surface and pressing down on both sides of the score. MOVODYL Chewable Tablets may be fed by hand or placed with food. Care should be taken to ensure that the dog consumes the complete dose. Half-tablets should be used within 90 days.

EFFECTIVENESS:
Confirmation of the effectiveness of carprofen for the relief of pain and inflammation associated with osteoarthritis, and for the control of postoperative pain associated with soft tissue and orthopedic surgeries, was demonstrated in 5 placebo-controlled, masked studies examining the anti-inflammatory and analgesic effectiveness of carprofen caplets in various breeds of dogs.

Separate placebo-controlled, masked, multicenter field studies confirmed the anti-inflammatory and analgesic effectiveness of carprofen caplets when dosed at 2 mg/lb once daily or when divided and administered at 1 mg/lb twice daily. In these 2 field studies, dogs diagnosed with osteoarthritis showed statistically significant overall improvement based on lameness evaluations by the veterinarian and owner observations when administered carprofen caplets at labeled doses.

Separate placebo-controlled, masked, multicenter field studies confirmed the effectiveness of carprofen caplets for the control of postoperative pain when dosed at 2 mg/lb once daily in various breeds of dogs. In these studies, dogs presented for ovariohysterectomy, cruciate repair and aural surgeries were administered carprofen preoperatively and for a maximum of 3 days (soft tissue) or 4 days (orthopedic) postoperatively. In general, dogs administered carprofen showed statistically significant reduction in pain scores compared to controls.

ANIMAL SAFETY:
Laboratory studies in unanesthetized dogs and clinical field studies have demonstrated that carprofen is well tolerated in dogs after oral administration.

In target animal safety studies, carprofen was administered orally to healthy Beagle dogs at 1, 3, and 5 mg/lb twice daily (1, 3 and 5 times the recommended total daily dose) for 42 consecutive days with no significant adverse reactions. Serum albumin for a single female dog receiving 5 mg/lb twice daily decreased to 2.1 g/dl after 2 weeks of treatment, returned to the pre-treatment value (2.6 g/dL) after 4 weeks of treatment, and was 2.3 g/dL at the final 6-week evaluation. Over the 6-week treatment period, black or bloody stools were observed in 1 dog (1 incident) treated with 1 mg/lb twice daily and in 1 dog (2 incidents) treated with 3 mg/lb twice daily. Redness of the colonic mucosa was observed in 1 male that received 3 mg/lb twice daily.

Two of 8 dogs receiving 10 mg/lb orally twice daily (10 times the recommended total daily dose) for 14 days exhibited hypoalbuminemia. The mean albumin level in the dogs receiving this dose was lower (2.38 g/dL) than each of 2 placebo control groups (2.88 and 2.93 g/dL, respectively). Three incidents of black or bloody stool were observed in 1 dog. Five of 8 dogs exhibited reddened areas of duodenal mucosa on gross pathologic examination. Histologic examination of these areas revealed no evidence of ulceration, but did show minimal congestion of the lamina propria in 2 of the 5 dogs.

In separate safety studies lasting 13 and 52 weeks, respectively, dogs were administered orally up to 11.4 mg/lb/day (5.7 times the recommended total daily dose of 2 mg/lb) of carprofen. In both studies, the drug was well tolerated clinically by all of the animals. No gross or histologic changes were seen in any of the treated animals. In both studies, dogs receiving the highest doses had average increases in serum L-alanine aminotransferase (ALT) of approximately 20 IU.

In the 52-week study, minor dermatologic changes occurred in dogs in each of the treatment groups but not in the control dogs. The changes were described as slight redness or rash and were diagnosed as non-specific dermatitis. The possibility exists that these mild lesions were treatment related, but no dose relationship was observed.

Clinical field studies were conducted with 549 dogs of different breeds at the recommended oral doses for 14 days (297 dogs were included in a study evaluating 1 mg/lb twice daily and 252 dogs were included in a separate study evaluating 2 mg/lb once daily). In both studies the drug was clinically well tolerated and the incidence of clinical adverse reactions for carprofen-treated animals was no higher than placebo-treated animals (placebo contained inactive ingredients found in carprofen). For animals receiving 1 mg/lb twice daily, the mean post-treatment serum ALT values were 11 IU greater and 9 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. Differences were not statistically significant. For animals receiving 2 mg/lb once daily, the mean post-treatment serum ALT values were 4.5 IU greater and 0.9 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. In the latter study, 3 carprofen-treated dogs developed a 3-fold or greater increase in (ALT) and/or (AST) during the course of therapy. One placebo-treated dog had a greater than 2-fold increase in ALT. None of these animals showed clinical signs associated with laboratory value changes. Changes in clinical laboratory values (hematology and clinical chemistry) were not considered clinically significant. The 1 mg/lb twice daily course of therapy was repeated as needed at 2-week intervals in 244 dogs, some for as long as 5 years.

Clinical field studies were conducted in 297 dogs of different breeds undergoing orthopedic or soft tissue surgery. Dogs were administered 2 mg/lb of carprofen two hours prior to surgery then once daily, as needed for 2 days (soft tissue surgery) or 3 days (orthopedic surgery). Carprofen was well tolerated when used in conjunction with a variety of anesthetic-related drugs. The type and severity of abnormal health observation in carprofen- and placebo-treated animals were approximately equal and few in number (see Adverse Reactions). The most frequent abnormal health observation was vomiting and was observed at approximately the same frequency in carprofen- and placebo-treated animals. Changes in clinicopathologic indices of hematopoietic, renal, hepatic, and clotting function were not clinically significant. The mean post-treatment serum ALT values were 7.3 IU and 2.5 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. The mean post-treatment AST values were 3.1 IU less for dogs receiving carprofen and 0.2 IU greater for dogs receiving placebo.

STORAGE:
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [See USP controlled room temperature.]
Protect from light.

HOW SUPPLIED:
MOVODYL Chewable Tablets are scored (except for the unscored 37.5 mg strength), and contain 25 mg, 50mg, 37.5 mg, 75 mg, or 100 mg of carprofen. Each tablet size is packaged in bottles containing 60 or 180 tablets.

REFERENCES:

1. Baruth H, *et al*: In Anti-Inflammatory and Anti-Rheumatic Drugs, Vol. II, Newer Anti-Inflammatory Drugs, Rainsford KD, ed. CRC Press, Boca Raton, p. 33, 1986.
2. Vane JR, Botting RM: Mechanism of action of anti-inflammatory drugs. *Scand J Rheumatol* 25:102, pp. 9–21.
3. Grossman CJ, Wiseman J, Lucas FS, *et al*: Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox-2 inhibitors. *Inflammation Research* 44:253–257, 1995.
4. Ricketts AP, Lundy KM, Seibel SB: Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. *Am J Vet Res* 59:11, pp. 1441–1446, November 1998.
5. Ceuppens JL, *et al*: Non-steroidal anti-inflammatory agents inhibit the synthesis of IgM rheumatoid factor *in vitro*. *Lancet* 1:528, 1982.
6. Ceuppens JL, *et al*: Endogenous prostaglandin E_2 enhances polyclonal immunoglobulin production by ionically inhibiting T suppressor cell activity. *Cell Immunol* 70:41, 1982.
7. Schleimer RP, *et al*: The effects of prostaglandin synthesis inhibition on the immune response. *Immunopharmacology* 3:205, 1981.
8. Leung KH, *et al*: Modulation of the development of cell mediated immunity: Possible roles of the products of cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism. *Int J Immunopharmacology* 4:195, 1982.
9. Veit BC: Immunoregulatory activity of cultured-induced suppressor macrophages. *Cell Immunol* 72:14, 1982.
10. Schmitt M, *et al*: Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. *Biopharm Drug Dispos* 11(7):585, 1990.
11. Kore AM: Toxicology of nonsteroidal anti-inflammatory drugs Veterinary Clinics of North America, *Small Animal Practice* 20, March 1990.
12. Binns SH: Pathogenesis and pathophysiology of ischemic injury in cases of acute renal failure. *Compend for Cont Ed* 16:1, January 1994.
13. Boothe DM: Prostaglandins: Physiology and clinical implications. *Compend for Cont Ed* 6:11, November 1984.
14. Rubin SI: Nonsteroidal anti-inflammatory drugs, prostaglandins, and the kidney. *JAVMA* 188:9, May 1986.
15. Ko CH, Lange DN, Mandsager RE, *et al*: Effects of butorphanol and carprofen on the minimal alveolar concentration of isoflurane in dogs. *JAVMA* 217:1025–1028, 2000.

Approved by FDA under ANADA # 200-687

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059
Fort Worth, TX 76161
1-800-338-3659
TS/DRUGS/24/2009
Made in India
Lb50146-3-00
Rev. No: 01

Issued: December 2021

PARASEDGE™ Multi for Dogs (imidacloprid + moxidectin) Topical Solution

Once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, kills adult fleas, is indicated for the treatment of flea infestations, the treatment and control of sarcoptic mange, as well as the treatment and control of intestinal parasite infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

WARNING

- **DO NOT ADMINISTER THIS PRODUCT ORALLY**
- **For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.**
- **Children should not come in contact with application sites for two (2) hours after application**
  (See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information.)

CAUTION:
Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:
PARASEDGE™ Multi for Dogs (10 % imidacloprid + 2.5 % moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of dogs. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin based on body weight.

Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name for imidacloprid is 1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete *Streptomyces cyaneogriseus noncyanogenus*. The chemical name for moxidectin is [6R, 23E, 25S(E)]-5-O-Demethyl-28-deoxy-25-[1,3-dimethyl-1-butenyl]-6,28-epoxy-23-(methoxyimino) milbemycin B.

INDICATIONS:
PARASEDGE™ Multi for Dogs is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* and the treatment of *Dirofilaria immitis* circulating microfilariae in heartworm-positive dogs. PARASEDGE™ Multi for Dogs kills adult fleas and is indicated for the treatment of flea infestations (*Ctenocephalides felis*). PARASEDGE™ Multi for Dogs is indicated for the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei var. canis*. PARASEDGE™ Multi for Dogs is also indicated for the treatment and control of the following intestinal parasites:

Intestinal Parasite		Intestinal Stage		
		Adult	Immature Adult	Fourth Stage Larvae
Hookworm Species	*Ancylostoma caninum*	X	X	X
	Uncinaria stenocephala	X	X	X
Roundworm Species	*Toxocara canis*	X		X
	Toxascaris leonina	X		
Whipworm	*Trichuris vulpis*	X		

CONTRAINDICATIONS:
Do not administer this product orally. (See WARNINGS.)
Do not use this product (containing 2.5 % moxidectin) on cats.

WARNINGS:
For the first 30 minutes after application:
Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs.

Separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion.

Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.

In avermectin sensitive dogs,[a] the signs may be more severe and may include coma and death.[b]

[a] Some dogs are more sensitive to avermectins due to a mutation in the MDR1 gene. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.

[b] Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care.

HUMAN WARNINGS:
Not for human use. Keep out of the reach of children.
Children should not come in contact with application sites for two (2) hours after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. **Wash hands thoroughly with soap and warm water after handling.**

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The safety data sheet (SDS) provides additional occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

PRECAUTIONS:
Do not dispense dose applicator tubes without complete safety and administration information.

Use with caution in sick, debilitated, or underweight animals. The safety of PARASEDGE™ Multi for Dogs has not been established in breeding, pregnant, or lactating dogs. The safe use of PARASEDGE™ Multi for Dogs has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.

Prior to administration of PARASEDGE™ Multi for Dogs, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of PARASEDGE™ Multi for Dogs has not been evaluated when administered on the same day as an adulticide. PARASEDGE™ Multi for Dogs is not effective against adult *D. immitis*. Although the number of circulating microfilariae is substantially reduced in most dogs following treatment with PARASEDGE™ Multi for Dogs, the microfilaria count in some heartworm-positive dogs may increase or remain unchanged following treatment with PARASEDGE™ Multi for Dogs alone or in a dosing regimen with melarsomine dihydrochloride.
(See ADVERSE REACTIONS and ANIMAL SAFETY - Safety Study in Heartworm-Positive Dogs.)

PARASEDGE™ Multi for Dogs has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease.

ADVERSE REACTIONS:

Heartworm-Negative Dogs

Field Studies: Following treatment with imidacloprid and moxidectin topical solution or an active control, dog owners reported the following post-treatment reactions:

OBSERVATION	imidacloprid and moxidectin topical solution n=128	Active Control n=68
Pruritus	19 dogs (14.8 %)	7 dogs (10.3 %)
Residue	9 dogs (7.0 %)	5 dogs (7.4 %)
Medicinal Odor	5 dogs (3.9 %)	None observed
Lethargy	1 dog (0.8 %)	1 dog (1.5 %)
Inappetence	1 dog (0.8 %)	1 dog (1.5 %)
Hyperactivity	1 dog (0.8 %)	None observed

During a field study using 61 dogs with pre-existing flea allergy dermatitis, one (1.6 %) dog experienced localized pruritus immediately after imidacloprid application, and one investigator noted hyperkeratosis at the application site of one dog (1.6 %).

In a field safety and effectiveness study, imidacloprid and moxidectin topical solution was administered to 92 client-owned dogs with sarcoptic mange. The dogs ranged in age from 2 months to 12.5 years and ranged in weight from 3 to 231.5 pounds. Adverse reactions in dogs treated with imidacloprid and moxidectin topical solution included hematochezia, diarrhea, vomiting, lethargy, inappetence, and pyoderma.

Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced weakness, depression, and unsteadiness between 6 and 9 days after application with imidacloprid and moxidectin topical solution. The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after application of imidacloprid and moxidectin topical solution.

The following clinical observations also occurred in laboratory effectiveness studies following application with imidacloprid and moxidectin topical solution and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vomiting, anorexia, lethargy, coughing, ocular discharge and nasal discharge. Observations at the application sites included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 hours.

Heartworm-Positive Dogs

Field Study: A 56-day field safety study was conducted in 214 *D. immitis* heartworm and microfilaria positive dogs with Class 1, 2 or 3 heartworm disease. All dogs received imidacloprid and moxidectin topical solution on Study Days 0 and 28; 108 dogs also received melarsomine dihydrochloride on Study Days -14, 14 and 15. All dogs were hospitalized for a minimum of 12 hours following each treatment. Effectiveness against circulating *D. immitis* microfilariae was > 90 % at five of six sites; however, one site had an effectiveness of 73.3 %. The microfilaria count in some heartworm-positive dogs increased or remained unchanged following treatment with imidacloprid and moxidectin topical solution alone or in a dosing regimen with melarsomine dihydrochloride.

Following treatment with imidacloprid and moxidectin topical solution alone or in a dosing regimen with melarsomine dihydrochloride, the following adverse reactions were observed:

Adverse Reaction	Dogs Treated with imidacloprid and moxidectin topical solution Only n=106	Dogs Treated with imidacloprid and moxidectin topical solution + Melarsomine n=108
Cough	24 (22.6 %)	25 (23.1 %)
Lethargy	14 (13.2 %)	42 (38.9 %)
Vomiting	11 (10.4 %)	18 (16.7 %)
Diarrhea, including hemorrhagic	10 (9.4 %)	22 (20.4 %)
Inappetence	7 (6.6 %)	19 (17.6 %)
Dyspnea	6 (5.7 %)	10 (9.3 %)
Tachypnea	1 (< 1 %)	7 (6.5 %)
Pulmonary Hemorrhage	0	1 (< 1 %)
Death	0	3 (2.8 %)

Three dogs treated with imidacloprid and moxidectin topical solution in a dosing regimen with melarsomine dihydrochloride died of pulmonary embolism from dead and dying heartworms. One dog, treated with imidacloprid and moxidectin topical solution and melarsomine dihydrochloride, experienced pulmonary hemorrhage and responded to supportive medical treatment. Following the first treatment with imidacloprid and moxidectin topical solution alone, two dogs experienced adverse reactions (coughing, vomiting, and dyspnea) that required hospitalization. In both groups, there were more adverse reactions to imidacloprid and moxidectin topical solution following the first treatment than the second treatment.

To report a suspected adverse reaction, call 1-800-338-3659.

Post-Approval Experience

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in dogs are listed in decreasing order of reporting frequency: depression/lethargy, vomiting, pruritus, diarrhea, anorexia, hyperactivity, ataxia, trembling, hypersalivation, application site reactions (alopecia, pruritus, lesions, and erythema), seizures, and anaphylaxis/anaphylactic reactions (hives, urticaria, facial swelling, edema of the head).

Serious reactions, including neurologic signs and death have been reported when cats have been exposed (orally and topically) to this product.

In humans, nausea, numbness or tingling of the mouth/lips and throat, ocular and dermal irritation, pruritus, headache, vomiting, diarrhea, depression and dyspnea have been reported following exposure to this product.

To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call VIRBAC AH, Inc. at 1-800-338-3659.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION:
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.

1. Use scissors to open the foil pack, taking care not to damage the tube inside. Remove one dose applicator tube from the package and hold the tube in an upright position. As specified in the following table, administer the entire contents of the PARASEDGE™ Multi for Dogs (imidacloprid + moxidectin) tube that correctly corresponds with the body weight of the dog.

Dog (lbs.)	PARASEDGE™ Multi for Dogs	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)
3 - 9	PARASEDGE™ Multi 9	0.4	40	10
9.1 - 20	PARASEDGE™ Multi 20	1.0	100	25
20.1 - 55	PARASEDGE™ Multi 55	2.5	250	62.5
55.1 - 88	PARASEDGE™ Multi 88	4.0	400	100
88.1 - 110*	PARASEDGE™ Multi 110	5.0	500	125

*Dogs over 110 lbs. should be treated with the appropriate combination of PARASEDGE™ Multi for Dogs tubes.

2. Bend the tip back until it snaps off. If it doesn't snap off at first, cut it using sossors.

3. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs. or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs., place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog.



4. Keep tube compressed on the final squeeze to avoid drawing liquid back into tube. While keeping tube squeezed, drag it away from liquid and lift up to remove.

5. Ensure tube is empty.

Do not let this product get in your dog's mouth or eyes. **Do not allow the dog to lick any of the application sites for 30 minutes.** In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. **(See WARNINGS.)**

Stiff hair, a damp appearance of the hair, pink skin, or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product.

Shampooing 90 minutes after treatment does not reduce the effectiveness of PARASEDGE™ Multi for Dogs in the prevention of heartworm disease. Shampooing or water immersion 4 days after treatment will not reduce the effectiveness of PARASEDGE™ Multi for Dogs in the treatment of flea infestations. However, shampooing as often as once weekly may reduce the effectiveness of the product against fleas.

Heartworm Prevention: For prevention of heartworm disease, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. PARASEDGE™ Multi for Dogs may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer PARASEDGE™ Multi for Dogs immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with PARASEDGE™ Multi for Dogs should be given within one month of the last dose of the former medication.

Treatment of Circulating Microfilaria: For the treatment of circulating *D. immitis* microfilaria in heartworm-positive dogs, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. Treatment with an approved adulticide therapy is recommended because PARASEDGE™ Multi for Dogs is not effective for the treatment of adult *D. immitis*.
(See PRECAUTIONS.)

Flea Treatment: For the treatment of flea infestations, PARASEDGE™ Multi for Dogs should be administered at one-month intervals. If the dog is already infested with fleas when the first dose of PARASEDGE™ Multi for Dogs is administered, adult fleas on the dog will be killed. However, reinfestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Dogs treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the dog.

Treatment and Control of Intestinal Nematode Infections:
For the treatment and control of intestinal hookworm infections caused by *Ancylostoma caninum* and *Uncinaria stenocephala* (adults, immature adults and fourth stage larvae) and roundworm infections caused by *Toxocara canis* (adults and fourth stage larvae), and *Toxascaris leonina* (adults), and whipworm infections caused by *Trichuris vulpis* (adults), PARASEDGE™ Multi for Dogs should be administered once as a single topical dose.

Treatment and Control of Sarcoptic Mange: For the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei var. canis*, PARASEDGE™ Multi for Dogs should be administered as a single topical dose. A second monthly dose may be administered if necessary.

ANIMAL SAFETY:

Heartworm-Negative Dogs

Field Study: In a controlled, double-masked, field safety study, imidacloprid and moxidectin topical solution was administered to 128 dogs of various breeds, 3 months to 15 years of age, weighing 4 to 157 pounds. Imidacloprid and moxidectin topical solution was used safely in dogs concomitantly receiving ACE inhibitors, anticonvulsants, antihistamines, antimicrobials, chondroprotectants, corticosteroids, immunotherapeutics, MAO inhibitors, NSAIDs, ophthalmic medications, sympathomimetics, synthetic estrogens, thyroid hormones, and urinary acidifiers. Owners reported the following signs in their dogs after application of imidacloprid and moxidectin topical solution: pruritus, flaky/greasy residue at the treatment site, medicinal odor, lethargy, inappetence, and hyperactivity.
(See ADVERSE REACTIONS.)

Safety Study in Puppies: Imidacloprid and moxidectin topical solution was applied topically at 1, 3 and 5X the recommended dose to 7-week-old Beagle puppies once every 2 weeks for 6 treatments on days 0, 14, 28, 42, 56 and 70. Loose stools and diarrhea were observed in all groups, including the controls, throughout the study. Vomiting was seen in one puppy from the 1X treatment group (day 57), in two puppies from the 3X treatment group (days 1 and 79), and in one puppy from the 5X treatment group (day 1). Two puppies each in the 1X, 3X, and 5X groups had decreased appetites within 24 hours post-dosing. One puppy in the 1X treatment group had pruritus for one hour following the fifth treatment. A puppy from the 5X treatment group displayed rapid, difficult breathing from 4 to 8 hours following the second treatment.

Dermal Dose Tolerance Study: Imidacloprid and moxidectin topical solution was administered topically to 8-month-old Beagle dogs at 10X the recommended dose once. One dog showed signs of treatment site irritation after application. Two dogs vomited, one at 6 hours and one at 6 days post-treatment. Increased RBC, hemoglobin, activated partial thromboplastin, and direct bilirubin were observed in the treated group. Dogs in the treated group did not gain as much weight as the control group.

Oral Safety Study in Beagles: Imidacloprid and moxidectin topical solution was administered once orally at the recommended topical dose to 12 dogs. Six dogs vomited within 1 hour of receiving the test article, 2 of these dogs vomited again at 2 hours, and 1 dog vomited again up to 18 hours post-dosing. One dog exhibited shaking (nervousness) 1 hour post-dosing. Another dog exhibited abnormal neurological signs (circling, ataxia, generalized muscle tremors, and dilated pupils with a slow pupillary light response) starting at 4 hours post-dosing through 18 hours post-dosing. Without treatment, this dog was neurologically normal at 24 hours and had a normal appetite by 48 hours post-dosing.
(See CONTRAINDICATIONS.)

Dermal Safety Study in Ivermectin-Sensitive Collies:
Imidacloprid and moxidectin topical solution was administered topically at 3 and 5X the recommended dose every 28 days for 3 treatments to Collies which had been pre-screened for avermectin sensitivity. No clinical abnormalities were observed.

Oral Safety Study in Ivermectin-Sensitive Collies:
Imidacloprid and moxidectin topical solution was administered orally to 5 pre-screened ivermectin-sensitive Collies. The Collies were asymptomatic after ingesting 10 % of the minimum labeled dose. At 40 % of the minimum recommended topical dose, 4 of the dogs experienced neurological signs indicative of avermectin toxicity including depression, ataxia, mydriasis, salivation, muscle fasciculation, and coma, and were euthanized.
(See CONTRAINDICATIONS.)

Heartworm-Positive Dogs

Laboratory Safety Study in Heartworm-Positive Dogs: Imidacloprid and moxidectin topical solution was administered topically at 1 and 5X the recommended dose every 14 days for 3 treatments to dogs with adult heartworm infections and circulating microfilaria. At 5X, one dog was observed vomiting three hours after the second treatment. Hypersensitivity reactions were not seen in the 5X treatment group. Microfilaria counts decreased with treatment.

STORAGE INFORMATION: Store below 25°C (77°F).

HOW SUPPLIED:
Applications Per Package : 3 x 0.4 mL tubes, 3 x 1.0 mL tubes, 3 x 2.5 mL tubes, 3 x 4.0 mL tubes, 3 x 5.0 mL tubes

Approved by FDA under ANADA # 200-700

Manufactured for: Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161

LA20679
Rev. 10/2021

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

PARASEDGE™ Multi for Cats (imidacloprid + moxidectin) Topical Solution

Once-a-month topical solution for cats for the prevention of heartworm disease, kills adult fleas, is indicated for the treatment of flea infestations, as well as the treatment and control of ear mite infestations and intestinal parasite infections in cats and kittens 9 weeks of age and older and that weigh at least 2 lbs.

CAUTION:
Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:
PARASEDGE™ Multi for Cats (10% imidacloprid + 1% moxidectin) is a colorless to yellow ready-to-use solution packaged in single dose applicator tubes for topical treatment of cats. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin based on body weight.

Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name of imidacloprid is 1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete *Streptomycetes cyaneogriseus noncyanogenus*. The chemical name of moxidectin is [6R,23E, 25S(E)]-5-O-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

INDICATIONS:
PARASEDGE™ Multi for Cats is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*. PARASEDGE™ Multi for Cats kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations. PARASEDGE™ Multi for Cats is also indicated for the treatment and control of ear mite (*Otodectes cynotis*) infestations and the following intestinal parasites:

Intestinal Parasite		Intestinal Stage		
		Adult	Immature Adult	Fourth Stage Larvae
Hookworm Species	*Ancylostoma tubaeforme*	X	X	X
Roundworm Species	*Toxocara cati*	X		X

WARNINGS:
Do not use on sick, debilitated, or underweight cats (See ADVERSE REACTIONS).

Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.

HUMAN WARNINGS:
Not for human use. Keep out of the reach of children. Children should not come in contact with the application site for 30 minutes after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. **Wash hands thoroughly with soap and warm water after handling.** If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice. The Safety Data Sheet (SDS) provides more detailed occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact VIRBAC AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

PRECAUTIONS:
Do not dispense dose applicator tubes without complete safety and administration information.

Avoid oral ingestion. Cats may experience hypersalivation, tremors, vomiting and decreased appetite if PARASEDGE™ Multi for Cats is inadvertently administered orally or through grooming/licking of the application site.

The safety of PARASEDGE™ Multi for Cats has not been established in breeding, pregnant, or lactating cats.

The effectiveness of PARASEDGE™ Multi for Cats against heartworm infections (*D. immitis*) after bathing has not been evaluated in cats.

Use of this product in geriatric patients with subclinical conditions has not been adequately studied. Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using this drug. **(See ADVERSE REACTIONS.)**

ADVERSE REACTIONS

Field Study: Following treatment with imidacloprid and moxidectin or an active control, cat owners reported the following post-treatment reactions:

OBSERVATION	Imidacloprid and moxidectin n=113	Active Control n=38
Lethargy (protracted sleeping, poorly responsive)	3 cats* (2.7 %)	None observed
Behavioral changes (e.g., agitated, excessive grooming, hiding, pacing, spinning)	9 cats (8.0 %)	1 cat (2.6%)
Discomfort (e.g., scratching, rubbing, head shaking)	5 cats (4.4 %)	None observed
Hypersalivation (within 1 hour after treatment)	3 cats (2.7 %)	None observed
Polydipsia	3 cats (2.7 %)	None observed
Coughing and gagging	1 cat (0.9 %)	None observed

*These three cats were from the same household and included one 13-yr-old cat in good health, one 15-yr-old FIV positive cat in good health, and one 15-yr-old, underweight cat in fair health. Lethargy was noted for 24 to 36 hrs after the first treatment only; one cat was unsteady at 48 hrs. These cats were not on other medications.

During another field study, a 16-year-old cat with renal disease slept in the same place without moving for two days following application. **(See PRECAUTIONS.)**

Laboratory Effectiveness Studies: Imidacloprid and moxidectin was administered at the recommended dose to 215 cats in 20 effectiveness studies. One random-sourced cat exhibited signs consistent with either moxidectin toxicity or viral respiratory disease and died 26 hours after product application; necropsy findings were inconclusive as to the cause of death. A second cat that became ill 3 days after application of imidacloprid and moxidectin responded to treatment for respiratory infection and completed the study. A third cat became ill on day 3 and died with signs and lesions attributable to panleukopenia on day 7 after moxidectin application.

Post-approval Experience: The following adverse events are based on post approval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in cats are listed in decreasing order of reporting frequency: hypersalivation, depression/lethargy, application site reactions (alopecia, pruritus, lesions, and erythema), decreased appetite, vomiting, hyperactivity, ataxia, trembling, and behavior disorder (hiding).

In some cases death has been reported.

In humans, ocular and dermal irritation, nausea, numbness or tingling of the mouth and lips, anaphylaxis, pruritus, vomiting, and tongue/taste abnormalities have been reported following exposure to this product. To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call VIRBAC AH, Inc. at 1-800-338-3659. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION:
The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Do not apply to irritated skin.

As specified in the following table, administer the entire contents of the PARASEDGE™ Multi for Cats (10% imidacloprid + 1% moxidectin) tube that correctly corresponds with the body weight of the cat.

Cat (lb.)	PARASEDGE™ MULTI For Cats	Volume (mL)	Imidacloprid (mg)	Moxidectin (mg)
2-5	PARASEDGE™ MULTI 5	0.23	23	2.3
5.1-9	PARASEDGE™ MULTI 9	0.4	40	4
9.1-18*	PARASEDGE™ MULTI 18	0.8	80	8

*Cats over 18 lbs. should be treated with the appropriate combination of PARASEDGE™ Multi for Cats tubes.

1. Use scissors to open the foil pack, taking care not to damage the tube inside. Remove the tube from the foil pack and hold upright with the lot and expiration at the bottom.

2. Bend the tip back until it snaps off. If it doesn't snap off at first, cut it using scissors.

3. Part the hair on the back of the cat's neck at the base of the neck, in front of the shoulder blades, until the skin is visible.

4. Place the tip of the PARASEDGE™ Multi for Cats tube on the skin. Squeeze the tube firmly 3-4 times in one spot until empty. Keep tube compressed on the final squeeze to avoid drawing liquid back into the tube. Avoid contact between PARASEDGE™ Multi for Cats and your fingers.

5. While keeping tube squeezed, drag it away from liquid and lift up to remove.

6. Ensure tube is empty.

Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site.

Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product.

Heartworm Prevention: For prevention of heartworm disease, PARASEDGE™ Multi for Cats should be administered at one-month intervals. PARASEDGE™ Multi for Cats may be administered year-around or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer PARASEDGE™ Multi for Cats immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with PARASEDGE™ Multi for Cats should be given within one month of the last dose of the former medication. At the discretion of the veterinarian, cats older than 6 months of age may be tested to determine the presence of existing heartworm infection before treatment with PARASEDGE™ Multi for Cats **(See ADVERSE REACTIONS Post-Approval Experience).**

Flea Treatment: For the treatment of flea infestations, PARASEDGE™ Multi for Cats should be administered at one-month intervals. If the cat is already infested with fleas when the first dose of PARASEDGE™ Multi for Cats is administered, adult fleas on the cat will be killed. However, re-infestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated. Cats treated with imidacloprid, including those with pre-existing flea allergy dermatitis have shown clinical improvement as a direct result of elimination of fleas from the cat.

Ear Mite Treatment: For the treatment of ear mites (*Otodectes cynotis*), PARASEDGE™ Multi for Cats should be administered once as a single topical dose. Monthly use of PARASEDGE™ Multi for Cats will control any subsequent ear mite infestations.

Intestinal Nematode Treatment: For the treatment and control of intestinal hookworm infections caused by *Ancylostoma tubaeforme* (adults, immature adults and fourth stage larvae) and roundworm infections caused by *Toxocara cati* (adults and fourth stage larvae), PARASEDGE™ Multi for Cats should be administered once as a single topical dose.

ANIMAL SAFETY:

Studies in Kittens: Imidacloprid and moxidectin was topically applied at 0, 1, 3, and 5X the maximum dose to 48 healthy 9-week-old kittens on days 0, 28, and 56. Lethargy was observed in 1 kitten from the 3X group and 1 from the 5X group on the day after initial treatment; the kitten from the 3X group was also disoriented and ataxic. One kitten from the 3X group had a slow pupillary light response two days after treatment and one had tremors the day after treatment. Hypersalivation was seen in one kitten from the 5X group approximately six hours post-treatment. One kitten from the 3X group was scratching at the treatment site 2 days after treatment. Slight cough was noted in 7 different kittens (2-0X, 2-1X, and 3-5X) during the 13-day period following the first treatment. Histopathology showed granulomatous inflammation at the treatment site in three 1X kittens. Causal relationship to the drug could not be determined. Pulmonary inflammation (1-5X) and lymphoid hyperplasia (2-1X, 4-3X) were seen in treated kittens. In a second study, imidacloprid and moxidectin was topically applied at 0, 1.7, 5.2 and 8.7X the maximum dose to 48 healthy 9-week-old kittens every two weeks for 6 doses. One kitten in the 8.7X group apparently ingested an unknown amount of the drug and developed the following clinical signs prior to euthanasia: mydriasis, salivation, depression, vomiting, unsteadiness, rapid to slow to difficult breathing, poor pupillary response, generalized tremors, inability to move, and nystagmus. Two kittens in the 5.2X group developed mydriasis, salivation, depression, squinting, and poor appetite. A kitten in the 1.7X group developed mydriasis.

Dose Tolerance Study: Eight healthy juvenile cats were topically dosed with a single application of imidicloprid and moxidectin at 10 times the recommended dose volume. Mild, transient hypersalivation occurred in two of the cats.

Oral Study in Cats: The oral safety of imidacloprid and moxidectin was tested in case of accidental oral ingestion. The maximum topical dose was orally administered to twelve healthy 9-week-old kittens. Hypersalivation (8 of 12 kittens) and vomiting (12 of 12 kittens) were observed immediately post-treatment. Tremors developed in one kitten within 1 hour, resolving without treatment within the next hour. All 12 kittens were either anorexic or had decreased appetite for at least 1 day following treatment. In 3 kittens, the anorexia or decreased appetite continued into the second week following treatment. There was a post-treatment loss of body weight in treated kittens compared to control kittens. In a pilot safety study using kittens younger in age and lighter in weight than allowed by product labeling, an 8-week old kitten weighing 0.6 kg orally received 2X of the label topical dose (0.46 mL/kg). Immediately after dosing, it vomited, had labored breathing and slight tremors. Within 4 hours, it was normal, but was found dead on day 6. Necropsy could not determine the cause of death.

Study in Heartworm Positive Cats: Young adult cats were inoculated subcutaneously with third-stage *D. Immitis* larvae. At 243-245 days post-infection, immunoserology and echocardiography were performed to identify cats with adult heartworm burdens similar to naturally-acquired infections. Two groups were treated topically with either imidacloprid and moxidectin at the label dose or placebo, once every 28 days, for three consecutive treatments. A third group was treated topically, once, with imidacloprid and moxidectin at 5X the label dose. Sporadic vomiting and labored breathing related to heartworm burden were observed in the treatment and control groups. There was no difference between treatment groups in the numbers of adult *D. immitis* recovered at study conclusion. No adverse reactions were associated with the topical application of imidacloprid and moxidectin to experimentally heartworm-infected cats.

STORAGE INFORMATION:
Store below 25°C (77°F).

HOW SUPPLIED:
Applications Per Package
3 x 0.23 mL tubes
3 x 0.4 mL tubes
3 x 0.8 mL tubes

Approved by FDA under ANADA # 200-701

PARASEDGE™ is a trademark of Virbac AH, Inc.

Manufactured for: Virbac AH, Inc.,
P.O. Box 162059, Fort Worth, TX 76161

01 - 09/21

LA20219

RILEXINE®
(cephalexin tablets)
Chewable Tablets

Antimicrobial for Oral Use in Dogs only

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: RILEXINE® Chewable Tablets are a chewable, bisected tablet supplied in 3 sizes containing 150 mg, 300 mg, and 600 mg of cephalexin. Cephalexin is a cephalosporin, beta-lactam, broad spectrum antibiotic. The full chemical name for cephalexin is 7-(D-α-amino- α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate.



INDICATION: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of *Staphylococcus pseudintermedius*.

DOSAGE AND ADMINISTRATION: The recommended dose is 22 mg/kg (10 mg/lb) of body weight twice daily for 28 days.

Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to cephalexin. Therapy with RILEXINE Chewable Tablets may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. If acceptable response to treatment is not observed, then the diagnosis should be re-evaluated and appropriate alternative therapy considered.

CONTRAINDICATIONS: RILEXINE Chewable Tablets are contraindicated in dogs with a known allergy to cephalexin or to the β-lactam (any of the penicillins or cephalosporins) group of antibiotics.

WARNINGS: For use in dogs only. Not for use in humans. Keep this drug out of the reach of children. Antimicrobials, including penicillins and cephalosporins, can cause allergic reactions in sensitized individuals. Sensitized individuals handling such antimicrobials, including cephalexin, should avoid contact of the product with the skin and mucous membranes in order to minimize the risk of allergic reactions.

In case of ingestion by humans contact a physician immediately. Physicians may contact a poison control center for advice concerning cases of ingestion by humans.

To obtain a copy of the Safety Data Sheet (SDS), or to report adverse reactions, call Virbac at 1-800-338-3659.

PRECAUTIONS: Prescribing antibacterial drugs in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant animal pathogens.

RILEXINE Chewable Tablets are designed to taste good. **Store RILEXINE Chewable Tablets out of reach of dogs, cats, and other pets in a secured location.** Post approval experience has shown that dogs and cats may willingly consume more than the recommended dosage of RILEXINE Chewable Tablets, which can result in overdose. Adverse reactions may occur if large quantities of tablets are ingested (see **Adverse Reactions, Animal Safety,** and **Information for Dog Owners** sections). If the product is dispensed in a container other than the original, prescribers should consider adding a statement on the bottle label reminding the owner that RILEXINE Chewable Tablets are designed to taste good and should be stored out of reach of pets in a secured location.

The safe use of RILEXINE Chewable Tablets in dogs intended for breeding and in pregnant or lactating bitches has not been evaluated.

Positive direct Coombs' test results and false positive reactions for glucose in the urine have been reported during treatment with some cephalosporin antimicrobials. Cephalosporin antimicrobials may also cause falsely elevated urine protein determinations. Some antimicrobials, including cephalosporins, can cause lowered albumin values due to interference with certain testing methods.

Occasionally, cephalosporins have been associated with myelotoxicity, thereby creating a toxic neutropenia[1]. Other hematological reactions observed with cephalosporin therapy include neutropenia, anemia, hypoprothrombinemia, thrombocytopenia, prolonged prothrombin time (PT) and partial thromboplastin time (PTT), platelet dysfunction, and transient increases in serum aminotransferases[2].

ADVERSE REACTIONS: The most common adverse reactions in dogs include diarrhea, vomiting, anorexia and lethargy. To report suspected adverse reactions call Virbac at 1-800-338-3659.

A total of 211 dogs were included in the field study safety analysis. Adverse reactions reported in dogs treated with RILEXINE Chewable Tablets and placebo are summarized in Table 1.

Table 1: Number of Adverse Reactions* Reported During the Field Study with RILEXINE Chewable Tablets

ADVERSE REACTION	RILEXINE Tablets n = 145	Placebo n = 66
Number of dogs with adverse reactions*	50 (34%)	22 (33%)
	# of Each Event*	# of Each Event*
Vomiting	29	9
Diarrhea	19	6
Anorexia	13	2
Lethargy	9	3
Pruritus	5	0
Dermatitis	4	3
Skin Lesions	5	1
Otitis Externa	4	2
Polydipsia	2	2
Somnolence	2	0
Flatulence	1	1
Tachypnea	1	1

*Some dogs may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.

No clinically significant differences were observed in the mean values for all laboratory tests including urinalysis between RILEXINE Chewable Tablets and placebo-treated dogs. At the end of treatment, group means for neutrophils, WBC, and globulin values were significantly higher in the placebo group than in the RILEXINE Chewable Tablets group; whereas, group mean values for eosinophils, A/G Ratio values, and total protein values were significantly higher in the RILEXINE Chewable Tablets group than in the placebo group. For all six of these parameters, the differences were not clinically significant and the mean values for each of the parameters remained within the normal range.

To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, contact Virbac at 1-800-338-3659. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at *http://www.fda.gov/AnimalVeterinary/SafetyHealth*

INFORMATION FOR DOG OWNERS: Owners should be advised that RILEXINE Chewable Tablets are designed to taste good. Owners should be instructed to keep the product in a secured storage area out of the reach of pets in order to prevent accidental ingestion or overdose. Post approval experience has shown that dogs and cats may willingly consume more than the recommended dosage of RILEXINE Chewable Tablets. Adverse reactions may occur if large quantities of tablets are ingested (see **Precautions, Adverse Reactions,** and **Animal Safety sections**).

Owners should be advised to contact their veterinarian immediately and notify Virbac (1-800-338-3659) if the dog ingests more tablets than prescribed or if other pets ingest RILEXINE Chewable Tablets. In the case of accidental ingestion by humans, contact a physician immediately.

CLINICAL PHARMACOLOGY: Cephalexin belongs to the cephalosporin family of bactericidal antibiotics.

Cephalexin is readily and almost completely absorbed following oral administration (90% absolute bioavailability). Blood concentrations are proportional to dose within the range of at least 15 to 45 mg/kg. Binding to canine plasma proteins is low, ranging from 9 to 13% for cephalexin concentrations of 0.5 to 100 µg/mL.

Food reduces the peak cephalexin concentrations but has negligible effect on the extent of absorption.

A summary of the pharmacokinetics (PK) observed in fed and fasted Beagle dogs administered a single 22 mg/kg dose is provided in Table 2.

Table 2: Pharmacokinetics Parameter values (mean ± standard deviation), protein-corrected in fasted and fed dogs following a single administration of 22 mg/kg dose of RILEXINE Chewable Tablets (N = 12)

Parameter	FASTED Mean ± SD[1]	FED Mean ± SD[1]
AUCINF_obs (mg.h/L)	105.36 ± 17.31	108.35 ± 25.85
AUClast (mg.h/L)	97.33 ± 13.18	95.19 ± 11.84
Cmax (mg/L)	21.66 ± 2.74	16.99 ± 2.71
$T_{1/2}$(h)	7.33 ± 4.30	8.79 ± 6.44
Tmax (h)	1.42 ± 0.42	1.17 ± 0.25

[1]SD = Standard Deviation

Cephalosporins are associated with time dependent killing effects. Accordingly, the pharmacodynamic (PD) target is time above MIC (T>MIC). For staphylococcal infections, the goal for time above MIC is 40% of the dosing interval (which translates to 4.8 hrs for a 8.0 hrs dosing schedule). For streptococcal infections, the target for time above MIC is 60% of the dosing interval (i.e., 7.2 hrs). To assess whether or not the PK-PD target is met with a 22 mg/kg BID dosing regimen under fed and fasted conditions, it was assumed that the MIC_{90} for *S. pseudintermedius* is 2 µg/mL. Plasma drug concentrations were normalized to exactly 22 mg/kg dose and corrected for 10% protein binding (protein binding observed in canine plasma).

Under fasted conditions, all targets were met in all dogs after the first daily dose. With food, the target for *S. aureus* was met by the second daily dose. Therefore, a 22 mg/kg BID dosing interval under fed or fasted conditions succeeded in attaining the PK-PD targets.

MICROBIOLOGY: Cephalexin is a cephalosporin antibiotic. Like other β-lactam antimicrobials, cephalexin exerts its inhibitory effect by interfering with bacterial cell wall synthesis. This interference is primarily due to its covalent binding to the penicillin-binding proteins (PBPs) (i.e., transpeptidase and carboxypeptidase), which are essential for synthesis of the bacterial wall. Minimum Inhibitory Concentrations (MICs) for cephalexin against label-claim pathogens isolated from canine pyoderma in a 2008-2009 U.S. field trial are presented in Table 3. All MICs were determined in accordance with the Clinical Laboratory Standards Institute (CLSI) standards.

Table 3: Summary of Cephalexin MIC values against *S. pseudintermedius* isolates from 88 dogs treated with RILEXINE® Chewable Tablets for bacterial pyoderma in a U.S. field study during 2008-2009

Microbial Treatment Outcome	Time of Sampling	MIC_{50} µg/mL	MIC_{90} µg/mL	MIC Range µg/mL
Success (n = 61)*	Pre-treatment	1	2	1-2
Failure (n = 27)**	Pre-treatment	1	2	1-8
	Post-treatment (n = 17)	2	16	1-32

*No post-treatment sampling was conducted due to the absence of lesions.
**Of the 27 failures, 10 did not have positive post-treatment cultures.

EFFECTIVENESS: The clinical effectiveness of RILEXINE Chewable Tablets was established in a randomized, multi-location, placebo-controlled field study (see Table 4). In this study, 131 dogs with secondary superficial bacterial pyoderma treated with either RILEXINE Chewable Tablets (n = 91) at 22 mg/kg (10 mg/lb) body weight or with a negative control (n = 40), twice daily for 28 days, were analyzed. RILEXINE Chewable Tablets were considered superior to the placebo (70% success rate vs. 13% respectively) in the treatment of secondary superficial bacterial pyoderma caused by susceptible strains of *S. pseudintermedius*.

Table 4: Primary endpoint: Percentage of Cure* in the Effectiveness population

Treatment	RILEXINE Tablets	Placebo	p-value
N	91	40	
Success	64 (70.3%)	5 (12.5%)	0.0009
Failures	27	35	

*Absence of lesions at the end of the study.

PALATABILITY: The palatability of RILEXINE Chewable Tablets was evaluated in two separate multi-location studies. In the first study, 39 client-owned dogs were dosed with RILEXINE Chewable Tablets at 22 mg/kg and evaluated for palatability of the product. Palatability testing was performed twice daily prior to feeding for 7 days. Dogs freely consumed (from empty bowl or open hand) 80.8% of their doses. In a second study, 64 client-owned dogs enrolled in the field efficacy study were evaluated in a similar manner and freely consumed 78.4% of their doses.

ANIMAL SAFETY: RILEXINE Chewable Tablets were administered orally three times a day to 12-week-old healthy Beagles at 0 mg/kg (placebo), 22 mg/kg (1X), 66 mg/kg (3X), and 110 mg/kg (5X) for 12 weeks, and at 22 mg/kg twice a day for 12 weeks. The most common clinical findings included epiphora, salivation, vomiting and diarrhea among all the dose groups. Three dogs had decreased activity (1 in each from the 22 mg/kg twice a day, 22 mg/kg three times a day, and the 66 mg/kg three times a day groups). These observations were mild and sporadic.

There were increases in alanine aminotransferase (ALT) in the 110 mg/kg three times a day group and in the 22 mg/kg twice a day group that increased in a dose-dependent pattern. There was an increase in sorbitol dehydrogenase (SDH) in the 110 mg/kg three times a day group compared to the controls. These changes were minimal and the values remained within expected historical control ranges. There were several decreases in total protein (in the 110 mg/kg three times a day group) and/or globulin (in the 22, 66, and 110 mg/kg three times a day groups) compared to the controls. These changes resulted in occasional increases in albumin/globulin ratios. Although a drug effect cannot be ruled-out, these changes were not clinically relevant.

A mild prolongation in prothrombin time (PT) was observed in the 22 mg/kg three times a day group. This was not considered clinically relevant due to the small change that remained within the reference ranges.

One dog in the 110 mg/kg three times a day group had moderate amounts of bilirubinuria at the Week 8 and Week 12 samplings. No clinical significance was noted.

Cephalexin was not present in any Day 1 samples prior to dosing or in any control animals. After dosing, cephalexin was well absorbed into systemic circulation of the treated dogs. Within gender and dosage level, Week 8 mean trough concentrations were generally higher than the Week 4 and 12 mean trough concentrations (between a 0.9 and 3.6-fold difference). The geometric mean plasma cephalexin trough concentration following three times daily administration of the 110 mg/kg dose was 11.2 µg/mL compared to 2.6 µg/mL and 8.7 µg/mL following 22 mg/kg and 66 mg/kg, respectively at Week 12. Geometric mean plasma cephalexin trough concentrations following administration of 22 mg/kg twice daily were 0.7, 1.3, and 1.0 µg/mL at Weeks 4, 8, and 12, respectively.

STORAGE INFORMATION: Store at 20°C-25°C (68°F-77°F), with excursions permitted between 15°C-30°C (59°F-86°F).

HOW SUPPLIED: RILEXINE (cephalexin tablets) Chewable Tablets are supplied in 150 mg, 300 mg, and 600 mg tablets packaged in bottles of 100 tablets.

Approved by FDA under NADA # 141- 326

Distributed by: Virbac AH, Inc.
Fort Worth, TX 76137 USA

150 mg 302054 - 05, 300 mg 302055-05 , 600 mg 302056-05

Revision date 7/2018

[1]Birchard SJ and Sherding RG. Saunders Manual of Small Animal Practice, 2nd edition. W.B. Saunders Co. 2000: p. 166.

[2]Adams HR. *Veterinary Pharmacology and Therapeutics*, 8th edition, 2001, p. 825.

RILEXINE is a registered trademark of Virbac S.A.

Shaping the future of animal health

SENERGY™ (selamectin)
Topical Parasiticide For Dogs and Cats

CAUTION:
US Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:
SENERGY (selamectin) Topical Parasiticide is available as a colorless to yellow, ready to use solution in single dose tubes for topical (dermal) treatment of dogs six weeks of age and older and cats eight weeks of age and older. The content of each tube is formulated to provide a minimum of 2.7 mg/lb (6 mg/kg) of body weight of selamectin. The chemical composition of selamectin is (5Z,25S)-25-cyclohexyl-4′-*O*-de(2,6-dideoxy-3-*O*-methyl-α-L-*arabino*-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22, 23-dihydro-5-hydroxyiminoavermectin A_{1a}.

INDICATIONS:
SENERGY is recommended for use in dogs six weeks of age or older and cats eight weeks of age and older for the following parasites and indications:

Dogs:
SENERGY kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations (*Ctenocephalides felis*), prevention of heartworm disease caused by *Dirofilaria immitis*, and the treatment and control of ear mite (*Otodectes cynotis*) infestations. SENERGY also is indicated for the treatment and control of sarcoptic mange (*Sarcoptes scabiei*) and for the control of tick infestations due to *Dermacentor variabilis*.

Cats:
SENERGY kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations (*Ctenocephalides felis*), prevention of heartworm disease caused by *Dirofilaria immitis*, and the treatment and control of ear mite (*Otodectes cynotis*) infestations. SENERGY is also indicated for the treatment and control of roundworm (*Toxocara cati*) and intestinal hookworm (*Ancylostoma tubaeforme*) infections in cats.

WARNINGS:
Not for human use. Keep out of the reach of children.
In humans, SENERGY may be irritating to skin and eyes. Reactions such as hives, itching and skin redness have been reported in humans in rare instances. Individuals with known hypersensitivity to SENERGY should use the product with caution or consult a health care professional. SENERGY contains isopropyl alcohol and the preservative butylated hydroxytoluene (BHT). Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If contact with eyes occurs, then flush eyes copiously with water. In case of ingestion by a human, contact a physician immediately. The safety data sheet (SDS) provides more detailed occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

Flammable - Keep away from heat, sparks, open flames or other sources of ignition.

Do not use in sick, debilitated or underweight animals (see SAFETY).

PRECAUTIONS:
Prior to administration of SENERGY, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. Selamectin is not effective against adult *D. immitis* and, while the number of circulating microfilariae may decrease following treatment, selamectin is not effective for microfilariae clearance.

Hypersensitivity reactions have not been observed in dogs with patent heartworm infections administered three times the recommended dose of selamectin. Higher doses were not tested.

ADVERSE REACTIONS:
Pre-approval clinical trials:
Following treatment with selamectin, transient localized alopecia with or without inflammation at or near the site of application was observed in approximately 1% of 691 treated cats. Other signs observed rarely (≤0.5% of 1743 treated cats and dogs) included vomiting, loose stool or diarrhea with or without blood, anorexia, lethargy, salivation, tachypnea, and muscle tremors.

Post-approval experience:
In addition to the aforementioned clinical signs that were reported in pre-approval clinical trials, there have been reports of pruritus, urticaria, erythema, ataxia, fever, and rare reports of death. There have also been rare reports of seizures in dogs (see **WARNINGS**).

DOSAGE:
The recommended minimum dose is 2.7 mg selamectin per pound (6 mg/kg) of body weight.

Administer the entire contents of a single dose tube (or two tubes used in combination for dogs weighing over 130 pounds) of SENERGY topically in accordance with the following tables. (See **ADMINISTRATION** for the recommended treatment intervals.)

Cats (lb)	Package Color	mg per tube	Potency (mg/mL)	Administered volume (mL)
Up to 5	Mauve	15 mg	60	0.25
5.1–15	Blue	45 mg	60	0.75
15.1–22	Taupe	60 mg	60	1.0

For cats over 22 lbs use the appropriate combination of tubes.

Dogs (lb)	Package Color	mg per tube	Potency (mg/mL)	Administered volume (mL)
Up to 5	Mauve	15 mg	60	0.25
5.1–10	Lavender	30mg	120	0.25
10.1–20	Brown	60 mg	120	0.5
20.1–40	Red	120 mg	120	1.0
40.1–85	Teal	240 mg	120	2.0
85.1–130	Plum	360 mg	120	3.0

For dogs over 130 lbs use the appropriate combination of tubes. Recommended for use in dogs 6 weeks of age and older and in cats 8 weeks of age and older.

ADMINISTRATION:
A veterinarian or veterinary technician should demonstrate or instruct the pet owner regarding the appropriate technique for applying SENERGY topically to dogs and cats prior to first use. Remove the tube from the package and hold upright with the lot and expiration at the bottom. Bend the tip back until it snaps off. To administer the product, part the hair on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the tube on the skin and squeeze the tube 3 or 4 times to empty its entire contents directly onto the skin in one spot. Keeping the tube squeezed, drag it away from the liquid and lift to remove. Check the tube to ensure that it is empty. Do not massage the product into the skin. Due to alcohol content, do not apply to broken skin. Avoid contact between the product and fingers. Do not apply when the haircoat is wet. Bathing or shampooing the dog 2 or more hours after treatment will not reduce the effectiveness of SENERGY against fleas or heartworm. Bathing or shampooing the cat 2 hours after treatment will not reduce the effectiveness of SENERGY against fleas. Bathing or shampooing the cat 24 hours after treatment will not reduce the effectiveness of SENERGY against heartworm. Stiff hair, clumping of hair, hair discoloration, or a slight powdery residue may be observed at the treatment site in some animals. These effects are temporary and do not affect the safety or effectiveness of the product. Discard empty tubes in your ordinary household refuse.

Flea Control in Dogs and Cats
For the prevention and control of flea infestations, SENERGY should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. In controlled laboratory studies >98% of fleas were killed within 36 hours. Results of clinical field studies using selamectin monthly demonstrated >90% control of flea infestations within 30 days of the first dose. Dogs and cats treated with selamectin, including those with pre-existing flea allergy dermatitis, showed improvement in clinical signs associated with fleas as a direct result of eliminating the fleas from the animals and their environment.

If the dog or cat is already infested with fleas when the first dose of selamectin is administered, adult fleas on the animal are killed and no viable fleas hatch from eggs after the first administration. However, an environmental infestation of fleas may persist for a short time after beginning treatment with selamectin because of the emergence of adult fleas from pupae.

Heartworm Prevention in Dogs and Cats
For the prevention of heartworm disease, SENERGY must be administered on a monthly basis. SENERGY may be administered year-round or at least within one month after the animal's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of SENERGY and resumption of monthly dosing will minimize the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of SENERGY must be given within a month of the last dose of the former medication.

Selamectin, the active ingredient in SENERGY, is a macrocyclic lactone compound. These compounds effectively prevent the development of adult heartworms when administered to dogs and cats within one month of exposure to infective (L_3) *Dirofilaria immitis* larvae. Efficacy of macrocyclic lactones decreases below 100% in dogs, however, if first administered >2 months after exposure to infective larvae. Thus, in heartworm endemic regions, delaying initiation of heartworm prevention using SENERGY beyond 2 months of first exposure to infective larvae (e.g., starting puppies and kittens at >8 weeks of age), or gaps of >2 months in the administration of SENERGY during periods of heartworm transmission, increases the risk of the animal acquiring heartworms. Animals with unknown heartworm history that test negative for heartworms prior to the initiation of SENERGY may be harboring pre-patent infections at the time SENERGY was started. Testing such animals 3–4 months after initiation of SENERGY would be necessary to confirm their negative heartworm status.

At the discretion of the veterinarian, cats ≥6 months of age may be tested to determine the presence of existing heartworm infections before beginning treatment with SENERGY. Cats already infected with adult heartworms can be given SENERGY monthly to prevent further infections.

Ear Mite Treatment in Dogs and Cats
For the treatment of ear mite (*O. cynotis*) infestations in dogs and cats, SENERGY should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of SENERGY will control any subsequent ear mite infestations. In the clinical field trials ears were not cleaned, and many animals still had debris in their ears after the second dose. Cleansing of the infested ears is recommended to remove the debris.

Sarcoptic Mange Treatment in Dogs
For the treatment of sarcoptic mange (*S. scabiei*) in dogs, SENERGY should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of SENERGY will control any subsequent sarcoptic mange mite infestations. Because of the difficulty in finding sarcoptic mange mites on skin scrapings, effectiveness assessments also were based on resolution of clinical signs. Resolution of the pruritus associated with the mite infestations was observed in approximately 50% of the dogs 30 days after the first treatment and in approximately 90% of the dogs 30 days after the second monthly treatment.

Tick Control in Dogs
For the control of tick (*Dermacentor variabilis*) infestations in dogs, SENERGY should be administered on a monthly basis. In heavy tick infestations, complete efficacy may not be achieved after the first dose. In these cases, one additional dose may be administered two weeks after the previous dose, with monthly dosing continued thereafter.

Nematode Treatment in Cats
For the treatment and control of intestinal hookworm (*A. tubaeforme*) and roundworm (*T. cati*) infections, SENERGY should be applied once as a single topical dose.

SAFETY:
Selamectin has been tested safe in over 100 different pure and mixed breeds of healthy dogs and over 15 different pure and mixed breeds of healthy cats, including pregnant and lactating females, breeding males and females, puppies six weeks of age and older, kittens eight weeks of age and older, and avermectin-sensitive collies. A kitten, estimated to be 5–6 weeks old (0.3 kg), died 8 1/2 hours after receiving a single treatment of selamectin at the recommended dosage. The kitten displayed clinical signs which included muscle spasms, salivation and neurological signs. The kitten was a stray with an unknown history and was malnourished and underweight (see **WARNINGS**).

DOGS: In safety studies, selamectin was administered at 1, 3, 5, and 10 times the recommended dose to six-week-old puppies, and no adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of selamectin at the recommended topical dose in 5- to 8-month-old beagles did not cause any adverse reactions. In a pre-clinical study selamectin was dosed orally to ivermectin-sensitive collies. Oral administration of 2.5, 10, and 15 mg/kg in this dose escalating study did not cause any adverse reactions; however, eight hours after receiving 5 mg/kg orally, one avermectin-sensitive collie became ataxic for several hours, but did not show any other adverse reactions after receiving subsequent doses of 10 and 15 mg/kg orally. In a topical safety study conducted with avermectin-sensitive collies at 1, 3 and 5 times the recommended dose of selamectin, salivation was observed in all treatment groups, including the vehicle control. Selamectin also was administered at 3 times the recommended dose to heartworm infected dogs, and no adverse effects were observed.

CATS: In safety studies, selamectin was applied at 1, 3, 5, and 10 times the recommended dose to six-week-old kittens. No adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of the recommended topical dose of selamectin to cats caused salivation and intermittent vomiting. Selamectin also was applied at 4 times the recommended dose to patent heartworm infected cats, and no adverse reactions were observed.

In well-controlled clinical studies, selamectin was used safely in animals receiving other frequently used veterinary products such as vaccines, anthelmintics, antiparasitics, antibiotics, steroids, collars, shampoos and dips.

STORAGE CONDITIONS: Store below 25°C (77°F).

HOW SUPPLIED: Available in eight separate dose strengths for dogs and cats of different weights (see **DOSAGE**). SENERGY for puppies and kittens is available in cartons containing 3 single dose tubes. SENERGY for cats and dogs is available in cartons containing 3 single dose tubes.

Virbac SENERGY™ (selamectin)

Distributed by:
Virbac AH, Inc.
P.O. Box 162059
Fort Worth, TX 76161

Approved by FDA under ANADA # 200-670

SENERGY™

LA13661

PRODUCT INSERTS/DISCLOSURES

Brief Summary: Before using STELFONTA® (tigilanol tiglate injection) consult the product insert, a summary of which follows:

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

WARNING: SEVERE WOUND FORMATION IN HUMANS; EXTENSIVE WOUND FORMATION, MAST CELL DEGRANULATION, AND DEATH IN DOGS DUE TO MAST CELL DEGRANULATION

Human Safety

- **Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary (see Dosage and Administration, Human Warnings and Adverse Reactions on the product insert).**

Dog Safety

- **Always administer a corticosteroid (e.g. prednisone or prednisolone), an H1 receptor blocking agent (e.g. diphenhydramine), and an H2 receptor blocking agent (e.g. famotidine) when treating with STELFONTA to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation (see Contraindications and Dosage and Administration on the product insert).**
- **Do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock (e.g. on the body, head, or neck). This may result in accumulation of necrotic debris in the subcutaneous space increasing the risk of systemic adverse reactions, including death, from mast cell degranulation (see Contraindications, Warnings and Adverse Events on the product insert).**
- **Treatment with STELFONTA has been associated with cellulitis and severe tissue sloughing extending away from the treated site resulting in extensive wounds that require additional treatment and prolonged recovery times (see Warnings, Precautions and Adverse Events on the product insert).**

Indications: STELFONTA injection is indicated for use in dogs for the treatment of:

- non-metastatic subcutaneous mast cell tumors located at or distal to the elbow or the hock
- non-metastatic cutaneous mast cell tumors

Concurrent Medications: Administer the following medications to decrease the potential for severe systemic adverse reactions from mast cell degranulation:

- **Corticosteroid (e.g. oral prednisone or prednisolone at anti-inflammatory dose):** Start medication 2 days prior to STELFONTA treatment and continue for 8 days post-treatment (10 days total).
- **H1 receptor blocking agent (e.g. oral diphenhydramine):** Start medication on the day of STELFONTA treatment and continue for a total of 8 days.
- **H2 receptor blocking agent (e.g. oral famotidine):** Start medication on the day of STELFONTA treatment and continue for a total of 8 days.

Dosing Instructions: STELFONTA is injected into the tumor at a dose of **0.5 mL per cm³** of tumor volume, as determined by measuring the tumor and calculating the dose based on **0.5 x length x width x height.**

The Tumor Volume is not to exceed 10 cm³. The dose of STELFONTA is not to exceed 0.25 mL/kg body weight. The dose is not to exceed 5 mL per dog, regardless of tumor volume or body weight. The minimum dose of STELFONTA is 0.1 mL, regardless of tumor volume or body weight. If the calculated dose is <0.1 mL, administer 0.1 mL.

Contraindications: Do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock (e.g. on the body, head, or neck). This may result in accumulation of necrotic debris in the subcutaneous space increasing the risk of systemic adverse reactions, including death, from mast cell degranulation (see Adverse Reactions on the product insert).

WARNINGS: NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.

Caution is required during treatment to avoid accidental self-injection. Dogs undergoing treatment with STELFONTA should be adequately restrained and sedation used if necessary. People with known hypersensitivity to tigilanol tiglate or to any of the excipients should avoid contact with STELFONTA.

Wear disposable gloves when cleaning the treated tumor site to avoid contact with any residual drug. Thoroughly wash your skin that comes in contact with the treated tumor site, wound, or wound discharge.

STELFONTA may cause side effects, even at the prescribed dose. Ensure the dog receives their prescribed medications to decrease the potential for severe, life-threatening side effects from mast cell degranulation. Counsel owners to monitor the dog during the healing process and contact their veterinarian if they notice excessive pain, lameness, tiredness, refusal to eat for more than one day, repeated vomiting or diarrhea, trouble breathing, changes to the treated tumor site (including increased or excessive swelling and bruising, extensive wound formation, increased irritation) or any other symptoms that concern them.

PRECAUTIONS: STELFONTA® (tigilanol tiglate injection) has not been evaluated in dogs with signs of systemic disease due to the mast cell tumor(s). STELFONTA is not intended for the treatment of metastatic mast cell tumors. The safe and effective use of STELFONTA has not been evaluated for simultaneous treatment of more than one mast cell tumor. The safe and effective use of STELFONTA has not been evaluated in dogs with a mast cell tumor volume >10 cm³.

Use STELFONTA with caution in tumors located within mucocutaneous regions (e.g., eyelids, vulva, prepuce, and anus) as tumor necrosis could cause a change in morphology of the mucocutaneous region resulting in loss of functional integrity.

Use STELFONTA with caution in mast cell tumors with significant ulceration as leakage of the drug from the ulcerated area may occur following treatment potentially reducing effectiveness.

The safe use of STELFONTA has not been evaluated in dogs with concurrent diseases that may result in delayed wound healing. After treatment with STELFONTA, dogs may require additional care of the treated site to aid in the healing process. An Elizabethan collar or a non-constricting dry gauze bandage may be needed to prevent the dog from self-traumatizing the treated site.

After treatment with STELFONTA, separation from other household animals may be necessary to prevent grooming and trauma to the treated site.

The safe use of STELFONTA under conditions of use has not been evaluated in dogs younger than 3.5 years old.

The safe use of STELFONTA has not been evaluated in dogs that are pregnant, lactating, or intended for breeding.

Adverse Reactions: In a field study, the most common adverse reactions seen out of 117 dogs included wound formation (94%), injection site pain (52.1%), lameness in the treated limb (24.8%), vomiting (20.5%), diarrhea (20.5%), and hypoalbuminemia (18%). Wound formation, vomiting, and diarrhea were mainly observed within the first 7 to 10 days after treatment. Injection site pain and lameness in the treated leg were mainly observed within the first 2 days after treatment. Hypoalbuminemia was mainly observed within the first 28 days after treatment. All dogs received concomitant medications as noted in the Effectiveness section of the product insert.

Wound Formation
Tumor observations were conducted at 2, 4, 8, and 24 hours and 4 days after treatment. The 81 dogs treated with STELFONTA on Day 0 were reported most frequently with swelling, bruising, pain and heat at all tumor observation timepoints. The following were reported at 24 hours post treatment:

- Swelling: 97.5% (79/81 dogs)
- Bruising: 91.4% (74/81 dogs)
- Pain: 69.1% (56/81 dogs)
- Heat: 53.1% (43/81 dogs)

At 24 hours post treatment, intact skin was reported in 71.6% (58/81 dogs) of STELFONTA treated dogs. On Day 4 intact skin was reported in 17.3% (14/81 dogs) of STELFONTA treated dogs. On Day 4, the following observations were reported with the highest frequency:

- Necrosis: 55.6% (45/81 dogs)
- Crater pockets: 37.0% (30/81 dogs)
- Exudate: 37.0% (30/81 dogs)
- Eschar: 28.4% (23/81 dogs)
- Ulceration: 11.1% (9/81 dogs)

A wound healing assessment was performed on the effectiveness dataset which included 80 dogs in the STELFONTA group and 38 dogs in the untreated control group. Wounds developed in 92.5% (74/80) of STELFONTA treated dogs and 2.6% (1/38) of untreated control dogs by Day 7. On Day 28, the presence of wounds was 40% (32/80) in the STELFONTA group and 2.6% (1/38) in the untreated group. On Day 42 and Day 84, the presence of wounds was 27.1% (16/59) and 1.8% (1/57), respectively, in the STELFONTA group.

Effectiveness: See full prescribing information for details on effectiveness.

Contact Information: To report suspected adverse reactions, to obtain a Safety Data Sheet (SDS), or for technical assistance or case consultation, call 800-338-3659. For additional information about adverse drug experience reporting for animal drugs, contact the FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

Approved by FDA under NADA # 141-541

STELFONTA is the registered trademark of QBiotics Pty Ltd, used under license.
Distributed by Virbac AH, Inc.
P.O Box 162059,
Fort Worth, Texas 76161
Tel. 1-800-338-3659
Version date: August 2020

LEGAL STATUS - In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. THIS PRODUCT IS INDEXED - MIF # 900-013. Extra-label use is prohibited. FOR USE IN FERRETS ONLY
This product is not to be used in animals intended for use as food for humans or food-producing animals.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Suprelorin® F

(DESLORELIN ACETATE) 4.7 mg Implant

DESCRIPTION

Suprelorin® F (4.7 mg) Implant is a synthetic GnRH analogue (deslorelin acetate) in a biocompatible, slow release subcutaneous implant. The implant is a solid, opaque, white to pale yellow cylinder, 2.3 mm x 12.5 mm in length and weighing 50 mg. The **Suprelorin® F** (4.7 mg) Implant comes pre-loaded in an implanting needle. Each implant contains 4.7 mg deslorelin (as deslorelin acetate) in an inert matrix.

Chemical Structure – Deslorelin acetate



[(6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide]GnRH

INDICATIONS

Suprelorin® F (4.7 mg) Implant is indicated for the management of adrenal gland cortical disease in the male and female domestic ferret.

DOSAGE AND ADMINISTRATION

The recommended dosage is one, 4.7 mg implant per ferret every 12 months. Appropriate clinical monitoring is suggested to determine that the symptoms of adrenal disease are being adequately controlled.

Do not use if the foil pouch is damaged.

Remove Luer Lock cap from the implanting needle. Attach the actuator syringe to the implanter using the luer lock connection. One implant should be implanting needle subcutaneously at the dorsal aspect of the base of the neck. Administer only one implant per ferret. Select the implant site by locating the area of the back midway between the shoulder blades. It is not necessary to prepare the implantation site. If the hair is long, a small section may be clipped if required. Lift the loose skin between the shoulder blades. Insert the entire length of the needle subcutaneously. Fully depress the actuator syringe plunger. Press the skin at the insertion site as the needle is slowly withdrawn, and maintain pressure for 30 seconds. Examine the implanting needle to verify that the implant has not remained within the needle, and that the blue plastic spacer is visible at the tip of the needle. It may be possible to palpate the implant *in situ*. The biocompatible implant does not require removal. Wash hands after use.

Repeat treatment every 12 months to maintain efficacy. Appropriate endocrine testing and clinical monitoring should be performed at appropriate intervals to monitor the response to therapy.

CONTRAINDICATIONS

Do not use this product in ferrets with known hypersensitivity to deslorelin acetate or other synthetic hormones.

HUMAN SAFETY WARNINGS

KEEP OUT OF REACH OF CHILDREN. DO NOT HANDLE THIS PRODUCT IF YOU ARE PREGNANT OR NURSING OR SUSPECT YOU MAY BE PREGNANT. Accidental administration may lead to a disruption of the menstrual cycle. Avoid direct skin contact with the implant; if skin contact occurs, wash the affected area immediately with soap and water. The use of gloves is advised. As with all injectable drugs causing profound physiological effects, routine precautions should be employed by practitioners when handling and using Suprelorin® F (4.7 mg) Implant to prevent accidental injection. In case of accidental human injection, a physician should be consulted and the implant should be removed.

PRECAUTION

Do not use in animals intended for breeding. The safe use of this product has not been evaluated in pregnant or lactating ferrets.

ADVERSE REACTIONS

It is possible that treated ferrets will exhibit signs of soreness and swelling at the implantation site which should resolve over one or two weeks. Undesirable histology at the site of implantation has not been reported in other species (canine). Other reported side effects include: weight gain, lethargy and failure to respond to therapy.

To report suspected adverse drug events, please call Virbac at 800-338-3659. For additional information about adverse drug experience reporting for animal drugs, contact the FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

PHARMACOLOGY

Suprelorin® F (4.7 mg) Implant is a controlled release implant containing the GnRH agonist deslorelin. Deslorelin acetate suppresses the reproductive endocrine system, preventing production of pituitary and gonadal hormones. Deslorelin acetate has not been shown to reduce the size of adrenal tumors and is not considered curative.

DISPOSAL

Each implanting needle (sterile) is a single use device. Used needles should immediately be placed in a designated and appropriately labeled "sharps" container. Each actuator syringe (non-sterile) is a multi-use device and should be saved for future use with the remaining implant(s) in the carton. Unused implants should be disposed of in accordance with local environmental requirements.

STORAGE

Store at temperatures between 2˚ and 8˚ C (36˚ and 46˚ F).
Do not freeze.

HOW SUPPLIED

Five (5) or two (2) implants pre-loaded in implanting needles and individually packaged per carton.

For technical assistance, to request an SDS, or to report suspected adverse drug events, please call Virbac at 1-800-338-3659.

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059
Fort Worth, TX 76161

Product of Australia MIF 900-013

Revision 11/2020
L-2000-F-US-3

PRODUCT INSERTS/DISCLOSURES

Brief Summary of Prescribing Info for Cattle

Tenotryl™ (enrofloxacin)
100 mg/mL Antimicrobial Injectable Solution
For Subcutaneous Use In Beef Cattle And Non-Lactating Dairy Cattle
Not For Use In Female Dairy Cattle 20 Months Of Age Or Older Or In Calves To Be Processed For Veal

CAUTION:
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law prohibits the extra-label use of this drug in food-producing animals.
PRODUCT DESCRIPTION:
Tenotryl™ is a sterile, ready-to-use injectable antimicrobial solution that contains enrofloxacin, a broad-spectrum fluoroquinolone antimicrobial agent.
Each mL of Tenotryl™ contains 100 mg of enrofloxacin. Excipients are L-arginine base 200 mg, n-butyl alcohol 30 mg, benzyl alcohol (as a preservative) 20 mg and water for injection q.s.
INDICATIONS:
Single-Dose Therapy: Tenotryl™ is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica, P. multocida, H. somni* and *M. bovis*.
Multiple-Day Therapy: Tenotryl™ is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida* and *Histophilus somni* in beef and non-lactating dairy cattle.
DOSAGE AND ADMINISTRATION:
Tenotryl™ provides flexible dosages and durations of therapy. Tenotryl™ may be administered as a single dose for one day for treatment and control of BRD, or for multiple days for BRD treatment. Selection of the appropriate dose and duration of therapy for BRD treatment in cattle should be based on an assessment of the severity of the disease, pathogen susceptibility and clinical response.
Single-Dose Therapy (BRD Treatment):
Administer, by subcutaneous injection, a single dose of 7.5-12.5 mg/kg of body weight (3.4-5.7 mL/100 lb).
Multiple-Day Therapy (BRD Treatment):
Administer daily, a subcutaneous dose of 2.5-5 mg/kg of body weight (1.1-2.3 mL/100 lb). Treatment should be repeated at 24-hour intervals for three days. Additional treatments may be given on Days 4 and 5 to animals that have shown clinical improvement but not total recovery.
Single-Dose Therapy (BRD Control):
Administer, by subcutaneous injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). Examples of conditions that may contribute to calves being at high risk of developing BRD include, but are not limited to, the following:

- Transportation with animals from two or more farm origins.
- An extended transport time with few to no rest stops.
- An environmental temperature change of ≥30°F during transportation.
- A ≥30°F range in temperature fluctuation within a 24-hour period.
- Exposure to wet or cold weather conditions.
- Excessive shrink (more than would be expected with a normal load of cattle).
- Stressful arrival processing procedures (e.g., castration or dehorning).
- Exposure within the prior 72 hours to animals showing clinical signs of BRD.

Administered dose volume should not exceed 20 mL per injection site.

Table 1 – Tenotryl™ Dose and Treatment Schedule for Cattle*

Weight (lb)	Treatment		Control
	Single-Dose Therapy 7.5-12.5 mg/kg Dose Volume (mL)	Multiple-Day Therapy 2.5-5.0 mg/kg Dose Volume (mL)	Single-Dose Therapy 7.5 mg/kg Dose Volume (mL)
100	3.5 - 5.5	1.5 - 2.0	3.5
200	7.0 - 11.0	2.5 - 4.5	7.0
300	10.5 - 17.0	3.5 - 6.5	10.5
400	14.0 - 22.5	4.5 - 9.0	14.0
500	17.0 - 28.5	5.5 - 11.5	17.0
600	20.5 - 34.0	7.0 - 13.5	20.5
700	24.0 - 39.5	8.0 - 16.0	24.0
800	27.5 - 45.5	9.0 - 18.0	27.5
900	31.0 - 51.0	10.0 - 20.5	31.0
1000	34.0 - 57.0	11.0 - 23.0	34.0
1100	37.5 - 62.5	12.5 - 25.0	37.5

*Dose volumes have been rounded to the nearest 0.5 mL within the dose range.

Use within 30 days of first puncture and puncture a maximum of 30 times with a 16-gauge needle or smaller, or 4 times with a draw-off spike 4.75 mm or smaller. Any product remaining beyond these parameters should be discarded.

RESIDUE WARNINGS:
Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

HUMAN WARNINGS:
Not for use in humans. Keep out of reach of children. To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, call 1-800-338-3659.
PRECAUTIONS:
The effects of enrofloxacin on cattle reproductive performance, pregnancy and lactation have not been adequately determined. Subcutaneous injection in cattle can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
Enrofloxacin injectable solution contains different excipients than other enrofloxacin products. The safety and efficacy of this formulation in species other than cattle and swine have not been determined.
Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare cases, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. See Animal Safety section for additional information.
ADVERSE REACTIONS:
No adverse reactions were observed during clinical trials.
To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Virbac AH, Inc at 1-800-338-3659 or us.virbac.com
For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.
STORAGE CONDITIONS:
Protect from direct sunlight. Do not refrigerate or freeze.
Store at 20-30°C (68-86°F), excursions permitted between 15°C (59°F) to 40°C (104°F). Precipitation may occur due to cold temperature. To redissolve, warm and then shake the vial.
HOW SUPPLIED:
Tenotryl™ (enrofloxacin) Injectable Solution:

100 mg/mL	100 mL Bottle
100 mg/mL	250 mL Bottle
100 mg/mL	500 mL Bottle

Virbac AH, Inc.
PO Box 162059
Fort Worth, TX 76161
Rev. 12/21

Approved by FDA under ANADA # 200-688
TENOTRYL is a trademark of Virbac S.A.

Brief Summary of Prescribing Info for Swine

Tenotryl™ (enrofloxacin)
100 mg/mL Antimicrobial Injectable Solution
For Intramuscular Or Subcutaneous Use In Swine

CAUTION:
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law prohibits the extra-label use of this drug in food-producing animals.
To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options.
INDICATIONS:
Tenotryl™ is indicated for the treatment and control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica* and *Mycoplasma hyopneumoniae*. Tenotryl™ is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with *Escherichia coli* has been diagnosed.
DOSAGE AND ADMINISTRATION:
Tenotryl™ provides flexible dosages and durations of therapy. Tenotryl™ may be administered for treatment and control of SRD or for control of colibacillosis. Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). Administered dose volume should not exceed 5 mL per injection site. For the control of colibacillosis, administration should be initiated within the first 60 days post-weaning when clinical signs are present in at least 2% of animals in the group. If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

Table 1 – Dose Schedule for Swine

Weight (lb)	Dose Volume (mL)
15	0.5
30	1.0
50	1.7
100	3.4
150	5.1
200	6.8
250	8.5

Dilution of Tenotryl: Tenotryl™ may be diluted with sterile water prior to injection. The diluted product should be used within 24 hours. Store diluted solution in amber glass bottles between 5°C - 40°C (41°F - 104°F), excursions are not permitted.

Table 2 – Dilution Schedule*

Swine Weight	mL of Tenotryl™	mL of sterile water	Number of doses
10 lb	34 mL	66 mL	100
15 lb	51 mL	49 mL	100
20 lb	68 mL	32 mL	100
25 lb	85 mL	15 mL	100

*For 1 mL dose volume from diluted solution

Use within 30 days of first puncture and puncture a maximum of 30 times with a 16-gauge needle or smaller, or 4 times with a draw-off spike 4.75 mm or smaller. Any product remaining beyond these parameters should be discarded.

RESIDUE WARNINGS:
Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose.

HUMAN WARNINGS:
Not for use in humans. Keep out of reach of children.
PRECAUTIONS:
The effects of enrofloxacin on swine reproductive performance, pregnancy and lactation have not been adequately determined.
The long-term effects on articular joint cartilage have not been determined in pigs above market weight.
Subcutaneous injection or intramuscular injection in swine can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
Enrofloxacin injectable solution contains different excipients than other enrofloxacin products. The safety and efficacy of this formulation in species other than cattle and swine have not been determined.
Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare cases, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. See Animal Safety Section in the full prescribing information for additional details.

ADVERSE REACTIONS:
No adverse reactions were observed during clinical trials.
To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, call 1-800-338-3659.
For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.
STORAGE CONDITIONS:
Protect from direct sunlight. Do not refrigerate or freeze.
Store at 20-30°C (68-86°F), excursions permitted between 15°C (59°F) to 40°C (104°F). Precipitation may occur due to cold temperature. To redissolve, warm and then shake the vial.
HOW SUPPLIED:
Tenotryl™ (enrofloxacin) Injectable Solution:

100 mg/mL	100 mL Bottle
100 mg/mL	250 mL Bottle
100 mg/mL	500 mL Bottle

Virbac AH, Inc.
PO Box 162059
Fort Worth, TX 76161
Rev. 12/21

Approved by FDA under ANADA # 200-688
TENOTRYL is a trademark of Virbac S.A.

For more information, call 1-800-338-3659 Option 1 or visit vet-us.virbac.com.

Brief Summary of Prescribing Information
Before using TIA 12.5% (tiamulin hydrogen fumarate) Liquid Concentrate consult the product insert, a summary of which follows:

TIA™ 12.5%
(tiamulin hydrogen fumarate)

Description:
TIA 12.5% (tiamulin hydrogen fumarate) Liquid Concentrate is a solution containing 12.5% tiamulin hydrogen fumarate
(w/v) in an aqueous solution.

The active ingredient, tiamulin hydrogen fumarate, chemically is 14-desoxy-14-[(2-diethylaminoethyl) mercaptoacetoxy] mutilin hydrogen fumarate, a semi-synthetic diterpene antibiotic. TIA 12.5% Liquid Concentrate is for use only in preparing medicated drinking water for swine.

Actions: Tiamulin is active against Brachyspira (formerly Serpulina or Treponema) hyodysenteriae and Actinobacillus pleuropneumoniae. It is readily absorbed from the gut and can be found in the blood within 30 minutes after dosing.

Indications: TIA 12.5% (tiamulin hydrogen fumarate), when administered in the drinking water for five consecutive days, is an effective antibiotic for the treatment of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hyodysenteriae susceptible to tiamulin at a dose level of 3.5 mg tiamulin hydrogen fumarate per pound of body weight daily and for treatment of swine pneumonia due to Actinobacillus pleuropneumoniae susceptible to tiamulin when given at 10.5 mg tiamulin hydrogen fumarate per pound of body weight daily.

Contraindications: Swine being treated with TIA 12.5% (tiamulin hydrogen fumarate) should not have access to feeds containing polyether ionophores (e.g. monensin, lasalocid, narasin, salinomycin and semduramicin) as adverse reactions may occur.

Warning: Keep out of reach of children. Avoid contact with skin. Direct contact with skin or mucous membranes may cause irritation.

Residue Warnings: Withdraw medicated water 3 days before slaughter after treatment at 3.5 mg per pound body weight and 7 days before slaughterafter treatment at 10.5 mg per pound body weight.

Caution: For use in drinking water of swine only - Not for use in humans. Prepare fresh medicated water daily. Use as the only source of drinking water for 5 days. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined.

Adverse Reactions: Overdoses of tiamulin hydrogen fumarate have sometimes produced transitory salivation, vomiting and an apparent calming effect on the pig. If signs of toxicity occur, discontinue use of medicated water and replace with clean, fresh water.

In rare cases, redness of the skin primarily over the ham and underline has been observed during medication. If these signs appear, discontinue use of this drug. Provide ample clean drinking water. Thoroughly rinse (hose down) the housing to remove urine and feces from animal contact surfaces or move the animals to clean pens. If the condition persists, consult your veterinarian.

Studies to evaluate the safety of the water soluble form of tiamulin in breeding swine have not been done.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

Use Directions: The concentration of tiamulin hydrogen fumarate in the drinking water must be adjusted to compensate for variation in water consumption due to weight or size of the pig, environmental temperature and other factors. It is important that pigs receive the proper drug dose, 3.5 mg tiamulin hydrogen fumarate per pound for swine dysentery or 10.5 mg tiamulin hydrogen fumarate per pound for swine pneumonia, each day for 5 consecutive days.

Directions for preparing TIA 12.5% medicated solutions: Determine the amount of TIA 12.5% (tiamulin hydrogen fumarate) Liquid Concentrate needed to medicate the desired volume of drinking water at the proper concentration. Carefully measure out this amount, add it to the water and stir to thoroughly mix. 1. Prepare fresh medicated drinking water every day for the 5 day treatment period. 2. Water medicated with TIA 12.5% (tiamulin hydrogen fumarate) should be the only source of drinking water during the treatment period. *3. Increase or decrease dilution rate as required to obtain proper daily drug dose.

Number of pigs this bottle will treat for ONE day based on water consumption per pig		One Liter	
Net tiamulin hydrogen fumarate content:			125,000 mg
Diseases to be treated:		**Swine Dysentery**	**Swine Pneumonia**
Daily tiamulin hydrogen fumarate required per pound body weight:		3.5 mg	10.5 mg
Required treatment duration:		5 days	5 days
Pig Weight, lb	Water Intake, gal	# of Pigs	# of Pigs
20	0.3 - 0.5	1,786	595
45	0.4 - 1.1	794	265
75	0.7 - 1.5	476	159
125	1.0 - 2.0	286	95
180	1.2 - 3.0	198	66
Suggested final dilution of:	1 bottle (1 Liter)	550 gal	183 gal
	3 bottles (3 Liters)	1650 gal	550 gal
	1/2 bottle (0.5 Liters)	275 gal	92 gal
Tiamulin hydrogen fumarate concentration per gallon at suggested final dilution*		227 mg (60 ppm)	681 mg (180 ppm)

Directions for using TIA 12.5%
In medicated proportioners: One liter of TIA 12.5% Liquid Concentrate mixed with water to make 4.3 gallons of stock solution and this stock solution metered at one fluid ounce per gallon will provide 227 mg of tiamulin hydrogen fumarate per gallon to 550 gallons of drinking water for treatment of swine dysentery. Three liters of TIA 12.5% Liquid Concentrate mixed with water to make 4.3 gallons of stock solution and this stock solution metered at one fluid ounce per gallon will provide 681 mg tiamulin hydrogen fumarate per gallon to a total of 550 gallons of drinking water for treatment of swine pneumonia.

In barrels or tanks: One liter (1000 mL) of TIA 12.5% (tiamulin hydrogen fumarate) Liquid Concentrate will medicate 550 gallons of drinking water at 227 mg per gallon for treatment of swine dysentery or 183 gallons at 681 mg per gallon for treatment of swine pneumonia.

Measure TIA 12.5% Liquid Concentrate carefully, pour into the proper amount of water and thoroughly mix. The concentration of tiamulin hydrogen fumarate in the stock solution and in the drinking water delivered must be adjusted to compensate for variation in water consumption by pigs due to body weight, environmental and other factors. It is important that the pigs receive the proper drug dose of 3.5 mg of tiamulin hydrogen fumarate per pound of body weight daily for 5 consecutive days for treatment of swine dysentery or a dose of 10.5 mg per pound body weight daily for 5 consecutive days for treatment of swine pneumonia.

Attention: If no response to treatment is obtained within 5 days re-establish the diagnosis. Failure of response may be related to the presence of non-susceptible organisms of other complicating disease conditions. Because of the tendency for the disease to recur on premises with a history of swine dysentery or with swine pneumonia, a control program should be implemented after treatment. Drugs are not substitutes for proper sanitary measures or good management, but should be used in conjunction with such practices.

How Supplied:

Container Size	Active Ingredients
1 Liter bottle	12.5% (125.0 g)
(33.8 fl oz; 1000 mL)	Tiamulin hydrogen fumarate

Store at or below 25˚C (77˚F). Excursions permitted up to 40˚C (104˚F).
Observe expiration date.

Restricted Drug (California): Use only as directed
Approved by FDA under ANADA # 200-695

Manufactured by: Virbac AH, Inc
P.O. Box 162059 Fort Worth, TX 76161

92601 302295-02

PRODUCT INSERTS/DISCLOSURES

Brief Summary of Prescribing Information for Cattle
Before using TULISSIN® 25 (tulathromycin injection) consult the product insert, a summary of which follows:

Tulissin®-25
(tulathromycin injection)
Injectable Solution

Antibiotic
25 mg of tulathromycin/mL
For use in suckling calves, dairy calves, and veal calves. Not for use in ruminating cattle.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS:
Suckling Calves, Dairy Calves, and Veal Calves
BRD - TULISSIN 25 Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni*, and *Mycoplasma bovis*.

DOSAGE AND ADMINISTRATION
Calves
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) body weight (BW). Do not inject more than 11.5 mL per injection site.

Table 1. TULISSIN 25 Injectable Solution Dosing Guide (25 mg/mL)
(refer to table 2 on product insert)

Animal Weight (Pounds)	Dose Volume (mL)
50	2.3
75	3.4
100	4.5
150	7.0
200	9.0
250	11.5

CONTRAINDICATIONS
The use of TULISSIN 25 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS
FOR USE IN ANIMALS ONLY.
NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.
NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNINGS
Calves
Calves intended for human consumption must not be slaughtered within 22 days from the last treatment with TULISSIN 25 Injectable Solution. This drug is not for use in ruminating cattle.

PRECAUTIONS
Cattle
The effects of TULISSIN 25 Injectable Solution on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS
Calves
In one BRD field study, two calves treated with tulathromycin injection (100 mg/mL) at 2.5 mg/kg BW exhibited transient hypersalivation. One of these calves also exhibited transient dyspnea, which may have been related to pneumonia.

Post Approval Experience
The following adverse events are based on post approval adverse drug experience reporting for tulathromycin injection (100 mg/mL). Not all adverse events are reported to the FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of reporting frequency in cattle: Injection site reactions and anaphylaxis/anaphylactoid reactions.

STORAGE CONDITIONS:
Store at or below 30°C (86°F). Use within 45 days of first puncture and puncture a maximum of 30 times. Consider using automatic injection equipment or a repeater syringe. When using a needle or draw-off spike larger than 16 gauge, discard any remaining product immediately after use.

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059, Fort Worth, TX 76161
Made in France

Approved by FDA under ANADA # 200-668

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

TAKE TIME OBSERVE LABEL DIRECTIONS

Rev. 06/21

Brief Summary of Prescribing Information for Cattle
Before using TULISSIN® 100 (tulathromycin injection) Injectable Solution consult the product insert, a summary of which follows:

Tulissin®-100
(tulathromycin injection)
Injectable Solution

Antibiotic
100 mg of tulathromycin/mL
For use in beef cattle (including suckling calves), non-lactating dairy cattle (including dairy calves), veal calves, and swine. Not for use in female dairy cattle 20 months of age or older.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS:
Beef and Non-Lactating Dairy Cattle
BRD - TULISSIN 100 Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni*, and *Mycoplasma bovis*; and for the control of respiratory disease in cattle at high risk of developing BRD associated with *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni*, and *Mycoplasma bovis*.

IBK - TULISSIN 100 Injectable Solution is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with *Moraxella bovis*.

Foot Rot - TULISSIN 100 Injectable Solution is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with *Fusobacterium necrophorum* and *Porphyromonas levii*.

Suckling Calves, Dairy Calves, and Veal Calves
BRD - TULISSIN 100 Injectable Solution is indicated for the treatment of BRD associated with *M. haemolytica, P. multocida, H. somni*, and *M. bovis*.

DOSAGE AND ADMINISTRATION
Cattle
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.

Table 1. TULISSIN 100 Injectable Solution Cattle Dosing Guide (100 mg/mL) (refer to Table 1 on product insert)

Animal Weight (Pounds)	Dose Volume (mL)
100	1.1
200	2.3
300	3.4
400	4.5
500	5.7
600	6.8
700	8.0
800	9.1
900	10.2
1000	11.4

CONTRAINDICATIONS
The use of TULISSIN 100 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS
FOR USE IN ANIMALS ONLY.
NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.
NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNINGS
Cattle
Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. This drug is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows.

PRECAUTIONS
Cattle
The effects of TULISSIN 100 Injectable Solution on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS
Cattle
In one BRD field study, two calves treated with tulathromycin injection (100 mg/mL) at 2.5 mg/kg BW exhibited transient hypersalivation. One of these calves also exhibited transient dyspnea, which may have been related to pneumonia.

STORAGE CONDITIONS:
Store at or below 30°C (86°F). Use within 45 days of first puncture and puncture a maximum of 20 times. Consider using automatic injection equipment or repeater syringe. When using a needle or draw-off spike larger than 16 gauge, discard any remaining product immediately after use.

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059, Fort Worth, TX 76161
Made in France

Approved by FDA under ANADA # 200-669

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

TAKE TIME OBSERVE LABEL DIRECTIONS

Rev. 06/22

Brief Summary of Prescribing Information for Swine
Before using TULISSIN® 25 (tulathromycin injection) consult the product insert, a summary of which follows:

Virbac Tulissin®-25 (tulathromycin injection) Injectable Solution

Antibiotic
25 mg of tulathromycin/mL
For use in swine

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS:
Swine
TULISSIN 25 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*; and for the control of SRD associated with *Actinobacillus pleuropneumoniae, Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

DOSAGE AND ADMINISTRATION
Swine
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) Body Weight (BW). Do not inject more than 4 mL per injection site.

Table 1. TULISSIN 25 Swine Dosing Guide (25 mg/mL)

Animal Weight (Pounds)	Dose Volume (mL)
4	0.2
10	0.5
15	0.7
20	0.9
22	1.0
25	1.1
30	1.4
50	2.3
70	3.2
90	4.0

CONTRAINDICATIONS
The use of TULISSIN 25 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS
FOR USE IN ANIMALS ONLY.
NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.
NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNINGS
Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.

PRECAUTIONS
Swine
The effects of TULISSIN 25 Injectable Solution on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS
Swine
In one field study, one out of 40 pigs treated with tulathromycin injection (100 mg/mL) at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.

STORAGE CONDITIONS:
Store at or below 30°C (86°F). Use within 45 days of first puncture and puncture a maximum of 30 times. Consider using automatic injection equipment or a repeater syringe. When using a needle or draw-off spike larger than 16 gauge, discard any remaining product immediately after use.

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059, Fort Worth, TX 76161
Made in France

Approved by FDA under ANADA # 200-668

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

TAKE TIME OBSERVE LABEL DIRECTIONS

Rev. 06/21

Brief Summary of Prescribing Information for Swine
Before using TULISSIN® 100 (tulathromycin injection) consult the product insert, a summary of which follows:

Virbac Tulissin®-100 (tulathromycin injection) Injectable Solution

Antibiotic
100 mg of tulathromycin/mL
For use in swine.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS:
Swine
TULISSIN 100 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*; and for the control of SRD associated with *Actinobacillus pleuropneumoniae, Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

DOSAGE AND ADMINISTRATION
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

Table 1. TULISSIN 100 Swine Dosing Guide. (refer to Table 2 on product insert)

Animal Weight (Pounds)	Dose Volume (mL)
15	0.2
30	0.3
50	0.6
70	0.8
90	1.0
110	1.3
130	1.5
150	1.7
170	1.9
190	2.2
210	2.4
230	2.6
250	2.8
270	3.1
290	3.3

CONTRAINDICATIONS
The use of TULISSIN 100 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS
FOR USE IN ANIMALS ONLY.
NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.
NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNINGS
Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.

PRECAUTIONS
Swine
The effects of TULISSIN 100 on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter

ADVERSE REACTIONS
Swine
In one field study, one out of 40 pigs treated with tulathromycin injection at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.

STORAGE CONDITIONS:
Store at or below 30°C (86°F). Use within 45 days of first puncture and puncture a maximum of 20 times. Consider using automatic injection equipment or repeater syringe. When using a needle or draw-off spike larger than 16 gauge, discard any remaining product immediately after use.

Manufactured for:
Virbac AH, Inc.
P.O. Box 162059, Fort Worth, TX 76161
Made in France

Approved by FDA under ANADA # 200-669

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

TAKE TIME OBSERVE LABEL DIRECTIONS

Rev. 06/22

Human Warning:
Keep this and all medication out of reach of children. To obtain product information, including a Safety Data Sheet (SDS), call 1-800-338-3659.
301796 - 03

Virbantel® Flavored Chewables

Package contents: bottle of 50 flavored chewables

Drug Facts

Active Ingredients (in each chewable):
pyrantel pamoate (30 mg) and praziquantel (30 mg)

Purpose: De-wormer for Small Dogs and Puppies Only (6.0 to 25 pounds).

Uses: For the treatment and control of:
- Roundworms (*Toxocara canis, Toxascaris leonina*)
- Hookworms (*Ancylostoma caninum, Ancylostoma braziliense*, and *Uncinaria stenocephala*)
- Tapeworms (*Dipylidium caninum, Taenia pisiformis*)

Human Warning:
Keep this and all medication out of the reach of children. To obtain product information, including a Safety Data Sheet (SDS), call 1-800-338-3659.

When Using This Product:
- Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
- Do not de-worm a dog or puppy that is sick. Consult a veterinarian for diagnosis of the illness.
- **VIRBANTEL** Flavored Chewables are safe for use in puppies 12 weeks or older and adult dogs. Safety in breeding dogs and pregnant bitches has not been tested.

You May Notice:
Vomiting, loose stools (with or without blood) and decreased activity following treatment.

If you notice these signs, contact a veterinarian.

Directions:
Each flavored chewable contains 30 mg of pyrantel pamoate and 30 mg of praziquantel. The dose for each drug is 2.27 mg per pound of body weight (5 mg/kg). Please refer to the following dosing table for help finding the right dose for your dog.

VIRBANTEL® Flavored Chewables Dosing Table

Dog Weight / Number of Chewables
6.0 to 12 pounds: 1 Chewable
12.1 to 25 pounds: 2 Chewables
More than 25 pounds: Use 114 mg size.

- You should weigh your dog to make sure you are giving the right dose.
- **VIRBANTEL** Flavored Chewables are palatable if offered by hand. If your dog does not voluntarily eat the chewable, you can hide the chewable in a small amount of food or place it in the back of the dog's mouth for forced swallowing.
- Make sure that the dog eats the complete dose.
- Watch your dog for a few minutes after dosing to make sure the chewable is not rejected.

Other Information:
Recommended De-Worming Schedule:
Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. De-worming schedules may vary depending on the climate where you live and the activity of your dog.

Re-treatment: Re-treatment of your dog may be necessary as determined by laboratory fecal examination and/or if your dog is living where re-infections are likely to occur. Consult your veterinarian for assistance in the diagnosis and prevention of re-infection. In case of re-infection with tapeworms (*Dipylidium caninum*), consult your veterinarian for advice on how to remove fleas from the dog and the environment.

Manufactured by:
Virbac AH, Inc.
Fort Worth, TX 76137
Storage: Store at controlled room temperature of 59 - 86˚F (15 - 30˚C).

Questions? Comments?
To report a suspected adverse reaction, call 1-800-338-3659.

02/19 301798 - 03

Approved by FDA under NADA # 141-261

Virbantel® Flavored Chewables

Package contents: bottle of 50 flavored chewables

Drug Facts

Active Ingredients (in each chewable):
pyrantel pamoate (114 mg) and praziquantel (114 mg)

Purpose: De-wormer for Medium and Large Dogs Only (Greater than 25 pounds).

Uses: For the treatment and control of:
- Roundworms (*Toxocara canis, Toxascaris leonina*)
- Hookworms (*Ancylostoma caninum, Ancylostoma braziliense*, and *Uncinaria stenocephala*)
- Tapeworms (*Dipylidium caninum, Taenia pisiformis*)

- You should weigh your dog to make sure you are giving the right dose.
- VIRBANTEL Flavored Chewables are palatable if offered by hand. If your dog does not voluntarily eat the chewable, you can hide the chewable in a small amount of food or place it in the back of the dog's mouth for forced swallowing.
- Make sure that the dog eats the complete dose.
- Watch your dog for a few minutes after dosing to make sure the chewable is not rejected.

Virbac

When Using This Product:
- Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
- Do not de-worm a dog or puppy that is sick. Consult a veterinarian for diagnosis of the illness.
- **VIRBANTEL** Flavored Chewables are safe for use in puppies 12 weeks or older and adult dogs. Safety in breeding dogs and pregnant bitches has not been tested.

You May Notice:
Vomiting, loose stools (with or without blood) and decreased activity following treatment. If you notice these signs, contact a veterinarian.

Human Warning:
Keep this and all medication out of the reach of children. To obtain product information, including a Safety Data Sheet (SDS), call 1-800-338-3659.

Other Information:
Recommended De-Worming Schedule:
Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. De-worming schedules may vary depending on the climate where you live and the activity of your dog.

Re-treatment: Re-treatment of your dog may be necessary as determined by laboratory fecal examination and/or if your dog is living where re-infections are likely to occur. Consult your veterinarian for assistance in the diagnosis and prevention of re-infection. In case of re-infection with tapeworms (*Dipylidium caninum*), consult your veterinarian for advice on how to remove fleas from the dog and the environment.

Directions: Each flavored chewable contains 114 mg of pyrantel pamoate and 114 mg of praziquantel. The dose for each drug is 2.27 mg per pound of body weight (5 mg/kg). Please refer to the following dosing table for help finding the right dose for your dog.

VIRBANTEL Flavored Chewables Dosing Table

Dog Weight	Number of Chewables
6.0 to 25 pounds	Use the 30 mg size.
25.1 to 50 pounds	1
50.1 to 100 pounds	2
100.1 to 150 pounds	3
150.1 to 200 pounds	4

Manufactured by:
Virbac AH, Inc.
Fort Worth, TX 76137

Storage:
Store at controlled room temperature of 59 - 86˚F (15 - 30˚C).

Questions? Comments?
To report a suspected adverse reaction, call 1-800-338-3659.

2/2019 301799-03

Approved by FDA under NADA # 141-261

PRODUCT INSERTS/DISCLOSURES

Virbac

Zoletil® for Injection
(tiletamine and zolazepam for injection) CIII

100 mg/mL total
(equivalent to 50 mg/mL tiletamine and 50 mg/mL zolazepam)
For Intramuscular and Intravenous Injection in Dogs
For Intramuscular Injection only in Cats

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

Zoletil™ for Injection (tiletamine and zolazepam for injection) is a nonnarcotic, nonbarbiturate, injectable anesthetic agent for dogs and cats. Chemically, Zoletil for Injection is a combination of equal parts by weight of base of tiletamine hydrochloride (2-[ethylamino]-2-[2-thienyl]-cyclohexanone hydrochloride), an arylaminocycloalkanone dissociative anesthetic, and zolazepam hydrochloride (4-[o-fluorophenyl]-6, 8-dihydro-1,3,8-trimethylpyrazolo [3,4-e] [1,4] diazepin-7 [1H]-1-hydrochloride), a nonphenothiazine diazepinone having minor tranquilizing properties. The product is supplied sterile in vials. The addition of 5 mL diluent produces a solution containing the equivalent of 50 mg tiletamine base, 50 mg zolazepam base and 57.7 mg mannitol per milliliter. This solution has a pH of 2 to 3.5 and is recommended for deep intramuscular injection.

INDICATIONS

Dogs

Zoletil for Injection is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia. (See Dogs under Dosage and Administration.)

Zoletil for Injection administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic.

Cats

Zoletil for Injection is indicated in cats for restraint or for anesthesia combined with muscle relaxation.

DOSAGE AND ADMINISTRATION

The dose is determined by the total combined concentration of 100 mg/mL (see HOW SUPPLIED)

Dogs

Intramuscular (IM) For Restraint and Minor Procedures of Short Duration Requiring Mild to Moderate Analgesia:

In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) Zoletil for Injection is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses of Zoletil for Injection are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg). (See Animal Safety.) Results from Zoletil for Injection anesthesia in dogs will be more satisfactory if the procedures are completed within one hour and if the procedures can be completed following single dose administration. In order to maintain at least a 2X margin of safety in dogs, the use of this product is limited to procedures that call for low doses (see Indications). Studies show that there is variation in response to different dosages of tiletamine and zolazepam for injection and that low doses do not give adequate levels of anesthesia, and in some instances do not give adequate analgesia, for extensive procedures.

Intravenous (IV) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic:

In dogs, for induction of anesthesia, administer Zoletil for Injection intravenously at 1-2 mg/lb (2.2-4.4 mg/kg) body weight to effect. Zoletil for Injection should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog's level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog's level of anesthesia is not sufficient for successful intubation, additional Zoletil for Injection may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Cats

In healthy cats, an initial Zoletil for Injection dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) IM is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovariohysterectomy and onychectomy. When supplemental doses of Zoletil for Injection are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg). (See Animal Safety.)

General Dosing Information

Fasting prior to induction of general anesthesia with Zoletil for Injection is not essential; however, when preparing for elective surgery, it is advisable to withhold food for at least 12 hours prior to Zoletil for Injection administration. As with other injectable anesthetic agents, the individual response to Zoletil for Injection is somewhat varied, depending upon the dose, general physical condition and age of the patient, duration of the surgical procedure, and any preanesthetics used. Therefore, recommendations for dosage regimens cannot be fixed absolutely. Specific dosage requirements must be determined by evaluation of the health status and condition of the patient and of the procedure to be performed.

Recovery varies with the age and physical condition of the animal and the dose of Zoletil for Injection administered. Recovery is extended with high dose or multiple injections, particularly in cats.

Intramuscular injection in dogs and cats:

There may be pain on injection. This is especially prevalent in cats.

Following a single, deep intramuscular injection of Zoletil for Injection in cats and dogs, onset of anesthetic effect usually occurs within 5 to 12 minutes. Muscle relaxation is optimum for approximately the first 20 to 25 minutes after Zoletil for Injection is administered, and then diminishes.

Repeated doses increase the duration of the effect of Zoletil for Injection but may not further diminish muscle tone. The quality of anesthesia with repeated doses varies because the ratio of the two components within the animal's body changes with each injection. This is due to the difference in the rates of metabolism and elimination of the two components. The quality of anesthesia will be improved and more predictable if the entire dose is given as a single injection rather than in several doses. The best method of evaluating the depth of Zoletil for Injection anesthesia is to monitor the patient for deliberate conscious response to nociceptive stimuli.

If adequate anesthesia is not produced by the recommended dosage regimen, supplemental anesthesia or another agent is indicated. This includes the use of barbiturates and volatile anesthetics. When used concurrently with Zoletil for Injection the dosage of these agents should be reduced.

PREPARATION OF SOLUTION FOR ADMINISTRATION

To each vial add 5 mL sterile water for injection, USP. Slight agitation will facilitate complete reconstitution. The resultant solution will contain 100 mg total Zoletil for Injection per one milliliter (50 mg tiletamine and 50 mg zolazepam per mL).

Discard unused solution after 4 days when stored at room temperature or after 14 days when kept refrigerated. Only use clear solution. Color of solution may vary from colorless to light amber.

CONTRAINDICATIONS

The use of Zoletil for Injection is contraindicated in dogs and cats with pancreatic disease. Zoletil for Injection should not be used in dogs and cats with severe cardiac or pulmonary dysfunction.

Because the teratogenic potential of Zoletil for Injection is unknown, it should not be used in pregnant bitches or queens at any stage of pregnancy. Also, a study has shown that tiletamine and zolazepam for injection crosses the placental barrier and produces respiratory depression in the newborn; therefore, its use for Cesarean section is contraindicated.

WARNINGS

FOR USE IN DOGS AND CATS ONLY.

When using Zoletil for Injection for induction of anesthesia, patients should be continuously monitored. Facilities for the maintenance of a patent airway, artificial ventilation and oxygen supplementation should be available.

Pulmonary edema has been reported to occur in cats with the use of tiletamine and zolazepam for injection. Signs and symptoms include dyspnea, lethargy, anorexia and abnormal behavior. Deaths have been reported occasionally in severely affected individuals. Cats should be observed closely for any signs and symptoms which may suggest pulmonary edema so that appropriate therapy may be instituted.

The principal route of excretion of both components in the cat is the urine; therefore, Zoletil for Injection is not recommended for use in cats suffering from renal insufficiency.

Balance studies in dogs indicated extensive biotransformation of both components with less than 4% of the dose excreted unchanged in the urine.

Zoletil for Injection is excreted predominantly by the kidneys. Preexistent renal pathology or impairment of renal function may be expected to result in prolonged duration of anesthesia.

Phenothiazine-derivative drugs should not be used with Zoletil for Injection at dosages indicated for intramuscular (IM) injection because the combination produces respiratory and myocardial depression, hypotension and hypothermia.

The safe use of Zoletil for Injection in pregnant animals or on reproduction has not been established. Zoletil for Injection crosses the placental barrier and causes respiratory depression in the neonate.

PRECAUTIONS

The dosage of Zoletil for Injection should be reduced in geriatric dogs and cats, in animals in debilitated condition and in animals with impairment of renal function. Death has occurred in both cats and dogs following intramuscular tiletamine and zolazepam for injection administration. Preexisting pulmonary disease, renal disease (see Contraindications and Warnings) and shock were causally implicated at necropsy; however, death was drug attributable in at least one dog (of 1072) and one cat (of 1095).

Intravenous tiletamine and zolazepam for injection has been demonstrated to be safe in a field study in dogs when used in conjunction with phenothiazine-derivative drugs (acepromazine) administered at dosages from 0.04-0.06 mg/kg IM.

Cats and smaller dogs with small body masses in relation to large body surfaces should be protected from heat loss during Zoletil for Injection anesthesia. Body temperature should be monitored, and supplemental heat may be required to control hypothermia. As with other anesthetics, it is prudent to provide for hemostasis during any surgical procedure.

During Zoletil for Injection anesthesia, athetoid movement may occur. This athetosis should not be mistaken for lack of anesthesia nor is it indicative of lack of analgesia. Do not give additional anesthesia in an attempt to abolish the athetoid movement. Efforts to eliminate athetoid movement with additional doses of Zoletil for Injection can result in anesthetic overdosage.

Zoletil for Injection does not abolish laryngeal, pharyngeal, pinnal, palpebral, and pedal reflexes, and may not be adequate as the sole anesthetic for surgical procedures in these areas. Endotracheal tubes are not well tolerated in connection with Zoletil for Injection anesthesia in the cat and their use may result in impaired respiration. After removal of the tube, normal respiration should resume.

The stimulation of surgical procedures aids in maintaining adequate ventilation. The anesthetized patient must be monitored throughout the procedure, and if cardiopulmonary problems do occur, measures must be taken to assure that alveolar ventilation and cardiovascular functions are maintained.

The eyes normally remain open with the pupils dilated. The use of a bland ophthalmic ointment is advisable to protect the corneas from desiccation. The concurrent use of chloramphenicol will prolong the duration of anesthesia in cats.

Copious salivation may occur during Zoletil for Injection anesthesia. Ptyalism may be controlled in dogs and cats by administering atropine sulfate, USP, 0.02 mg/lb (0.04 mg/kg) body weight (IV, IM, or SC) as concurrent medication. Exaggerated swallowing, reflex action and accumulation of saliva may give rise to vomiting and retching.

ADVERSE REACTIONS

For Restraint and Minor Procedures of Short Duration Requiring Mild to Moderate Analgesia

Respiratory depression may occur following administration of high doses of Zoletil for Injection. If at any time respiration becomes excessively depressed and the animal becomes cyanotic, resuscitative measures should be instituted promptly. Adequate pulmonary ventilation using either oxygen or room air is recommended as a resuscitative measure.

Adverse reactions reported include emesis during emergence, excessive salivation, transient apnea, vocalization, erratic recovery and prolonged recovery, excessive tracheal and bronchial secretions when atropine sulfate, was not given before anesthesia, involuntary muscular twitching, hypertonicity, cyanosis, cardiac arrest, pulmonary edema and muscle rigidity during surgical procedures. Central nervous system stimulation and convulsions have also been reported. Tachycardia frequently occurs, particularly in the dog. This rise in heart rate usually lasts about 30 minutes. Either hypertension or hypotension may also occur. Insufficient anesthesia has been reported in dogs. Death has been reported in dogs and cats following tiletamine and zolazepam for injection administration.

Intravenous Induction of Anesthesia followed by Maintenance with Inhalant Anesthesia in Dogs

In a field study to assess the effectiveness and safety of tiletamine and zolazepam for injection administered intravenously at 1-2 mg/lb (2.2-4.4 mg/kg) for the induction of anesthesia followed by maintenance with inhalant anesthesia in dogs, 144 dogs were intravenously administered tiletamine and zolazepam for injection (See Effectiveness). Sixteen adverse reactions occurred during the study: nystagmus (5), emesis (4), diarrhea (2), and one occurrence each of hypersalivation, urticaria, anorexia, hyperthermia, and lethargy. All adverse reactions resolved by the end of the study.

Physiologic abnormalities related to general anesthesia were transient and not severe.

Post-induction apnea (time from induction to first inspiration ≥30 seconds) was observed in 49.3% of dogs across all treatment groups with a mean duration of one minute. The highest overall frequency and duration of post-induction apnea was in the alpha$_2$-agonist + opioid groups.

Overall, 36 dogs received assisted ventilation. Assisted ventilation was needed most frequently early in the procedure (at procedure start, possibly after an apneic period) then decreased in frequency as the procedure continued.

Sixteen dogs experienced oxygen saturation (SpO_2) ≤90 mmHg: 7 in the alpha$_2$-agonist + opioid groups, 6 in the phenothiazine + opioid groups, and 3 in the opioid alone groups.

Twenty-five dogs had a temperature ≥103°F during the study, with 12 of these occurring prior to preanesthetic administration only. Of the remaining 13 dogs, 7 were in the alpha$_2$-agonist + opioid groups, 5 were in the opioid alone groups, and 1 in the phenothiazine + opioid groups. One dog was reported with hyperthermia as an adverse reaction in the alpha$_2$-agonist + opioid treatment groups. The dog became excitable during recovery and its temperature elevated to 105.7°F. Hyperthermia resolved with treatment of IV fluids and cooling.

Twenty-seven dogs experienced temperatures ≤96°F at one or more timepoints. Most dogs received supplemental heat during surgery.

Fifty-nine dogs had mean blood pressure (BP) values ≤60 mmHg. These values are spread among all treatment groups. No dogs were reported with adverse reactions due to hypotension or hypertension in any dose groups. Elevated or low BP values were transient.

Ventricular premature depolarizations were noted in 3 dogs in the alpha$_2$-agonist + opioid group. This transient rhythm disturbance is not uncommon in dogs receiving alpha$_2$-agonists or inhalant anesthetics. One dog in the phenothiazine + opioid group showed transient ST depression that could have been due to cardiac hypoxia. All dogs recovered normally.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com.
For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

CLINICAL PHARMACOLOGY

Mechanism of Action

Zoletil for Injection is a rapid-acting anesthetic combination of tiletamine hydrochloride and zolazepam hydrochloride. Tiletamine hydrochloride is a dissociative anesthetic agent whose pharmacologic action is characterized by profound analgesia, normal pharyngeal-laryngeal reflexes and cataleptoid anesthesia.

The anesthetic state produced does not fit into the conventional classification of stages of anesthesia, but instead Zoletil for Injection produces a state of unconsciousness which has been termed "dissociative" anesthesia in that it appears to selectively interrupt association pathways to the brain before producing somesthetic sensory blockade.

Cranial nerve and spinal reflexes remain active; however, these reflexes must not be confused with inadequate anesthesia. Analgesia results from apparent selective interruption of sensory inputs to the brain and usually persists after the anesthetic effect has subsided.

Protective reflexes, such as coughing and swallowing, are maintained under tiletamine anesthesia. Other reflexes, e.g., corneal, pedal, are maintained during tiletamine anesthesia, and should not be used as criteria for judging depth of anesthesia. The eyes normally remain open with the pupil dilated. It is suggested that a bland ophthalmic ointment be applied to the cornea if anesthesia is to be prolonged.

Used alone, tiletamine hydrochloride does not provide adequate muscle relaxation for abdominal surgical procedures. When combined with zolazepam hydrochloride, good muscle relaxation is generally attained during the phase of deep surgical anesthesia.

Pharmacokinetics

The pharmacokinetics of tiletamine and zolazepam for injection, injectable solution was evaluated in 12 healthy adult Beagle dogs, following a single intravenous (IV) administration of 2.2 mg/kg bodyweight, which is equivalent to 1.1 mg/kg for both tiletamine hydrochloride and zolazepam hydrochloride. After administration of 2.2 mg/kg tiletamine and zolazepam for injection IV, the initial mean concentration of tiletamine (C_0) was 1018 ng/mL, the systemic clearance (CL) was 6223 mL/kg/h, the area under the curve to the last measured concentration (AUC_{0-last}) was 178 ng*hr/mL, and steady state volume of distribution (V_{ss}) was 3250 mL/kg. The mean elimination half-life of tiletamine was 0.87 hours. For zolazepam, the mean C_0 was 2594 ng/mL, CL was 1993 mL/kg/h and V_{ss} was 604 mL/kg. The mean elimination half-life of zolazepam was 0.41 hours. The mean C_0 and $AUC_{0-infinity}$ were approximately 2.5 and 3 times, respectively, greater for zolazepam than for tiletamine. However, the mean half-life ($T_{1/2}$) of tiletamine was approximately 2.5 times longer than for zolazepam, resulting in quantifiable plasma concentrations up to 2 hours longer.

Pretreatment with an alpha$_2$-agonist or phenothiazine followed by inhalant isoflurane has been shown to increase in the initial concentration of both tiletamine and zolazepam.

EFFECTIVENESS

Dogs

Preanesthesia

In a field study conducted at 6 veterinary hospitals, 144 dogs of various breeds, ranging in age from 4 months to 14 years (mean age 5 years) and body weights from 1.2- 85.5 kg, were enrolled for completion of a veterinary procedure requiring anesthesia. Dogs were preanesthetized with a phenothiazine + opioid, an opioid alone, or an alpha$_2$-agonist + opioid at the study Investigator's discretion based on individual patient needs. Approximately 20 minutes later, dogs were intravenously administered tiletamine and zolazepam for injection at 1-2 mg/lb (2.2-4.4 mg/kg) 'to effect' of anesthesia and were intubated. After induction, dogs received either isoflurane or sevoflurane for anesthetic maintenance for at least 30 minutes. Procedures conducted included dental prophylaxis with or without extractions (64), ovariohysterectomy (31), castration (18), and mass removal (14). Upon completion of the procedure, dogs were monitored in recovery for 4 hours, then followed at home for 2-4 days, monitoring for the presence of abnormal clinical signs.

Of 144 dogs enrolled in the study, 142 (98.6%) were successfully intubated after intravenous administration of tiletamine and zolazepam for injection at a mean dosage of 1.2 mg/lb (2.7 mg/kg). The mean dosage range was lowest in the alpha$_2$-agonist + opioid preanesthetic treatment group (0.9 mg/lb; 2 mg/kg) and highest in the opioid alone preanesthetic group (1.8 mg/lb; 3.9 mg/kg).

Overall induction quality evaluated on a scale of acceptable, intermediate, or unacceptable was acceptable in 131/142 (91.6%) dogs and intermediate in 12/143(8.4%) dogs. On a scale of good, fair, or poor, study participants rated the quality of recovery from anesthesia as good in 75% of dogs (118/144) and fair in 18.1% (26/144). In an overall assessment of anesthesia, considering induction, maintenance, and recovery, was scored as excellent or good in 128/144 (88.9%) of dogs. Three dogs (2.1%) were rated with an overall assessment of anesthesia as poor, and for these dogs, recovery was also rated poor. Physiologic measurements of heart rate, respiratory rate, body temperature, oxygen saturation, and blood pressure during anesthetic induction, maintenance, and recovery showed that the administration of tiletamine and zolazepam for injection did not severely impact these variables. A variety of concomitant treatments were used during the study including intravenous fluid solutions, non-steroidal anti-inflammatory medications, antimicrobials, and antiparasitics that were consistent with routine canine practice.

ANIMAL SAFETY

Tiletamine and zolazepam for injection has a wider margin of safety in cats than in dogs. Dogs have survived repeated IM dosage regimens of 13.6 mg/lb (30 mg/kg) (maximum safe dose) for eight successive days. This is approximately two times the maximum recommended therapeutic dose. Cats have survived IM dosage regimens of up to 32.7 mg/lb (72 mg/kg) (maximum safe dose) on alternate days for seven episodes. This is 4.6 times the maximum recommended therapeutic dose for cats. However, these reports should not obviate prudent anesthetic practices. Some degree of tolerance has been reported. This tolerance appears to be species-variable.

Cats

In cats, the duration of effect of zolazepam exceeds that of tiletamine so that as the animal recovers there is a greater degree of tranquilization than anesthetization. There is a slight lowering of blood pressure during the first hour after injection. Heart rate and electrocardiogram readings are unaffected by tiletamine and zolazepam for injection. Arterial pO_2 levels are decreased three minutes after injection but usually return to normal within 15 to 35 minutes.

Dogs

In dogs, the duration of effect of tiletamine exceeds that of zolazepam so there is a lesser degree of tranquilization than anesthetization in this species. The total effect of tiletamine and zolazepam for injection in dogs is of shorter duration than in cats.

Following administration of tiletamine and zolazepam for injection in dogs, a marked, persistent tachycardia occurs within two minutes following either 4.5 or 9 mg/lb (10 or 20 mg/kg) tiletamine and zolazepam for injection intramuscularly. Stroke volume decreases proportionately to the increased rate at the 4.5 mg/lb (10 mg/kg) dose, with little change in net cardiac output. There is an initial increase in systolic blood pressure, with a slight drop in pressure within five minutes. The systolic blood pressure remains at this decreased level throughout the duration of the anesthetic effect. Diastolic pressure increases throughout this same period. Following a 9 mg/lb (20 mg/kg) dose of tiletamine and zolazepam for injection in dogs, the relationship between stroke volume and heart rate is disproportionate, with a resultant substantial decrease in cardiac output. Contractility and mean blood pressure are decreased, indicating direct myocardial depression. Ventricular function is adequate. During surgical manipulations, tachycardia and hypertension may be observed, and may be brought on by sympathetic reaction to painful stimuli. Epinephrine is markedly less arrhythmogenic in animals under tiletamine and zolazepam for injection anesthesia than in those under halothane anesthesia.

During tiletamine and zolazepam for injection anesthesia, the assurance of a patent airway is greatly enhanced by virtue of maintaining pharyngeal-laryngeal reflexes. During the first 15 minutes after intramuscular administration of 9 mg/lb (20 mg/kg) of tiletamine and zolazepam for injection, the respiratory rate is doubled while the tidal volume is decreased to less than one-half of control values. Arterial pO_2 levels also decrease. This may be evidenced by hypoxemia and cyanosis. The pulmonary function usually returns to normal within 35 minutes after the administration of tiletamine and zolazepam for injection.

Preanesthetic Compatibility Study in Dogs

Six healthy Beagle dogs (3 males and 3 females), at least 8 months of age, ranging in body weight between 5.6 and 9.4 kg, were fitted with a telemetry device that captured systemic arterial blood pressures, electrocardiogram, and body temperature. Each dog received a total of 6 treatments with at least a 7-day washout between periods. During each period, dogs received 1 of the following 6 preanesthetics prior to the tiletamine and zolazepam for injection administration: placebo (0.9% saline), acepromazine low dose (0.1 mg/kg body weight [BW]), acepromazine high dose (1.1 mg/kg BW), dexmedetomidine low dose (125 mcg/m^2 body surface area [BSA]), dexmedetomidine high dose (375 mcg/m^2 BSA), or butorphanol (0.4 mg/kg BW). Blood samples were collected at intubation, end of isoflurane administration, and after anesthesia when the dogs were able to walk. Plasma concentrations of tiletamine and zolazepam were measured using a validated method. Preanesthetic treatment with high dose acepromazine and both high and low doses of dexmedetomidine resulted in substantial increases in plasma concentrations of tiletamine and zolazepam at intubation. The increase in the tiletamine plasma concentrations was approximately 2X higher for the high dose of acepromazine and 2.7 to 4.5X higher for the low and high doses of dexmedetomidine, respectively, compared to saline. The increase in zolazepam plasma concentrations was 1.5X higher for the high dose acepromazine, and 1.8 to 2.8X higher for the low and high doses of dexmedetomidine, respectively, compared to saline.

No information on the dose-sparing of tiletamine and zolazepam for injection was obtained during the study because the dogs were given the full initial half-dose (2.2 mg/kg) and not actually administered tiletamine and zolazepam for injection 'to effect'. The average total dose of test article administered to the dogs was 2.6 mg/kg for the saline group and 2.2 mg/kg for the other treatment groups. One dog (saline group) required more than the initial 2.2 mg/kg bolus to achieve intubation at the first attempt.

Without preanesthesia (saline group), dogs retained a strong cough reflex, chewing motions, tachycardia and increased muscle tone during intubation. With preanesthesia, half of the dogs in the high dose dexmedetomidine group had no laryngeal reflex response to intubation and all experienced post-intubation apnea. The post-intubation apnea suggests that the 2.2 mg/kg dose of tiletamine and zolazepam for injection was higher than necessary in some groups.

All dogs in all treatment groups achieved successful anesthetic plane following tiletamine and zolazepam for injection administration and were intubated and induced to isoflurane anesthesia uneventfully. The quality of intubation, and occurrence and severity of adverse reactions (e.g., apnea and bradypnea) following tiletamine and zolazepam for injection administration and intubation revealed differences among preanesthetic treatment groups. The cardiovascular and respiratory changes observed were typical of each preanesthetic medication used in combination with tiletamine and zolazepam for injection. Acepromazine and isoflurane administration decreased arterial blood pressure. Dexmedetomidine decreased heart rate. Intubation transiently increased heart rate and/or blood pressure (sympathetic stimulations). Mild to severe respiratory depression was observed after tiletamine and zolazepam for injection administration and each preanesthetic agent. Adverse reactions were manageable with appropriate care.

STORAGE CONDITIONS

Store at controlled room temperature 20° to 25° C (68° to 77° F). Discard unused solution after 4 days when stored at room temperature or after 14 days when kept refrigerated. Only use clear solution. Color of solution may vary from colorless to light amber.

HOW SUPPLIED

Zoletil for Injection (tiletamine and zolazepam for injection) is available in individual vials of 5 mL solution when reconstituted. The addition of 5 mL diluent produces a solution containing the equivalent of 50 mg tiletamine base, 50 mg zolazepam base and 57.7 mg mannitol per milliliter.

5 mL vial – 100 mg/mL total (equivalent to 50 mg/mL tiletamine and 50 mg/mL zolazepam) when reconstituted.

Approved by FDA under ANADA # 200-618

Manufactured in France for Virbac AH, Inc.
P.O. Box 162059, Fort Worth, TX, 76161
1-800-338-3659

Rev. 05/2022

 005U4040204

Every pet, everywhere, deserves a life of care. That's why we created The Every Pet Project. Each month Virbac will donate $2,500 to **2 animal charities** — organizations that work hard to make sure pets are cared for and get the protection they need for a happy, healthy life.

Nominate

Visit The Every Pet Project and submit your nomination for the charity you want to win. Each month Virbac will conduct a random drawing. It's up to you to nominate the charities **you want to win.**

Gallery of Goodwill

Share photos or videos of your pets in The Every Pet Project online gallery, then watch as our animal-loving community grows bigger every day.

Spread the Word

Share your nomination story using **#EveryPetProject,** and let us know what your favorite charity means to you and the pets in your community.

January 2023

Shaping the future of animal health